[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fhhZmKUo00TGIUSe03pC3HbMjEHGya1IyR8j65SfnjVk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":37,"phaseBuckets":88,"rows":95},"Masonic Cancer Center, University of Minnesota",[4],285,false,48,12,16102,97,49,[14,17,20,23,25,28,31,34],{"name":15,"count":16},"Leukemia",30,{"name":18,"count":19},"Lymphoma",27,{"name":21,"count":22},"Myelodysplastic Syndromes",24,{"name":24,"count":22},"Ovarian Cancer",{"name":26,"count":27},"Acute Myeloid Leukemia",22,{"name":29,"count":30},"Breast Cancer",21,{"name":32,"count":33},"Multiple Myeloma",19,{"name":35,"count":36},"Lung Cancer",14,[38,43,48,53,58,63,68,73,78,83],{"nctId":39,"briefTitle":40,"date":41,"intervention":42},"NCT03674411","Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy","2020-06-23","Fludarabine",{"nctId":44,"briefTitle":45,"date":46,"intervention":47},"NCT04514029","Neurotoxicity Prophylaxis With Intrathecal Dexamethasone and Simvastatin Post Axi-Cel","2023-11-03","Simvastatin",{"nctId":49,"briefTitle":50,"date":51,"intervention":52},"NCT03642626","MT2017-45: CAR-T Cell Therapy for Heme Malignancies","2024-02-09","KYMRIAH",{"nctId":54,"briefTitle":55,"date":56,"intervention":57},"NCT04003805","Biomarkers of Exposure and Effect in Standardized Research E-cigarette (SREC) Users","2024-05-31","Standardized Research E-cigarette",{"nctId":59,"briefTitle":60,"date":61,"intervention":62},"NCT03998735","Nornicotine in Smokeless Tobacco as a Precursor for Carcinogen Exposure","2025-08-01","Herbal Snuff",{"nctId":64,"briefTitle":65,"date":66,"intervention":67},"NCT05634512","Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.","2025-10-28","Laronidase therapy and a stem cell transplant",{"nctId":69,"briefTitle":70,"date":71,"intervention":72},"NCT01652092","Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies","2025-12-30","Alemtuzumab 0.3 mg",{"nctId":74,"briefTitle":75,"date":76,"intervention":77},"NCT02171104","MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis","2026-01-05","Stem Cell Transplantation",{"nctId":79,"briefTitle":80,"date":81,"intervention":82},"NCT06342986","Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer","2026-03-26","FT536",{"nctId":84,"briefTitle":85,"date":86,"intervention":87},"NCT01666080","Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)","2026-06","Busulfan",[89,90,91,92,93,94],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[96,985,1176,1373,1496,1598,1650,1737,1810,1840,1862,1884,1930,1975,2009,2059,2093,2171,2223,2264,2298,2320,2342,2367,2389,2421,2439,2457,2475,2493,2511,2529,2547,2565,2583,2601,2619,2637,2655,2673,2703,2721,2739,2757,2775,2793,2811,2829,2847,2877,2895,2913,2931,2949,2967,2985,3012,3030,3048,3066,3084,3102,3120,3138,3156,3174,3192,3210,3228,3282,3359,3385,3407,3436,3461,3488,3506,3531,3553,3575,3593,3618,3657,3675,3711,3741,3770,3792,3819,3840,3868,3886,3913,3931,3949,3967,3985,4003,4033,4059,4081,4103,4125,4143,4161,4189,4207,4225,4250,4277,4344,4404,4476,4520,4550,4580,4619,4649,4682,4730,4756,4789,4818,4848,4887,4917,4939,4961,4983,5012,5047,5069,5096,5118,5146,5168,5190,5213,5231,5249,5276,5298,5316,5343,5361,5379,5397,5420,5442,5460,5478,5504,5529,5547,5565,5587,5605,5623,5651,5669,5687,5705,5731,5754,5775,5793,5816,5834,5852,5870,5888,5906,5928,5956,5974,5992,6010,6028,6052,6070,6088,6114,6132,6150,6168,6191,6216,6234,6252,6273,6298,6316,6339,6357,6375,6397,6415,6433,6451,6469,6493,6519,6537,6555,6573,6591,6613,6638,6664,6682,6700,6718,6736,6754,6772,6798,6822,6840,6858,6876,6898,6916,6934,6952,6974,6996,7014,7032,7059,7077,7095,7126,7162,7184,7217,7244,7266,7292,7310,7328,7346,7364,7382,7407,7425,7446,7469,7493,7517,7538,7564,7588,7606,7624,7642,7665,7687,7705,7726,7747,7771,7797,7815,7833,7851,7873,7891,7909,7927,7951,7969,7993,8011,8037,8064,8089,8107,8135,8153,8171,8189,8214,8308,8390,8456,8522,8556,8591,8621,8651,8681,8707,8736,8762,8793,8815,8846,8868,8890,8908,8926,8944,8962,8980,8998,9027,9045,9063,9081,9099,9117,9139,9161,9179,9197,9220,9244,9262,9280,9298,9316,9334],{"intervention":97,"totalTrials":98,"cells":99},"Cyclophosphamide",68,{"EARLY_PHASE1":100,"PHASE1":103,"PHASE2":179,"PHASE3":794,"PHASE4":853,"NA":855},{"trials":101,"activeCount":102},[],0,{"trials":104,"activeCount":102},[105,122,137,152,166],{"nctId":106,"briefTitle":107,"status":108,"phases":109,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":113,"interventions":117},"NCT00376519","Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases","TERMINATED",[90],"2008-03","2007-05",3,[114,15,18,115,21,116],"Graft Versus Host Disease","Multiple Myeloma and Plasma Cell Neoplasm","Secondary Myelofibrosis",[118,119,120,121],"cyclophosphamide","cyclosporine","fludarabine phosphate","mycophenolate mofetil",{"nctId":123,"briefTitle":124,"status":125,"phases":126,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":134},"NCT04714372","FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia","COMPLETED",[90],"2024-01-09","2024-10-15","2021-11-03",9,[26,132,133],"Myeloid Leukemia","Monocytic Leukemia",[135,136,42,97],"Daratumumab\u002FrHuPH20","FT538",{"nctId":138,"briefTitle":139,"status":125,"phases":140,"primaryCompletion":141,"completion":142,"start":143,"enrollment":144,"conditions":145,"interventions":147},"NCT00602693","T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer",[90],"2014-09-25","2015-04-16","2007-07-23",41,[15,18,32,146,21],"Plasma Cell Neoplasm",[148,149,120,97,150,151],"umbilical cord blood transplantation","Allopurinol","Treg","Sirolimus",{"nctId":153,"briefTitle":154,"status":125,"phases":155,"primaryCompletion":156,"completion":156,"start":157,"enrollment":158,"conditions":159,"interventions":162},"NCT02118285","Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",[90],"2015-11-12","2014-07-28",2,[24,160,161],"Fallopian Tube Carcinoma","Primary Peritoneal Carcinoma",[42,97,163,164,165],"NK cells","IL-2","INCB024360",{"nctId":167,"briefTitle":168,"status":125,"phases":169,"primaryCompletion":170,"completion":171,"start":172,"enrollment":9,"conditions":173,"interventions":176},"NCT00686556","Total Marrow Irradiation for Refractory Acute Leukemia",[90],"2016-11","2016-12","2012-08",[174,175,32],"Acute Lymphoblastic Leukemia","Myelodysplastic Syndrome",[118,119,42,121,177,178],"Granulocyte colony-stimulating factor","HLA-matched related donor bone marrow",{"trials":180,"activeCount":130,"soonestReadout":41},[181,212,226,244,254,289,304,315,324,333,351,361,374,383,397,421,432,453,463,473,486,500,517,527,537,546,553,563,574,594,603,613,627,639,655,664,675,692,702,712,721,732,743,757,767,776,783],{"nctId":182,"briefTitle":183,"status":125,"phases":184,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":189,"interventions":206},"NCT02661035","Allo HSCT Using RIC for Hematological Diseases",[91],"2023-04-17","2023-05-29","2017-03-09",156,[190,191,192,193,21,194,195,196,197,198,199,200,201,202,203,32,204,205],"Acute Myelogenous Leukemia","Acute Lymphocytic Leukemia","Chronic Myelogenous Leukemia","Plasma Cell Leukemia","Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma","B-Cell Lymphoma","Follicular Lymphoma","Lymphoplasmacytic Lymphoma","Mantle-Cell Lymphoma","Prolymphocytic Leukemia","Lymphoblastic Lymphoma","Burkitt's Lymphoma","Non-Hodgkin's Lymphoma","Myeloproliferative Syndromes","Hematological Diseases",[149,42,97,207,208,209,210,211],"ATG","Tacrolimus","MMF","Peripheral Blood Stem Cells","Related or Unrelated Bone Marrow Cells",{"nctId":213,"briefTitle":214,"status":125,"phases":215,"primaryCompletion":216,"completion":216,"start":217,"enrollment":36,"conditions":218,"interventions":220},"NCT00258427","Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia",[91],"2020-10-10","2002-03-26",[219],"Fanconi Anemia",[221,222,223,118,120,224,225],"anti-thymocyte globulin","filgrastim","busulfan","methylprednisolone","Hematopoietic stem cell transplantation",{"nctId":227,"briefTitle":228,"status":229,"phases":230,"primaryCompletion":231,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":238},"NCT03125642","Auto Stem Cell Transplant for Lymphoma Patients","RECRUITING",[91],"2026-09-30","2027-04-30","2017-04-20",150,[236,237],"Non-Hodgkin Lymphoma","Hodgkin Lymphoma",[239,240,241,242,243,97],"Etoposide","BCNU","AraC","Melphalan","G-CSF",{"nctId":245,"briefTitle":246,"status":108,"phases":247,"primaryCompletion":248,"completion":249,"start":250,"enrollment":158,"conditions":251,"interventions":252},"NCT00871689","Chemotherapy, Total-Body Irradiation, Donor Natural Killer Cell Infusion, Aldesleukin, and UCB Transplant in Treating Patients With Relapsed or Refractory AML",[91],"2010-03","2011-10","2009-01",[15],[253,118,120],"aldesleukin",{"nctId":255,"briefTitle":256,"status":229,"phases":257,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":262,"interventions":284},"NCT05735717","MT2021-08T Cell Receptor Alpha\u002FBeta Depletion PBSC Transplantation for Heme Malignancies",[91],"2027-11-30","2030-11-30","2023-05-11",70,[263,264,265,26,174,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,201,283],"Hematologic Malignancy","Acute Leukemia","Remission","AML","TP53","Intrachromosomal Amplification of Chromosome 21","Cytogenetic Abnormality","CNS Leukemia","Minimal Residual Disease","Myelodysplasia","Juvenile Myelomonocytic Leukemia","Somatic Mutation","PTPN11 Gene Mutation","N-RAS Gene Amplification","Neurofibromatosis 1","NF1 Mutation","CBL Gene Mutation","Monosomy 7","Chromosome Abnormality","Fetal Hemoglobin","High Grade Non-Hodgkin's Lymphoma, Adult",[42,87,242,285,286,287,288,97],"Rituximab","Levetiracetam","Alpha\u002FBeta T Cell-Depleted Hematopoietic Stem Cells","Thymoglobulin",{"nctId":290,"briefTitle":291,"status":125,"phases":292,"primaryCompletion":293,"completion":293,"start":294,"enrollment":295,"conditions":296,"interventions":299},"NCT01105650","Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer",[91],"2014-04","2010-07",13,[24,297,298,29],"Fallopian Tube Cancer","Primary Peritoneal Cancer",[42,97,300,301,164,302,302,303],"Cyclosporine","Natural killer cells","Methylprednisolone","Interleukin-2",{"nctId":305,"briefTitle":306,"status":307,"phases":308,"primaryCompletion":309,"completion":309,"start":310,"enrollment":102,"conditions":311,"interventions":313},"NCT05114837","Ph I\u002FII Study of CAR19 Regulatory T Cells (CAR19-tTreg) for R\u002FR CD19+ B-ALL","WITHDRAWN",[90,91],"2028-08","2024-09",[312],"Lymphoma Leukemia",[314,42,97],"allogeneic CAR19 regulatory T cells",{"nctId":316,"briefTitle":317,"status":125,"phases":318,"primaryCompletion":319,"completion":319,"start":320,"enrollment":30,"conditions":321,"interventions":322},"NCT00274846","Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia",[91],"2008-06","2005-03",[15],[253,323,118,120],"therapeutic allogeneic lymphocytes",{"nctId":325,"briefTitle":326,"status":108,"phases":327,"primaryCompletion":328,"start":329,"conditions":330,"interventions":331},"NCT00005986","Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia",[91],"2004-09","2000-08",[15],[223,118,222,332],"recombinant interferon alfa",{"nctId":334,"briefTitle":335,"status":307,"phases":336,"primaryCompletion":337,"completion":337,"start":338,"enrollment":102,"conditions":339,"interventions":347},"NCT01163201","T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies",[90,91],"2015-01","2014-01",[263,26,191,340,341,342,194,195,343,197,198,199,344,345,201,202,346],"Chronic Myelogenous Leukemia in Blast Crisis","Anemia, Refractory, With Excess of Blasts","Chronic Myeloproliferative Disease","Marginal Zone B-cell Lymphoma","Prolymphocytic Lymphoma","Large Cell Non-Hodgkin's Lymphoma","High Grade Non-Hodgkin's Lymphoma",[348,349,42,97,350],"Treg cells","CD3+ Teff cells","Umbilical cord blood transplantation",{"nctId":352,"briefTitle":353,"status":125,"phases":354,"primaryCompletion":355,"completion":356,"start":357,"enrollment":358,"conditions":359,"interventions":360},"NCT01181258","Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies",[91],"2015-09","2016-07","2010-08",16,[236,194],[285,303,301,97,302,42],{"nctId":362,"briefTitle":363,"status":125,"phases":364,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":369,"interventions":373},"NCT00309842","Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases",[91],"2019-07-29","2019-11-22","2005-07-28",213,[26,191,192,370,371,372,194,200,203,15,18,32,21],"Myelofibrosis","MDS","Refractory Anemia",[222,118,119,120,121],{"nctId":375,"briefTitle":376,"status":108,"phases":377,"primaryCompletion":378,"completion":378,"start":249,"enrollment":112,"conditions":379,"interventions":381},"NCT01464359","T-Cell Depleted Double UCB for Refractory AML",[91],"2013-10",[190,380],"Refractory Acute Myelogenous Leukemia",[149,42,97,286,87,382,303],"Umbilical Cord Blood Transplantation",{"nctId":384,"briefTitle":385,"status":307,"phases":386,"primaryCompletion":387,"completion":387,"start":388,"enrollment":102,"conditions":389,"interventions":390},"NCT00005998","Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease",[91],"2003-03","2000-01",[18],[391,118,392,393,394,222,395,396],"carmustine","cytarabine","dexamethasone","etoposide","mitoxantrone hydrochloride","retrovirus vector LN",{"nctId":398,"briefTitle":399,"status":229,"phases":400,"primaryCompletion":401,"completion":402,"start":403,"enrollment":404,"conditions":405,"interventions":415},"NCT05805605","Allo HSCT Using RIC and PTCy for Hematological Diseases",[91],"2027-10-22","2028-10-22","2023-05-01",56,[190,191,406,407,200,192,193,21,408,409,410,411,412,195,413,197,414,370],"Biphenotypic Acute Leukemia","Undifferentiated Leukemia","Leukemia, Myeloid","Myelodysplastic Syndrome With Excess Blasts-1","Burkitt Lymphoma","Relapsed T-Cell Lymphoma","Relapsed Chronic Lymphocytic Leukemia","Marginal Zone Lymphoma","Myeloproliferative Neoplasm",[416,417,42,97,418,419,420],"Peripheral Blood Stem Cell Transplant","Allopurinol 300 MG","Bone Marrow Cell Transplant","Sirolimus Pill","Mycophenolate Mofetil",{"nctId":422,"briefTitle":423,"status":108,"phases":424,"primaryCompletion":249,"completion":425,"start":294,"enrollment":426,"conditions":427,"interventions":429},"NCT01106950","Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)",[91],"2012-12",15,[428],"Leukemia, Myelogenous, Acute",[430,42,97,431,164],"Natural Killer Cells","Denileukin diftitox",{"nctId":433,"briefTitle":434,"status":125,"phases":435,"primaryCompletion":436,"completion":437,"start":438,"enrollment":426,"conditions":439,"interventions":451},"NCT02722668","UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep",[91],"2023-02-22","2024-02-22","2017-05-15",[264,26,440,202,441,192,175,442,237,32,412,443,343,197,198,444,200,445,446,447,448,449,411,450,193],"Acute Lymphoblastic Leukemia\u002FLymphoma","Natural Killer Cell Malignancies","Large-cell Lymphoma","Relapsed Small Lymphocytic Lymphoma","Mantle-cell Lymphoma","Bone Marrow Failure Syndromes","Myeloproliferative Neoplasms\u002FMyelofibrosis","Biphenotypic\u002FUndifferentiated\u002FProlymphocytic Leukemias","MRD Positive Leukemia","Leukemia or MDS in Aplasia","Relapsed Multiple Myeloma",[42,97,209,151,452,207],"Umbilical cord blood cell",{"nctId":454,"briefTitle":455,"status":108,"phases":456,"primaryCompletion":457,"completion":458,"start":459,"enrollment":460,"conditions":461,"interventions":462},"NCT00376805","Allogeneic Natural Killer (NK) Cells in Patients With Advanced Metastatic Breast Cancer",[91],"2009-09","2010-01","2006-04",6,[29],[42,97,303],{"nctId":464,"briefTitle":465,"status":125,"phases":466,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":470,"interventions":471},"NCT00345865","Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma",[91],"2019-06-28","2005-08-24",473,[18],[391,118,394,243,472],"Cytarabine",{"nctId":39,"briefTitle":40,"status":474,"phases":475,"primaryCompletion":41,"completion":476,"start":477,"enrollment":27,"conditions":478,"interventions":482},"ACTIVE_NOT_RECRUITING",[91],"2026-12-01","2019-01-02",[26,191,479,192,272,480,481,237,410,411,198],"Biphenotypic\u002FUndifferentiated Leukemia","Relapsed Large Cell Lymphoma","Mantle Cell Lymphoma",[42,97,483,208,420,484,87,242,485],"Total Body Irradiation","Granulocyte Colony-Stimulating Factor","MGTA 456",{"nctId":487,"briefTitle":488,"status":229,"phases":489,"primaryCompletion":490,"completion":491,"start":492,"enrollment":9,"conditions":493,"interventions":495},"NCT02605421","Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma",[91],"2026-10-01","2026-12","2016-06",[494],"Neuroblastoma",[496,97,242,239,497,498,499],"Thiotepa","Carboplatin","Autologous Stem Cell","Granulocyte colony stimulating factor",{"nctId":501,"briefTitle":502,"status":229,"phases":503,"primaryCompletion":504,"completion":505,"start":506,"enrollment":507,"conditions":508,"interventions":513},"NCT06412497","MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.",[91],"2035-05-01","2036-05-01","2024-06-05",60,[509,510,511,512],"Severe Aplastic Anemia","Acquired Amegakaryocytic Thrombocytopenia","Acquired Pure Red Cell Aplasia","Paroxysmal Nocturnal Hemoglobinuria",[285,514,97,42,515,516,208,420],"Rabbit ATG","Cell","Post-Transplant G-CSF",{"nctId":518,"briefTitle":519,"status":125,"phases":520,"primaryCompletion":216,"completion":216,"start":521,"enrollment":522,"conditions":523,"interventions":524},"NCT00630253","Cytoxan, Fludara, and Antithymocyte Globulin Conditioning Followed By Stem Cell Transplant in Treating Fanconi Anemia",[90,91],"2000-02-17",31,[219],[525,97,42,302,526,300,420],"Anti-Thymocyte Globulin","Filgrastim",{"nctId":528,"briefTitle":529,"status":125,"phases":530,"primaryCompletion":531,"completion":532,"start":533,"enrollment":460,"conditions":534,"interventions":535},"NCT00612716","Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia",[91],"2019-11-15","2019-12-15","1999-10-06",[15,18,115],[223,118,536],"Stem cell",{"nctId":538,"briefTitle":539,"status":108,"phases":540,"primaryCompletion":172,"completion":541,"start":248,"enrollment":522,"conditions":542,"interventions":543},"NCT00963872","Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer",[90,91],"2013-08",[15,18,32,21],[118,120,544,545],"Umbilical cord blood unit with C3a fragment","Unmanipulated UCB Unit",{"nctId":547,"briefTitle":548,"status":125,"phases":549,"primaryCompletion":550,"completion":550,"start":329,"enrollment":368,"conditions":551,"interventions":552},"NCT00005985","Filgrastim and Chemotherapy Followed by Peripheral Stem Cell Transplant in Treating Patients With Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma",[91],"2007-02",[18],[222,391,118,392,393,394,395],{"nctId":554,"briefTitle":555,"status":307,"phases":556,"primaryCompletion":557,"completion":557,"start":558,"enrollment":102,"conditions":559,"interventions":560},"NCT01677949","Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia",[91],"2016-01","2013-12",[26,174],[561,239,97,562],"Clofarabine","allogeneic hematopoietic cell transplantation",{"nctId":564,"briefTitle":565,"status":108,"phases":566,"primaryCompletion":567,"completion":568,"start":569,"enrollment":460,"conditions":570,"interventions":571},"NCT00625729","Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia",[90,91],"2009-12","2010-04","2008-01",[15,18],[253,572,573,118,120],"allogeneic natural killer cells","rituximab",{"nctId":575,"briefTitle":576,"status":108,"phases":577,"primaryCompletion":578,"completion":578,"start":110,"enrollment":579,"conditions":580,"interventions":592},"NCT00668564","Hematopoietic Stem Cell Transplantation (HCT) for Inborn Errors of Metabolism",[91],"2010-02",18,[581,582,583,584,585,586,587,588,589,590,591],"Hurler's Syndrome","Maroteaux-Lamy Syndrome","Sly Syndrome","Alpha Mannosidosis","Fucosidosis","Aspartylglucosaminuria","Sphingolipidoses","Krabbe Disease","Wolman's Disease","Niemann-Pick Disease Type B","Niemann-Pick Disease, Type C",[97,593,87],"Campath-1H",{"nctId":595,"briefTitle":596,"status":108,"phases":597,"primaryCompletion":598,"completion":598,"start":599,"enrollment":358,"conditions":600,"interventions":601},"NCT00354172","Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.",[91],"2008-08","2006-02",[15,21],[253,222,602,118,119,120,224,121],"natural killer cell (NK) therapy",{"nctId":604,"briefTitle":605,"status":307,"phases":606,"primaryCompletion":607,"completion":607,"start":378,"enrollment":102,"conditions":608,"interventions":609},"NCT01639456","CD3\u002FCD19 Depleted or CD3 Depleted\u002FCD56 Selected Haploid Donor Natural Killer Cell Treatment in Older AML in First Complete Remission",[91],"2017-01",[190],[610,611,97,42,612],"CD3-\u002FCD19- natural killer cells","CD3-CD56+ natural killer cells","Aldesleukin",{"nctId":614,"briefTitle":615,"status":229,"phases":616,"primaryCompletion":617,"completion":618,"start":619,"enrollment":620,"conditions":621,"interventions":625},"NCT06872333","Allo HSCT for High Risk Hemoglobinopathies",[91],"2030-06-01","2032-06-01","2024-11-19",62,[622,623,624],"Graft Failure","Sickle Cell Disease","Hemoglobinopathies",[626,515,288,42,87,496,97,151,208,420],"Alemtuzumab",{"nctId":628,"briefTitle":629,"status":229,"phases":630,"primaryCompletion":631,"completion":632,"start":633,"enrollment":579,"conditions":634,"interventions":637},"NCT07591649","Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT",[90,91],"2030-03-01","2035-03-01","2026-05-08",[635,636,190],"Relapsed Adult AML","Refractory AML",[638,42,97,164],"AdaptNK",{"nctId":640,"briefTitle":641,"status":125,"phases":642,"primaryCompletion":643,"completion":644,"start":567,"enrollment":645,"conditions":646,"interventions":653},"NCT01043640","Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders",[91],"2015-06","2017-06",46,[647,648,649,582,583,584,585,586,650,588,651,587,652],"Mucopolysaccharidosis","Hurler Syndrome","Hunter Syndrome","Adrenoleukodystrophy (ALD)","Metachromatic Leukodystrophy (MLD)","Peroxisomal Disorders",[593,97,87,654,420],"Cyclosporine A",{"nctId":656,"briefTitle":657,"status":108,"phases":658,"primaryCompletion":659,"completion":659,"start":329,"enrollment":660,"conditions":661,"interventions":662},"NCT00005987","Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma",[91],"2003-07",87,[115],[391,118,393,394,222,395,332,663],"sargramostim",{"nctId":665,"briefTitle":666,"status":125,"phases":667,"primaryCompletion":355,"completion":355,"start":668,"enrollment":669,"conditions":670,"interventions":673},"NCT01581970","Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer",[91],"2012-06",7,[671,672],"Head and Neck Cancer","Head and Neck Squamous Cell Carcinoma",[97,674],"Cetuximab",{"nctId":676,"briefTitle":677,"status":678,"phases":679,"primaryCompletion":680,"completion":491,"start":681,"enrollment":16,"conditions":682,"interventions":687},"NCT04855253","Ph I\u002FII Study of E7777 Prior to CAR-T for R\u002FR LBCL","SUSPENDED",[90,91],"2026-09","2021-06-09",[683,684,685,686],"DLBCL","Diffuse Large B Cell Lymphoma","High-grade B-cell Lymphoma","DLBCL Arising From Follicular Lymphoma",[688,42,97,689,690,691],"E7777","Tisagenlecleucel","Axicabtagene Ciloleucel","Lisocabtagene Maraleucel Intravenous Suspension",{"nctId":693,"briefTitle":694,"status":125,"phases":695,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":699,"interventions":701},"NCT00365287","Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer",[90,91],"2005-12","2000-06",148,[29,700,15,18,115,21],"Kidney Cancer",[221,118,119,120,121],{"nctId":703,"briefTitle":704,"status":125,"phases":705,"primaryCompletion":706,"completion":706,"start":707,"enrollment":708,"conditions":709,"interventions":711},"NCT00305682","Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant",[91],"2019-12-12","2005-06",295,[710,15,18,21],"Myeloproliferative Disorders",[221,118,42,121,151],{"nctId":713,"briefTitle":714,"status":108,"phases":715,"primaryCompletion":716,"completion":716,"start":217,"enrollment":717,"conditions":718,"interventions":719},"NCT00303719","Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy",[91],"2019-05-08",342,[700,15,18,32,146,21],[221,118,119,720,121,222],"fludarabine",{"nctId":722,"briefTitle":723,"status":125,"phases":724,"primaryCompletion":725,"completion":725,"start":726,"enrollment":727,"conditions":728,"interventions":729},"NCT00303667","Donor Natural Killer Cells and Aldesleukin in Treating Patients w\u002FHigh Risk AML Undergoing Donor Stem Cell Transplant",[90,91],"2011-03","2005-01",50,[190],[253,730,118,120,288,731,118,120],"natural killer cells","Cyclosporin A",{"nctId":733,"briefTitle":734,"status":125,"phases":735,"primaryCompletion":736,"completion":736,"start":458,"enrollment":737,"conditions":738,"interventions":740},"NCT01033552","Biochemical Correction of Severe EB by Allo HSCT and \"Off-the-shelf\" MSCs",[90,91],"2021-08-12",32,[739],"Epidermolysis Bullosa",[97,42,741,742],"Anti-thymocyte globulin","Myeloablative Busulfan",{"nctId":744,"briefTitle":745,"status":229,"phases":746,"primaryCompletion":747,"completion":748,"start":749,"enrollment":8,"conditions":750,"interventions":756},"NCT03579875","Alpha\u002FBeta TCD HCT in Patients With Inherited BMF Disorders",[91],"2027-01-01","2029-01-05","2018-11-13",[219,509,21,751,752,753,754,755],"T Cell Receptor Alpha\u002FBeta Depletion","Telomere Biology Disorder","Bone Marrow Failure","Dyskeratosis Congenita","Telomere Biology Disorders",[483,97,42,302,243,97,285,87,626,242,285],{"nctId":758,"briefTitle":759,"status":108,"phases":760,"primaryCompletion":761,"completion":761,"start":110,"enrollment":36,"conditions":762,"interventions":764},"NCT00652899","Allogeneic Natural Killer Cells in Patients With Recurrent Ovarian Cancer, Fallopian Tube, and Primary Peritoneal Cancer",[91],"2009-08",[297,24,763],"Peritoneal Cavity Cancer",[149,97,765,766,612],"Fludarabine phosphate","Allogeneic natural killer cells",{"nctId":768,"briefTitle":769,"status":307,"phases":770,"primaryCompletion":771,"completion":771,"start":492,"enrollment":102,"conditions":772,"interventions":774},"NCT02118311","Treg Cells for AGVHD in Non-myeloablative UCB Transplant",[91],"2018-09",[773],"Hematologic Malignancies",[775,42,97],"T Regulatory cells",{"nctId":777,"briefTitle":778,"status":108,"phases":779,"primaryCompletion":780,"completion":780,"start":329,"enrollment":27,"conditions":781,"interventions":782},"NCT00005984","Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia",[91],"2005-09",[15],[118,222,332],{"nctId":784,"briefTitle":785,"status":125,"phases":786,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":791,"interventions":792},"NCT02582775","MT2015-20: Biochemical Correction of Severe EB by Allo HSCT and Serial Donor MSCs",[91],"2022-11-15","2023-07-26","2016-03",17,[739],[288,97,42,208,420,793,87],"Donor mesenchymal stem cell infusions",{"trials":795,"activeCount":102},[796,805,814,826,836,845],{"nctId":797,"briefTitle":798,"status":307,"phases":799,"primaryCompletion":800,"completion":800,"start":801,"enrollment":102,"conditions":802,"interventions":803},"NCT00006451","Bone Marrow Transplantation in Treating Patients With Leukemia",[92],"2000-11","1996-04",[114,15,18],[221,118,119,804,224],"methotrexate",{"nctId":806,"briefTitle":807,"status":125,"phases":808,"primaryCompletion":809,"completion":809,"start":810,"enrollment":811,"conditions":812,"interventions":813},"NCT00352976","TBI Dose De-escalation for Fanconi Anemia",[91,92],"2020-10-09","2006-05-18",83,[219],[97,42,420,151],{"nctId":815,"briefTitle":816,"status":125,"phases":817,"primaryCompletion":818,"completion":492,"start":819,"enrollment":820,"conditions":821,"interventions":823},"NCT00455312","Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA",[91,92],"2015-03","2007-08",36,[754,822],"Aplastic Anemia",[824,97,42,825,302],"Campath 1H","antithymocyte globulin",{"nctId":827,"briefTitle":828,"status":108,"phases":829,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":833,"interventions":835},"NCT00176839","Stem Cell Transplantation for Hematological Malignancies",[91,92],"2012-02","2000-06-07",11,[834,266,371],"Leukemia, Lymphocytic, Acute",[87,97,242,243,207],{"nctId":837,"briefTitle":838,"status":125,"phases":839,"primaryCompletion":840,"completion":840,"start":598,"enrollment":669,"conditions":841,"interventions":843},"NCT00775931","Allogeneic Transplantation For Severe Osteopetrosis",[91,92],"2013-06",[842],"Severe Osteopetrosis",[593,97,87,844],"Fludarabine monophosphate",{"nctId":846,"briefTitle":847,"status":108,"phases":848,"primaryCompletion":849,"completion":849,"start":850,"enrollment":9,"conditions":851,"interventions":852},"NCT00630565","Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia",[91,92],"2022-07-28","2006-07-26",[15],[663,223,118,393,394],{"trials":854,"activeCount":102},[],{"trials":856,"activeCount":158,"soonestReadout":71},[857,868,879,889,901,913,926,933,949,973],{"nctId":858,"briefTitle":859,"status":125,"phases":860,"primaryCompletion":861,"completion":862,"start":863,"enrollment":864,"conditions":865,"interventions":866},"NCT02162420","Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia",[94],"2024-08-08","2025-03-11","2015-01-10",61,[754,822],[626,42,97,867,741],"Stem Cell Transplant",{"nctId":869,"briefTitle":870,"status":108,"phases":871,"primaryCompletion":872,"completion":873,"start":874,"enrollment":158,"conditions":875,"interventions":877},"NCT02145039","Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases",[94],"2018-01","2019-01","2014-10",[876,202,192],"Acute Leukemias",[42,97,878],"Haploidentical stem cell transplant",{"nctId":880,"briefTitle":881,"status":125,"phases":882,"primaryCompletion":883,"completion":883,"start":884,"enrollment":98,"conditions":885,"interventions":887},"NCT00290641","Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer",[94],"2006-01","2001-04",[886,15,18,21],"Chronic Myeloproliferative Disorders",[222,888,118,119,120,121],"graft-versus-tumor induction therapy",{"nctId":890,"briefTitle":891,"status":108,"phases":892,"primaryCompletion":893,"completion":893,"start":894,"enrollment":895,"conditions":896,"interventions":897},"NCT01685411","Busulfan and Cyclophosphamide Followed By ALLO BMT",[94],"2020-02-10","2013-01",5,[174,26,175],[149,898,87,97,208,899,900,526,825],"Keppra","Mycophenolate mofetil","Allogeneic hematopoietic stem cell transplant",{"nctId":902,"briefTitle":903,"status":108,"phases":904,"primaryCompletion":905,"completion":905,"start":906,"enrollment":907,"conditions":908,"interventions":911},"NCT00290628","Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer",[94],"2007-04","1999-10",43,[886,909,219,114,15,18,115,21,910],"Diamond-blackfan Anemia","Myelodysplastic\u002FMyeloproliferative Diseases",[221,223,118,119,222,912,224,121],"melphalan",{"nctId":914,"briefTitle":915,"status":108,"phases":916,"primaryCompletion":917,"completion":917,"start":171,"enrollment":918,"conditions":919,"interventions":923},"NCT01962636","Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases",[94],"2026-05-14",200,[920,921,192,193,370,272,194,195,922,197,198,199,200,684,201,202,236,32],"Acute Myeloid Leukemia (AML)","Acute Lymphocytic Leukemia (ALL)","Marginal Zone B-Cell Lymphoma",[42,97,654,924,925],"Mycophenylate mofetil","Umbilical cord blood",{"nctId":927,"briefTitle":928,"status":108,"phases":929,"primaryCompletion":930,"completion":930,"start":905,"enrollment":669,"conditions":931,"interventions":932},"NCT00478244","Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa",[94],"2011-08",[739],[223,118,120],{"nctId":934,"briefTitle":935,"status":108,"phases":936,"primaryCompletion":937,"completion":937,"start":938,"enrollment":939,"conditions":940,"interventions":946},"NCT00176930","Stem Cell Transplant for Hematological Malignancy",[94],"2019-12","2001-10",330,[941,266,834,371,942,943,944,945,32],"Leukemia, Myeloid, Chronic","Leukemia, Lymphocytic, Chronic","JMML","Hodgkin's Disease","Non-hodgkin's Lymphoma",[867,97,87,947,948],"Equine ATG","CD4+\u002FCD25+ cells",{"nctId":69,"briefTitle":70,"status":474,"phases":950,"primaryCompletion":71,"completion":491,"start":951,"enrollment":952,"conditions":953,"interventions":968},[94],"2012-09-04",57,[954,955,956,957,958,959,960,961,962,963,964,965,966,967],"SCID","Omenn's Syndrome","Reticular Dysgenesis","Wiskott-Aldrich Syndrome","Bare Lymphocyte Syndrome","Common Variable Immunodeficiency","Chronic Granulomatous Disease","CD40 Ligand Deficiency","Hyper IgM Syndrome","X-linked Lymphoproliferative Disease","Hemophagocytic Lymphohistiocytosis","Griscelli Syndrome","Chediak-Higashi Syndrome","Langerhan's Cell Histiocytosis",[72,97,87,77,969,242,970,87,971,972],"Fludarabine phosphate 40 mg","Alemtuzumab 0.2 mg","Fludarabine phosphate 30 mg","MESNA",{"nctId":974,"briefTitle":975,"status":229,"phases":976,"primaryCompletion":977,"completion":978,"start":979,"enrollment":727,"conditions":980,"interventions":983},"NCT02161783","Treatment of Graft Failure After Hematopoietic Stem Cell Transplantation",[],"2032-01-24","2032-01-30","2014-10-06",[981,982],"Primary Graft Failure","Secondary Graft Failure",[42,97,984],"Hematopoietic stem cell",{"intervention":42,"totalTrials":986,"cells":987},37,{"EARLY_PHASE1":988,"PHASE1":990,"PHASE2":1014,"PHASE3":1138,"PHASE4":1148,"NA":1150},{"trials":989,"activeCount":102},[],{"trials":991,"activeCount":1013,"soonestReadout":81},[992,996,1005,1009],{"nctId":123,"briefTitle":124,"status":125,"phases":993,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":994,"interventions":995},[90],[26,132,133],[135,136,42,97],{"nctId":79,"briefTitle":80,"status":474,"phases":997,"primaryCompletion":81,"completion":998,"start":999,"enrollment":112,"conditions":1000,"interventions":1003},[90],"2027-06-30","2024-07-11",[1001,24,297,1002],"Gynecologic Cancer","Primary Peritoneal Cavity Cancer",[82,42,1004],"CY",{"nctId":153,"briefTitle":154,"status":125,"phases":1006,"primaryCompletion":156,"completion":156,"start":157,"enrollment":158,"conditions":1007,"interventions":1008},[90],[24,160,161],[42,97,163,164,165],{"nctId":167,"briefTitle":168,"status":125,"phases":1010,"primaryCompletion":170,"completion":171,"start":172,"enrollment":9,"conditions":1011,"interventions":1012},[90],[174,175,32],[118,119,42,121,177,178],1,{"trials":1015,"activeCount":1137,"soonestReadout":41},[1016,1020,1024,1028,1032,1036,1040,1044,1048,1052,1056,1060,1064,1068,1072,1084,1088,1092,1096,1109,1113,1117,1121,1125,1129,1133],{"nctId":182,"briefTitle":183,"status":125,"phases":1017,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":1018,"interventions":1019},[91],[190,191,192,193,21,194,195,196,197,198,199,200,201,202,203,32,204,205],[149,42,97,207,208,209,210,211],{"nctId":255,"briefTitle":256,"status":229,"phases":1021,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":1022,"interventions":1023},[91],[263,264,265,26,174,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,201,283],[42,87,242,285,286,287,288,97],{"nctId":290,"briefTitle":291,"status":125,"phases":1025,"primaryCompletion":293,"completion":293,"start":294,"enrollment":295,"conditions":1026,"interventions":1027},[91],[24,297,298,29],[42,97,300,301,164,302,302,303],{"nctId":305,"briefTitle":306,"status":307,"phases":1029,"primaryCompletion":309,"completion":309,"start":310,"enrollment":102,"conditions":1030,"interventions":1031},[90,91],[312],[314,42,97],{"nctId":334,"briefTitle":335,"status":307,"phases":1033,"primaryCompletion":337,"completion":337,"start":338,"enrollment":102,"conditions":1034,"interventions":1035},[90,91],[263,26,191,340,341,342,194,195,343,197,198,199,344,345,201,202,346],[348,349,42,97,350],{"nctId":352,"briefTitle":353,"status":125,"phases":1037,"primaryCompletion":355,"completion":356,"start":357,"enrollment":358,"conditions":1038,"interventions":1039},[91],[236,194],[285,303,301,97,302,42],{"nctId":375,"briefTitle":376,"status":108,"phases":1041,"primaryCompletion":378,"completion":378,"start":249,"enrollment":112,"conditions":1042,"interventions":1043},[91],[190,380],[149,42,97,286,87,382,303],{"nctId":398,"briefTitle":399,"status":229,"phases":1045,"primaryCompletion":401,"completion":402,"start":403,"enrollment":404,"conditions":1046,"interventions":1047},[91],[190,191,406,407,200,192,193,21,408,409,410,411,412,195,413,197,414,370],[416,417,42,97,418,419,420],{"nctId":422,"briefTitle":423,"status":108,"phases":1049,"primaryCompletion":249,"completion":425,"start":294,"enrollment":426,"conditions":1050,"interventions":1051},[91],[428],[430,42,97,431,164],{"nctId":433,"briefTitle":434,"status":125,"phases":1053,"primaryCompletion":436,"completion":437,"start":438,"enrollment":426,"conditions":1054,"interventions":1055},[91],[264,26,440,202,441,192,175,442,237,32,412,443,343,197,198,444,200,445,446,447,448,449,411,450,193],[42,97,209,151,452,207],{"nctId":454,"briefTitle":455,"status":108,"phases":1057,"primaryCompletion":457,"completion":458,"start":459,"enrollment":460,"conditions":1058,"interventions":1059},[91],[29],[42,97,303],{"nctId":39,"briefTitle":40,"status":474,"phases":1061,"primaryCompletion":41,"completion":476,"start":477,"enrollment":27,"conditions":1062,"interventions":1063},[91],[26,191,479,192,272,480,481,237,410,411,198],[42,97,483,208,420,484,87,242,485],{"nctId":501,"briefTitle":502,"status":229,"phases":1065,"primaryCompletion":504,"completion":505,"start":506,"enrollment":507,"conditions":1066,"interventions":1067},[91],[509,510,511,512],[285,514,97,42,515,516,208,420],{"nctId":518,"briefTitle":519,"status":125,"phases":1069,"primaryCompletion":216,"completion":216,"start":521,"enrollment":522,"conditions":1070,"interventions":1071},[90,91],[219],[525,97,42,302,526,300,420],{"nctId":1073,"briefTitle":1074,"status":125,"phases":1075,"primaryCompletion":172,"completion":1076,"start":1077,"enrollment":33,"conditions":1078,"interventions":1082},"NCT00176865","Stem Cell Transplant for Immunologic or Histiocytic Disorders",[91],"2014-08","2002-08",[964,1079,966,965,1080,1081],"X-Linked Lymphoproliferative Disorders","Immunologic Deficiency Syndromes","Langerhans-Cell Histiocytosis",[42,242,741,824,731,899,1083],"Intravenous immunoglobulin",{"nctId":604,"briefTitle":605,"status":307,"phases":1085,"primaryCompletion":607,"completion":607,"start":378,"enrollment":102,"conditions":1086,"interventions":1087},[91],[190],[610,611,97,42,612],{"nctId":614,"briefTitle":615,"status":229,"phases":1089,"primaryCompletion":617,"completion":618,"start":619,"enrollment":620,"conditions":1090,"interventions":1091},[91],[622,623,624],[626,515,288,42,87,496,97,151,208,420],{"nctId":628,"briefTitle":629,"status":229,"phases":1093,"primaryCompletion":631,"completion":632,"start":633,"enrollment":579,"conditions":1094,"interventions":1095},[90,91],[635,636,190],[638,42,97,164],{"nctId":1097,"briefTitle":1098,"status":229,"phases":1099,"primaryCompletion":1100,"completion":1101,"start":1102,"enrollment":1103,"conditions":1104,"interventions":1105},"NCT07493538","MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases",[91],"2030-03","2035-03","2026-04-10",132,[266,371,264,26,21],[1106,42,208,420,1107,1108],"Treosulfan","Cyclophosphamid","Stem Cell",{"nctId":676,"briefTitle":677,"status":678,"phases":1110,"primaryCompletion":680,"completion":491,"start":681,"enrollment":16,"conditions":1111,"interventions":1112},[90,91],[683,684,685,686],[688,42,97,689,690,691],{"nctId":703,"briefTitle":704,"status":125,"phases":1114,"primaryCompletion":706,"completion":706,"start":707,"enrollment":708,"conditions":1115,"interventions":1116},[91],[710,15,18,21],[221,118,42,121,151],{"nctId":713,"briefTitle":714,"status":108,"phases":1118,"primaryCompletion":716,"completion":716,"start":217,"enrollment":717,"conditions":1119,"interventions":1120},[91],[700,15,18,32,146,21],[221,118,119,720,121,222],{"nctId":733,"briefTitle":734,"status":125,"phases":1122,"primaryCompletion":736,"completion":736,"start":458,"enrollment":737,"conditions":1123,"interventions":1124},[90,91],[739],[97,42,741,742],{"nctId":744,"briefTitle":745,"status":229,"phases":1126,"primaryCompletion":747,"completion":748,"start":749,"enrollment":8,"conditions":1127,"interventions":1128},[91],[219,509,21,751,752,753,754,755],[483,97,42,302,243,97,285,87,626,242,285],{"nctId":768,"briefTitle":769,"status":307,"phases":1130,"primaryCompletion":771,"completion":771,"start":492,"enrollment":102,"conditions":1131,"interventions":1132},[91],[773],[775,42,97],{"nctId":784,"briefTitle":785,"status":125,"phases":1134,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":1135,"interventions":1136},[91],[739],[288,97,42,208,420,793,87],8,{"trials":1139,"activeCount":102},[1140,1144],{"nctId":806,"briefTitle":807,"status":125,"phases":1141,"primaryCompletion":809,"completion":809,"start":810,"enrollment":811,"conditions":1142,"interventions":1143},[91,92],[219],[97,42,420,151],{"nctId":815,"briefTitle":816,"status":125,"phases":1145,"primaryCompletion":818,"completion":492,"start":819,"enrollment":820,"conditions":1146,"interventions":1147},[91,92],[754,822],[824,97,42,825,302],{"trials":1149,"activeCount":102},[],{"trials":1151,"activeCount":158,"soonestReadout":86},[1152,1156,1160,1164,1172],{"nctId":858,"briefTitle":859,"status":125,"phases":1153,"primaryCompletion":861,"completion":862,"start":863,"enrollment":864,"conditions":1154,"interventions":1155},[94],[754,822],[626,42,97,867,741],{"nctId":869,"briefTitle":870,"status":108,"phases":1157,"primaryCompletion":872,"completion":873,"start":874,"enrollment":158,"conditions":1158,"interventions":1159},[94],[876,202,192],[42,97,878],{"nctId":914,"briefTitle":915,"status":108,"phases":1161,"primaryCompletion":917,"completion":917,"start":171,"enrollment":918,"conditions":1162,"interventions":1163},[94],[920,921,192,193,370,272,194,195,922,197,198,199,200,684,201,202,236,32],[42,97,654,924,925],{"nctId":84,"briefTitle":85,"status":229,"phases":1165,"primaryCompletion":86,"completion":1166,"start":172,"enrollment":16,"conditions":1167,"interventions":1170},[94],"2027-06",[1168,624,1169],"Hematologic Disorders","Immunodeficiencies",[87,42,1171,898],"Stem cell transplant",{"nctId":974,"briefTitle":975,"status":229,"phases":1173,"primaryCompletion":977,"completion":978,"start":979,"enrollment":727,"conditions":1174,"interventions":1175},[],[981,982],[42,97,984],{"intervention":242,"totalTrials":33,"cells":1177},{"EARLY_PHASE1":1178,"PHASE1":1180,"PHASE2":1210,"PHASE3":1300,"PHASE4":1317,"NA":1319},{"trials":1179,"activeCount":102},[],{"trials":1181,"activeCount":102},[1182,1198],{"nctId":1183,"briefTitle":1184,"status":108,"phases":1185,"primaryCompletion":1077,"completion":1186,"start":1187,"enrollment":295,"conditions":1188,"interventions":1195},"NCT00003926","Amifostine to Protect From Side Effects of PSCT in Treating Patients With Solid Tumors",[90],"2003-08","1998-11",[1189,1190,1191,700,1192,494,24,1193,1194],"Brain and Central Nervous System Tumors","Childhood Germ Cell Tumor","Chordoma","Liver Cancer","Retinoblastoma","Sarcoma",[1196,223,222,912,1197],"amifostine trihydrate","thiotepa",{"nctId":1199,"briefTitle":1200,"status":108,"phases":1201,"primaryCompletion":1202,"completion":1203,"start":1204,"enrollment":1205,"conditions":1206,"interventions":1207},"NCT00623077","MT2004-30: Tomotherapy for Solid Tumors",[90],"2012-07","2016-10","2005-08",23,[1189,700,1192,1193,1194],[222,223,394,1208,912,1197,1209],"ifosfamide","Mesna",{"trials":1211,"activeCount":460,"soonestReadout":41},[1212,1216,1226,1230,1234,1238,1252,1271,1275,1296],{"nctId":227,"briefTitle":228,"status":229,"phases":1213,"primaryCompletion":231,"completion":232,"start":233,"enrollment":234,"conditions":1214,"interventions":1215},[91],[236,237],[239,240,241,242,243,97],{"nctId":1217,"briefTitle":1218,"status":108,"phases":1219,"primaryCompletion":1220,"completion":1220,"start":1221,"enrollment":1013,"conditions":1222,"interventions":1224},"NCT00618540","Reduced Intensity Hematopoietic Cell Transplantation for Patients With Resistant Langerhans Cell Histiocytosis",[91],"2013-05","2007-01",[1223],"Histiocytosis, Langerhans-cell",[1225,120,912],"alemtuzumab",{"nctId":255,"briefTitle":256,"status":229,"phases":1227,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":1228,"interventions":1229},[91],[263,264,265,26,174,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,201,283],[42,87,242,285,286,287,288,97],{"nctId":39,"briefTitle":40,"status":474,"phases":1231,"primaryCompletion":41,"completion":476,"start":477,"enrollment":27,"conditions":1232,"interventions":1233},[91],[26,191,479,192,272,480,481,237,410,411,198],[42,97,483,208,420,484,87,242,485],{"nctId":487,"briefTitle":488,"status":229,"phases":1235,"primaryCompletion":490,"completion":491,"start":492,"enrollment":9,"conditions":1236,"interventions":1237},[91],[494],[496,97,242,239,497,498,499],{"nctId":1239,"briefTitle":1240,"status":229,"phases":1241,"primaryCompletion":1242,"completion":1243,"start":1244,"enrollment":1245,"conditions":1246,"interventions":1249},"NCT06377540","MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma",[91],"2026-09-01","2027-09-01","2024-12-04",28,[1247,1248],"Autologous Stem Cell Transplant","Classic Hodgkin Lymphoma",[1250,1251,239,472,242],"Pembrolizumab","Carmustine",{"nctId":1253,"briefTitle":1254,"status":125,"phases":1255,"primaryCompletion":1256,"completion":862,"start":1257,"enrollment":1258,"conditions":1259,"interventions":1270},"NCT00357565","Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia",[91],"2024-06","2005-11",34,[15,21,1260,1261,1262,1263,1264,1265,1266,1267,372,1268,1269],"Childhood Acute Myeloid Leukemia in Remission","Recurrent Childhood Acute Myeloid Leukemia","Secondary Acute Myeloid Leukemia","Childhood Acute Lymphoblastic Leukemia in Remission","Previously Treated Myelodysplastic Syndrome","Secondary Myelodysplastic Syndrome","Refractory Anemia With Excess Blasts in Transformation","Refractory Anemia With Excess Blasts","De Novo Myelodysplastic Syndrome","Childhood Myelodysplastic Syndrome",[222,223,119,120,912,121],{"nctId":1073,"briefTitle":1074,"status":125,"phases":1272,"primaryCompletion":172,"completion":1076,"start":1077,"enrollment":33,"conditions":1273,"interventions":1274},[91],[964,1079,966,965,1080,1081],[42,242,741,824,731,899,1083],{"nctId":1276,"briefTitle":1277,"status":125,"phases":1278,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":1282,"interventions":1292},"NCT00383448","HSCT for High Risk Inherited Inborn Errors",[91],"2014-09","2006-09",38,[1283,1284,1285,1286,1287,1288,1289,1290,1291],"Adrenoleukodystrophy","Metachromatic Leukodystrophy","Globoid Cell Leukodystrophy","Tay Sachs Disease","Sandhoffs Disease","Wolman Disease","I-Cell Disease","Sanfilippo Syndrome","GM1 Gangliosidosis",[561,242,1293,626,1294,1295],"Hematopoietic Stem Cell Transplantation","mycophenylate mofetil","Hydroxyurea",{"nctId":744,"briefTitle":745,"status":229,"phases":1297,"primaryCompletion":747,"completion":748,"start":749,"enrollment":8,"conditions":1298,"interventions":1299},[91],[219,509,21,751,752,753,754,755],[483,97,42,302,243,97,285,87,626,242,285],{"trials":1301,"activeCount":102},[1302,1313],{"nctId":1303,"briefTitle":1304,"status":125,"phases":1305,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1308,"conditions":1309,"interventions":1310},"NCT00177047","Autologous Transplant for Multiple Myeloma",[91,92],"2020-08-01","2004-04-20",363,[32],[1311,242,1312],"Cyclophosphamide + Mesna","Granulocyte-colony stimulating factor",{"nctId":827,"briefTitle":828,"status":108,"phases":1314,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":1315,"interventions":1316},[91,92],[834,266,371],[87,97,242,243,207],{"trials":1318,"activeCount":102},[],{"trials":1320,"activeCount":1013,"soonestReadout":71},[1321,1325,1335,1345,1369],{"nctId":902,"briefTitle":903,"status":108,"phases":1322,"primaryCompletion":905,"completion":905,"start":906,"enrollment":907,"conditions":1323,"interventions":1324},[94],[886,909,219,114,15,18,115,21,910],[221,223,118,119,222,912,224,121],{"nctId":1326,"briefTitle":1327,"status":125,"phases":1328,"primaryCompletion":1329,"completion":1329,"start":1330,"enrollment":112,"conditions":1331,"interventions":1334},"NCT01626092","Reduced-Intensity Hematopoietic Stem Cell Transplant for High Risk Lysosomal and Peroxisomal Disorders",[94],"2013-11","2012-07-11",[1332,1333],"Lysosomal Storage Disease","Peroxisomal Disorder",[593,561,242,225,654,899],{"nctId":1336,"briefTitle":1337,"status":125,"phases":1338,"primaryCompletion":1339,"completion":1339,"start":1340,"enrollment":295,"conditions":1341,"interventions":1342},"NCT01526603","High Dose Chemotherapy and Autologous Transplant for Neuroblastoma",[94],"2023-05-30","2012-03-28",[494],[497,1343,499,1344,242,239],"Autologous stem cell","Isotretinoin",{"nctId":1346,"briefTitle":1347,"status":125,"phases":1348,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":1352,"interventions":1364},"NCT01505569","Auto Transplant for High Risk or Relapsed Solid or CNS Tumors",[94],"2024-02-01","2011-10-20",44,[1353,1354,1355,1356,1357,1358,1193,1359,1360,1361,1362,1363],"Ewing's Family Tumors","Renal Tumors","Hepatoblastoma","Rhabdomyosarcoma","Soft Tissue Sarcoma","Primary Malignant Brain Neoplasms","Medulloblastoma","Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET)","Atypical Teratoid\u002FRhabdoid Tumor (AT\u002FRT)","CNS Tumors","Germ Cell Tumors",[1365,239,1209,243,87,242,496,1343,497,1366,1367,1368],"Ifosfamide","Paclitaxel","Anti-seizure prophylaxis","Ursodiol",{"nctId":69,"briefTitle":70,"status":474,"phases":1370,"primaryCompletion":71,"completion":491,"start":951,"enrollment":952,"conditions":1371,"interventions":1372},[94],[954,955,956,957,958,959,960,961,962,963,964,965,966,967],[72,97,87,77,969,242,970,87,971,972],{"intervention":87,"totalTrials":1374,"cells":1375},25,{"EARLY_PHASE1":1376,"PHASE1":1378,"PHASE2":1388,"PHASE3":1439,"PHASE4":1464,"NA":1466},{"trials":1377,"activeCount":102},[],{"trials":1379,"activeCount":102},[1380,1384],{"nctId":1183,"briefTitle":1184,"status":108,"phases":1381,"primaryCompletion":1077,"completion":1186,"start":1187,"enrollment":295,"conditions":1382,"interventions":1383},[90],[1189,1190,1191,700,1192,494,24,1193,1194],[1196,223,222,912,1197],{"nctId":1199,"briefTitle":1200,"status":108,"phases":1385,"primaryCompletion":1202,"completion":1203,"start":1204,"enrollment":1205,"conditions":1386,"interventions":1387},[90],[1189,700,1192,1193,1194],[222,223,394,1208,912,1197,1209],{"trials":1389,"activeCount":1438,"soonestReadout":41},[1390,1394,1398,1402,1406,1410,1414,1418,1422,1426,1430,1434],{"nctId":213,"briefTitle":214,"status":125,"phases":1391,"primaryCompletion":216,"completion":216,"start":217,"enrollment":36,"conditions":1392,"interventions":1393},[91],[219],[221,222,223,118,120,224,225],{"nctId":255,"briefTitle":256,"status":229,"phases":1395,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":1396,"interventions":1397},[91],[263,264,265,26,174,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,201,283],[42,87,242,285,286,287,288,97],{"nctId":325,"briefTitle":326,"status":108,"phases":1399,"primaryCompletion":328,"start":329,"conditions":1400,"interventions":1401},[91],[15],[223,118,222,332],{"nctId":375,"briefTitle":376,"status":108,"phases":1403,"primaryCompletion":378,"completion":378,"start":249,"enrollment":112,"conditions":1404,"interventions":1405},[91],[190,380],[149,42,97,286,87,382,303],{"nctId":39,"briefTitle":40,"status":474,"phases":1407,"primaryCompletion":41,"completion":476,"start":477,"enrollment":27,"conditions":1408,"interventions":1409},[91],[26,191,479,192,272,480,481,237,410,411,198],[42,97,483,208,420,484,87,242,485],{"nctId":528,"briefTitle":529,"status":125,"phases":1411,"primaryCompletion":531,"completion":532,"start":533,"enrollment":460,"conditions":1412,"interventions":1413},[91],[15,18,115],[223,118,536],{"nctId":1253,"briefTitle":1254,"status":125,"phases":1415,"primaryCompletion":1256,"completion":862,"start":1257,"enrollment":1258,"conditions":1416,"interventions":1417},[91],[15,21,1260,1261,1262,1263,1264,1265,1266,1267,372,1268,1269],[222,223,119,120,912,121],{"nctId":575,"briefTitle":576,"status":108,"phases":1419,"primaryCompletion":578,"completion":578,"start":110,"enrollment":579,"conditions":1420,"interventions":1421},[91],[581,582,583,584,585,586,587,588,589,590,591],[97,593,87],{"nctId":614,"briefTitle":615,"status":229,"phases":1423,"primaryCompletion":617,"completion":618,"start":619,"enrollment":620,"conditions":1424,"interventions":1425},[91],[622,623,624],[626,515,288,42,87,496,97,151,208,420],{"nctId":640,"briefTitle":641,"status":125,"phases":1427,"primaryCompletion":643,"completion":644,"start":567,"enrollment":645,"conditions":1428,"interventions":1429},[91],[647,648,649,582,583,584,585,586,650,588,651,587,652],[593,97,87,654,420],{"nctId":744,"briefTitle":745,"status":229,"phases":1431,"primaryCompletion":747,"completion":748,"start":749,"enrollment":8,"conditions":1432,"interventions":1433},[91],[219,509,21,751,752,753,754,755],[483,97,42,302,243,97,285,87,626,242,285],{"nctId":784,"briefTitle":785,"status":125,"phases":1435,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":1436,"interventions":1437},[91],[739],[288,97,42,208,420,793,87],4,{"trials":1440,"activeCount":102},[1441,1445,1449,1460],{"nctId":827,"briefTitle":828,"status":108,"phases":1442,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":1443,"interventions":1444},[91,92],[834,266,371],[87,97,242,243,207],{"nctId":837,"briefTitle":838,"status":125,"phases":1446,"primaryCompletion":840,"completion":840,"start":598,"enrollment":669,"conditions":1447,"interventions":1448},[91,92],[842],[593,97,87,844],{"nctId":1450,"briefTitle":1451,"status":125,"phases":1452,"primaryCompletion":1453,"completion":1453,"start":697,"enrollment":1454,"conditions":1455,"interventions":1459},"NCT00176878","Stem Cell Transplant for Bone Marrow Failure Syndromes",[91,92],"2009-03",10,[1456,1457,1458],"Diamond-Blackfan Anemia","Kostmann's Neutropenia","Shwachman-Diamond Syndrome",[844,87,221],{"nctId":846,"briefTitle":847,"status":108,"phases":1461,"primaryCompletion":849,"completion":849,"start":850,"enrollment":9,"conditions":1462,"interventions":1463},[91,92],[15],[663,223,118,393,394],{"trials":1465,"activeCount":102},[],{"trials":1467,"activeCount":158,"soonestReadout":71},[1468,1472,1476,1480,1484,1488,1492],{"nctId":890,"briefTitle":891,"status":108,"phases":1469,"primaryCompletion":893,"completion":893,"start":894,"enrollment":895,"conditions":1470,"interventions":1471},[94],[174,26,175],[149,898,87,97,208,899,900,526,825],{"nctId":902,"briefTitle":903,"status":108,"phases":1473,"primaryCompletion":905,"completion":905,"start":906,"enrollment":907,"conditions":1474,"interventions":1475},[94],[886,909,219,114,15,18,115,21,910],[221,223,118,119,222,912,224,121],{"nctId":927,"briefTitle":928,"status":108,"phases":1477,"primaryCompletion":930,"completion":930,"start":905,"enrollment":669,"conditions":1478,"interventions":1479},[94],[739],[223,118,120],{"nctId":934,"briefTitle":935,"status":108,"phases":1481,"primaryCompletion":937,"completion":937,"start":938,"enrollment":939,"conditions":1482,"interventions":1483},[94],[941,266,834,371,942,943,944,945,32],[867,97,87,947,948],{"nctId":84,"briefTitle":85,"status":229,"phases":1485,"primaryCompletion":86,"completion":1166,"start":172,"enrollment":16,"conditions":1486,"interventions":1487},[94],[1168,624,1169],[87,42,1171,898],{"nctId":1346,"briefTitle":1347,"status":125,"phases":1489,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":1490,"interventions":1491},[94],[1353,1354,1355,1356,1357,1358,1193,1359,1360,1361,1362,1363],[1365,239,1209,243,87,242,496,1343,497,1366,1367,1368],{"nctId":69,"briefTitle":70,"status":474,"phases":1493,"primaryCompletion":71,"completion":491,"start":951,"enrollment":952,"conditions":1494,"interventions":1495},[94],[954,955,956,957,958,959,960,961,962,963,964,965,966,967],[72,97,87,77,969,242,970,87,971,972],{"intervention":121,"totalTrials":27,"cells":1497},{"EARLY_PHASE1":1498,"PHASE1":1500,"PHASE2":1510,"PHASE3":1572,"PHASE4":1578,"NA":1580},{"trials":1499,"activeCount":102},[],{"trials":1501,"activeCount":102},[1502,1506],{"nctId":106,"briefTitle":107,"status":108,"phases":1503,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":1504,"interventions":1505},[90],[114,15,18,115,21,116],[118,119,120,121],{"nctId":167,"briefTitle":168,"status":125,"phases":1507,"primaryCompletion":170,"completion":171,"start":172,"enrollment":9,"conditions":1508,"interventions":1509},[90],[174,175,32],[118,119,42,121,177,178],{"trials":1511,"activeCount":895,"soonestReadout":41},[1512,1516,1520,1524,1528,1532,1536,1540,1544,1548,1552,1556,1560,1564,1568],{"nctId":362,"briefTitle":363,"status":125,"phases":1513,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":1514,"interventions":1515},[91],[26,191,192,370,371,372,194,200,203,15,18,32,21],[222,118,119,120,121],{"nctId":398,"briefTitle":399,"status":229,"phases":1517,"primaryCompletion":401,"completion":402,"start":403,"enrollment":404,"conditions":1518,"interventions":1519},[91],[190,191,406,407,200,192,193,21,408,409,410,411,412,195,413,197,414,370],[416,417,42,97,418,419,420],{"nctId":39,"briefTitle":40,"status":474,"phases":1521,"primaryCompletion":41,"completion":476,"start":477,"enrollment":27,"conditions":1522,"interventions":1523},[91],[26,191,479,192,272,480,481,237,410,411,198],[42,97,483,208,420,484,87,242,485],{"nctId":501,"briefTitle":502,"status":229,"phases":1525,"primaryCompletion":504,"completion":505,"start":506,"enrollment":507,"conditions":1526,"interventions":1527},[91],[509,510,511,512],[285,514,97,42,515,516,208,420],{"nctId":518,"briefTitle":519,"status":125,"phases":1529,"primaryCompletion":216,"completion":216,"start":521,"enrollment":522,"conditions":1530,"interventions":1531},[90,91],[219],[525,97,42,302,526,300,420],{"nctId":1253,"briefTitle":1254,"status":125,"phases":1533,"primaryCompletion":1256,"completion":862,"start":1257,"enrollment":1258,"conditions":1534,"interventions":1535},[91],[15,21,1260,1261,1262,1263,1264,1265,1266,1267,372,1268,1269],[222,223,119,120,912,121],{"nctId":1073,"briefTitle":1074,"status":125,"phases":1537,"primaryCompletion":172,"completion":1076,"start":1077,"enrollment":33,"conditions":1538,"interventions":1539},[91],[964,1079,966,965,1080,1081],[42,242,741,824,731,899,1083],{"nctId":595,"briefTitle":596,"status":108,"phases":1541,"primaryCompletion":598,"completion":598,"start":599,"enrollment":358,"conditions":1542,"interventions":1543},[91],[15,21],[253,222,602,118,119,120,224,121],{"nctId":614,"briefTitle":615,"status":229,"phases":1545,"primaryCompletion":617,"completion":618,"start":619,"enrollment":620,"conditions":1546,"interventions":1547},[91],[622,623,624],[626,515,288,42,87,496,97,151,208,420],{"nctId":1097,"briefTitle":1098,"status":229,"phases":1549,"primaryCompletion":1100,"completion":1101,"start":1102,"enrollment":1103,"conditions":1550,"interventions":1551},[91],[266,371,264,26,21],[1106,42,208,420,1107,1108],{"nctId":640,"briefTitle":641,"status":125,"phases":1553,"primaryCompletion":643,"completion":644,"start":567,"enrollment":645,"conditions":1554,"interventions":1555},[91],[647,648,649,582,583,584,585,586,650,588,651,587,652],[593,97,87,654,420],{"nctId":693,"briefTitle":694,"status":125,"phases":1557,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":1558,"interventions":1559},[90,91],[29,700,15,18,115,21],[221,118,119,120,121],{"nctId":703,"briefTitle":704,"status":125,"phases":1561,"primaryCompletion":706,"completion":706,"start":707,"enrollment":708,"conditions":1562,"interventions":1563},[91],[710,15,18,21],[221,118,42,121,151],{"nctId":713,"briefTitle":714,"status":108,"phases":1565,"primaryCompletion":716,"completion":716,"start":217,"enrollment":717,"conditions":1566,"interventions":1567},[91],[700,15,18,32,146,21],[221,118,119,720,121,222],{"nctId":784,"briefTitle":785,"status":125,"phases":1569,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":1570,"interventions":1571},[91],[739],[288,97,42,208,420,793,87],{"trials":1573,"activeCount":102},[1574],{"nctId":806,"briefTitle":807,"status":125,"phases":1575,"primaryCompletion":809,"completion":809,"start":810,"enrollment":811,"conditions":1576,"interventions":1577},[91,92],[219],[97,42,420,151],{"trials":1579,"activeCount":102},[],{"trials":1581,"activeCount":102},[1582,1586,1590,1594],{"nctId":880,"briefTitle":881,"status":125,"phases":1583,"primaryCompletion":883,"completion":883,"start":884,"enrollment":98,"conditions":1584,"interventions":1585},[94],[886,15,18,21],[222,888,118,119,120,121],{"nctId":890,"briefTitle":891,"status":108,"phases":1587,"primaryCompletion":893,"completion":893,"start":894,"enrollment":895,"conditions":1588,"interventions":1589},[94],[174,26,175],[149,898,87,97,208,899,900,526,825],{"nctId":902,"briefTitle":903,"status":108,"phases":1591,"primaryCompletion":905,"completion":905,"start":906,"enrollment":907,"conditions":1592,"interventions":1593},[94],[886,909,219,114,15,18,115,21,910],[221,223,118,119,222,912,224,121],{"nctId":1326,"briefTitle":1327,"status":125,"phases":1595,"primaryCompletion":1329,"completion":1329,"start":1330,"enrollment":112,"conditions":1596,"interventions":1597},[94],[1332,1333],[593,561,242,225,654,899],{"intervention":208,"totalTrials":1137,"cells":1599},{"EARLY_PHASE1":1600,"PHASE1":1602,"PHASE2":1614,"PHASE3":1640,"PHASE4":1642,"NA":1644},{"trials":1601,"activeCount":102},[],{"trials":1603,"activeCount":1013,"soonestReadout":1608},[1604],{"nctId":1605,"briefTitle":1606,"status":229,"phases":1607,"primaryCompletion":1608,"completion":1608,"start":1609,"enrollment":1137,"conditions":1610,"interventions":1612},"NCT06692426","Trial of Cell Based Therapy for DMD",[90],"2027-03-03","2025-03-20",[1611],"Duchenne Muscular Dystrophy",[1613,208],"MyoPAXon",{"trials":1615,"activeCount":1438,"soonestReadout":41},[1616,1620,1624,1628,1632,1636],{"nctId":182,"briefTitle":183,"status":125,"phases":1617,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":1618,"interventions":1619},[91],[190,191,192,193,21,194,195,196,197,198,199,200,201,202,203,32,204,205],[149,42,97,207,208,209,210,211],{"nctId":39,"briefTitle":40,"status":474,"phases":1621,"primaryCompletion":41,"completion":476,"start":477,"enrollment":27,"conditions":1622,"interventions":1623},[91],[26,191,479,192,272,480,481,237,410,411,198],[42,97,483,208,420,484,87,242,485],{"nctId":501,"briefTitle":502,"status":229,"phases":1625,"primaryCompletion":504,"completion":505,"start":506,"enrollment":507,"conditions":1626,"interventions":1627},[91],[509,510,511,512],[285,514,97,42,515,516,208,420],{"nctId":614,"briefTitle":615,"status":229,"phases":1629,"primaryCompletion":617,"completion":618,"start":619,"enrollment":620,"conditions":1630,"interventions":1631},[91],[622,623,624],[626,515,288,42,87,496,97,151,208,420],{"nctId":1097,"briefTitle":1098,"status":229,"phases":1633,"primaryCompletion":1100,"completion":1101,"start":1102,"enrollment":1103,"conditions":1634,"interventions":1635},[91],[266,371,264,26,21],[1106,42,208,420,1107,1108],{"nctId":784,"briefTitle":785,"status":125,"phases":1637,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":1638,"interventions":1639},[91],[739],[288,97,42,208,420,793,87],{"trials":1641,"activeCount":102},[],{"trials":1643,"activeCount":102},[],{"trials":1645,"activeCount":102},[1646],{"nctId":890,"briefTitle":891,"status":108,"phases":1647,"primaryCompletion":893,"completion":893,"start":894,"enrollment":895,"conditions":1648,"interventions":1649},[94],[174,26,175],[149,898,87,97,208,899,900,526,825],{"intervention":285,"totalTrials":1454,"cells":1651},{"EARLY_PHASE1":1652,"PHASE1":1654,"PHASE2":1668,"PHASE3":1731,"PHASE4":1733,"NA":1735},{"trials":1653,"activeCount":102},[],{"trials":1655,"activeCount":102},[1656],{"nctId":1657,"briefTitle":1658,"status":125,"phases":1659,"primaryCompletion":1660,"completion":1661,"start":1662,"enrollment":669,"conditions":1663,"interventions":1666},"NCT04555811","FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL",[90],"2023-02-08","2023-11-30","2020-09-22",[1664,1665,684,685],"NHL","Non Hodgkin Lymphoma",[1667,285],"FT596",{"trials":1669,"activeCount":1438,"soonestReadout":747},[1670,1674,1683,1687,1691,1703,1707,1716,1727],{"nctId":255,"briefTitle":256,"status":229,"phases":1671,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":1672,"interventions":1673},[91],[263,264,265,26,174,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,201,283],[42,87,242,285,286,287,288,97],{"nctId":1675,"briefTitle":1676,"status":108,"phases":1677,"primaryCompletion":1678,"completion":171,"start":1453,"enrollment":112,"conditions":1679,"interventions":1681},"NCT00869323","Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders",[91],"2013-03",[1680],"Lymphoproliferative Disorder",[573,1682],"bortezomib",{"nctId":352,"briefTitle":353,"status":125,"phases":1684,"primaryCompletion":355,"completion":356,"start":357,"enrollment":358,"conditions":1685,"interventions":1686},[91],[236,194],[285,303,301,97,302,42],{"nctId":501,"briefTitle":502,"status":229,"phases":1688,"primaryCompletion":504,"completion":505,"start":506,"enrollment":507,"conditions":1689,"interventions":1690},[91],[509,510,511,512],[285,514,97,42,515,516,208,420],{"nctId":1692,"briefTitle":1693,"status":229,"phases":1694,"primaryCompletion":1695,"completion":1696,"start":1697,"enrollment":1698,"conditions":1699,"interventions":1700},"NCT06792825","HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL",[91],"2029-07-08","2031-07-08","2025-08-07",65,[197,413],[1701,285,1702],"Tafasitamab","Lenalidomide",{"nctId":564,"briefTitle":565,"status":108,"phases":1704,"primaryCompletion":567,"completion":568,"start":569,"enrollment":460,"conditions":1705,"interventions":1706},[90,91],[15,18],[253,572,573,118,120],{"nctId":1708,"briefTitle":1709,"status":108,"phases":1710,"primaryCompletion":874,"completion":1711,"start":569,"enrollment":9,"conditions":1712,"interventions":1714},"NCT00617929","Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant",[91],"2015-10",[1713],"Cancer",[221,573,1715],"clofarabine",{"nctId":1717,"briefTitle":1718,"status":125,"phases":1719,"primaryCompletion":1720,"completion":1721,"start":1722,"enrollment":16,"conditions":1723,"interventions":1725},"NCT02141451","ADAM17 Inhibitor\u002F Rituximab After Auto HCT for DLBCL",[90,91],"2019-01-23","2019-06","2014-05",[1724],"Diffuse Large B Cell Non-Hodgkin Lymphoma",[285,1726],"INCB7839",{"nctId":744,"briefTitle":745,"status":229,"phases":1728,"primaryCompletion":747,"completion":748,"start":749,"enrollment":8,"conditions":1729,"interventions":1730},[91],[219,509,21,751,752,753,754,755],[483,97,42,302,243,97,285,87,626,242,285],{"trials":1732,"activeCount":102},[],{"trials":1734,"activeCount":102},[],{"trials":1736,"activeCount":102},[],{"intervention":394,"totalTrials":295,"cells":1738},{"EARLY_PHASE1":1739,"PHASE1":1741,"PHASE2":1747,"PHASE3":1792,"PHASE4":1798,"NA":1800},{"trials":1740,"activeCount":102},[],{"trials":1742,"activeCount":102},[1743],{"nctId":1199,"briefTitle":1200,"status":108,"phases":1744,"primaryCompletion":1202,"completion":1203,"start":1204,"enrollment":1205,"conditions":1745,"interventions":1746},[90],[1189,700,1192,1193,1194],[222,223,394,1208,912,1197,1209],{"trials":1748,"activeCount":112,"soonestReadout":1242},[1749,1753,1757,1761,1765,1769,1773,1777,1781],{"nctId":227,"briefTitle":228,"status":229,"phases":1750,"primaryCompletion":231,"completion":232,"start":233,"enrollment":234,"conditions":1751,"interventions":1752},[91],[236,237],[239,240,241,242,243,97],{"nctId":384,"briefTitle":385,"status":307,"phases":1754,"primaryCompletion":387,"completion":387,"start":388,"enrollment":102,"conditions":1755,"interventions":1756},[91],[18],[391,118,392,393,394,222,395,396],{"nctId":464,"briefTitle":465,"status":125,"phases":1758,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":1759,"interventions":1760},[91],[18],[391,118,394,243,472],{"nctId":487,"briefTitle":488,"status":229,"phases":1762,"primaryCompletion":490,"completion":491,"start":492,"enrollment":9,"conditions":1763,"interventions":1764},[91],[494],[496,97,242,239,497,498,499],{"nctId":1239,"briefTitle":1240,"status":229,"phases":1766,"primaryCompletion":1242,"completion":1243,"start":1244,"enrollment":1245,"conditions":1767,"interventions":1768},[91],[1247,1248],[1250,1251,239,472,242],{"nctId":547,"briefTitle":548,"status":125,"phases":1770,"primaryCompletion":550,"completion":550,"start":329,"enrollment":368,"conditions":1771,"interventions":1772},[91],[18],[222,391,118,392,393,394,395],{"nctId":554,"briefTitle":555,"status":307,"phases":1774,"primaryCompletion":557,"completion":557,"start":558,"enrollment":102,"conditions":1775,"interventions":1776},[91],[26,174],[561,239,97,562],{"nctId":656,"briefTitle":657,"status":108,"phases":1778,"primaryCompletion":659,"completion":659,"start":329,"enrollment":660,"conditions":1779,"interventions":1780},[91],[115],[391,118,393,394,222,395,332,663],{"nctId":1782,"briefTitle":1783,"status":125,"phases":1784,"primaryCompletion":1785,"completion":1785,"start":1786,"enrollment":1205,"conditions":1787,"interventions":1789},"NCT00432094","Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors",[91],"2021-03","2006-12-19",[1190,24,1788],"Teratoma",[1790,394,1208,1791,1197,1209,222],"carboplatin","paclitaxel",{"trials":1793,"activeCount":102},[1794],{"nctId":846,"briefTitle":847,"status":108,"phases":1795,"primaryCompletion":849,"completion":849,"start":850,"enrollment":9,"conditions":1796,"interventions":1797},[91,92],[15],[663,223,118,393,394],{"trials":1799,"activeCount":102},[],{"trials":1801,"activeCount":102},[1802,1806],{"nctId":1336,"briefTitle":1337,"status":125,"phases":1803,"primaryCompletion":1339,"completion":1339,"start":1340,"enrollment":295,"conditions":1804,"interventions":1805},[94],[494],[497,1343,499,1344,242,239],{"nctId":1346,"briefTitle":1347,"status":125,"phases":1807,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":1808,"interventions":1809},[94],[1353,1354,1355,1356,1357,1358,1193,1359,1360,1361,1362,1363],[1365,239,1209,243,87,242,496,1343,497,1366,1367,1368],{"intervention":288,"totalTrials":1438,"cells":1811},{"EARLY_PHASE1":1812,"PHASE1":1814,"PHASE2":1816,"PHASE3":1834,"PHASE4":1836,"NA":1838},{"trials":1813,"activeCount":102},[],{"trials":1815,"activeCount":102},[],{"trials":1817,"activeCount":158,"soonestReadout":258},[1818,1822,1826,1830],{"nctId":255,"briefTitle":256,"status":229,"phases":1819,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":1820,"interventions":1821},[91],[263,264,265,26,174,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,201,283],[42,87,242,285,286,287,288,97],{"nctId":614,"briefTitle":615,"status":229,"phases":1823,"primaryCompletion":617,"completion":618,"start":619,"enrollment":620,"conditions":1824,"interventions":1825},[91],[622,623,624],[626,515,288,42,87,496,97,151,208,420],{"nctId":722,"briefTitle":723,"status":125,"phases":1827,"primaryCompletion":725,"completion":725,"start":726,"enrollment":727,"conditions":1828,"interventions":1829},[90,91],[190],[253,730,118,120,288,731,118,120],{"nctId":784,"briefTitle":785,"status":125,"phases":1831,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":1832,"interventions":1833},[91],[739],[288,97,42,208,420,793,87],{"trials":1835,"activeCount":102},[],{"trials":1837,"activeCount":102},[],{"trials":1839,"activeCount":102},[],{"intervention":483,"totalTrials":158,"cells":1841},{"EARLY_PHASE1":1842,"PHASE1":1844,"PHASE2":1846,"PHASE3":1856,"PHASE4":1858,"NA":1860},{"trials":1843,"activeCount":102},[],{"trials":1845,"activeCount":102},[],{"trials":1847,"activeCount":158,"soonestReadout":41},[1848,1852],{"nctId":39,"briefTitle":40,"status":474,"phases":1849,"primaryCompletion":41,"completion":476,"start":477,"enrollment":27,"conditions":1850,"interventions":1851},[91],[26,191,479,192,272,480,481,237,410,411,198],[42,97,483,208,420,484,87,242,485],{"nctId":744,"briefTitle":745,"status":229,"phases":1853,"primaryCompletion":747,"completion":748,"start":749,"enrollment":8,"conditions":1854,"interventions":1855},[91],[219,509,21,751,752,753,754,755],[483,97,42,302,243,97,285,87,626,242,285],{"trials":1857,"activeCount":102},[],{"trials":1859,"activeCount":102},[],{"trials":1861,"activeCount":102},[],{"intervention":515,"totalTrials":158,"cells":1863},{"EARLY_PHASE1":1864,"PHASE1":1866,"PHASE2":1868,"PHASE3":1878,"PHASE4":1880,"NA":1882},{"trials":1865,"activeCount":102},[],{"trials":1867,"activeCount":102},[],{"trials":1869,"activeCount":158,"soonestReadout":617},[1870,1874],{"nctId":501,"briefTitle":502,"status":229,"phases":1871,"primaryCompletion":504,"completion":505,"start":506,"enrollment":507,"conditions":1872,"interventions":1873},[91],[509,510,511,512],[285,514,97,42,515,516,208,420],{"nctId":614,"briefTitle":615,"status":229,"phases":1875,"primaryCompletion":617,"completion":618,"start":619,"enrollment":620,"conditions":1876,"interventions":1877},[91],[622,623,624],[626,515,288,42,87,496,97,151,208,420],{"trials":1879,"activeCount":102},[],{"trials":1881,"activeCount":102},[],{"trials":1883,"activeCount":102},[],{"intervention":1197,"totalTrials":669,"cells":1885},{"EARLY_PHASE1":1886,"PHASE1":1888,"PHASE2":1898,"PHASE3":1920,"PHASE4":1922,"NA":1924},{"trials":1887,"activeCount":102},[],{"trials":1889,"activeCount":102},[1890,1894],{"nctId":1183,"briefTitle":1184,"status":108,"phases":1891,"primaryCompletion":1077,"completion":1186,"start":1187,"enrollment":295,"conditions":1892,"interventions":1893},[90],[1189,1190,1191,700,1192,494,24,1193,1194],[1196,223,222,912,1197],{"nctId":1199,"briefTitle":1200,"status":108,"phases":1895,"primaryCompletion":1202,"completion":1203,"start":1204,"enrollment":1205,"conditions":1896,"interventions":1897},[90],[1189,700,1192,1193,1194],[222,223,394,1208,912,1197,1209],{"trials":1899,"activeCount":158,"soonestReadout":490},[1900,1904,1912,1916],{"nctId":487,"briefTitle":488,"status":229,"phases":1901,"primaryCompletion":490,"completion":491,"start":492,"enrollment":9,"conditions":1902,"interventions":1903},[91],[494],[496,97,242,239,497,498,499],{"nctId":1905,"briefTitle":1906,"status":108,"phases":1907,"primaryCompletion":1908,"completion":1908,"start":1909,"enrollment":22,"conditions":1910,"interventions":1911},"NCT00392782","Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease",[91],"2011-05","2005-07",[15,21],[221,120,1197],{"nctId":614,"briefTitle":615,"status":229,"phases":1913,"primaryCompletion":617,"completion":618,"start":619,"enrollment":620,"conditions":1914,"interventions":1915},[91],[622,623,624],[626,515,288,42,87,496,97,151,208,420],{"nctId":1782,"briefTitle":1783,"status":125,"phases":1917,"primaryCompletion":1785,"completion":1785,"start":1786,"enrollment":1205,"conditions":1918,"interventions":1919},[91],[1190,24,1788],[1790,394,1208,1791,1197,1209,222],{"trials":1921,"activeCount":102},[],{"trials":1923,"activeCount":102},[],{"trials":1925,"activeCount":102},[1926],{"nctId":1346,"briefTitle":1347,"status":125,"phases":1927,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":1928,"interventions":1929},[94],[1353,1354,1355,1356,1357,1358,1193,1359,1360,1361,1362,1363],[1365,239,1209,243,87,242,496,1343,497,1366,1367,1368],{"intervention":243,"totalTrials":460,"cells":1931},{"EARLY_PHASE1":1932,"PHASE1":1934,"PHASE2":1936,"PHASE3":1950,"PHASE4":1956,"NA":1958},{"trials":1933,"activeCount":102},[],{"trials":1935,"activeCount":102},[],{"trials":1937,"activeCount":158,"soonestReadout":231},[1938,1942,1946],{"nctId":227,"briefTitle":228,"status":229,"phases":1939,"primaryCompletion":231,"completion":232,"start":233,"enrollment":234,"conditions":1940,"interventions":1941},[91],[236,237],[239,240,241,242,243,97],{"nctId":464,"briefTitle":465,"status":125,"phases":1943,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":1944,"interventions":1945},[91],[18],[391,118,394,243,472],{"nctId":744,"briefTitle":745,"status":229,"phases":1947,"primaryCompletion":747,"completion":748,"start":749,"enrollment":8,"conditions":1948,"interventions":1949},[91],[219,509,21,751,752,753,754,755],[483,97,42,302,243,97,285,87,626,242,285],{"trials":1951,"activeCount":102},[1952],{"nctId":827,"briefTitle":828,"status":108,"phases":1953,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":1954,"interventions":1955},[91,92],[834,266,371],[87,97,242,243,207],{"trials":1957,"activeCount":102},[],{"trials":1959,"activeCount":102},[1960,1971],{"nctId":1961,"briefTitle":1962,"status":125,"phases":1963,"primaryCompletion":1964,"completion":1964,"start":558,"enrollment":426,"conditions":1965,"interventions":1968},"NCT01850888","MIBG for Refractory Neuroblastoma and Pheochromocytoma",[94],"2025-10-20",[1966,1967],"Relapsed Neuroblastoma","Metastatic Pheochromocytoma",[1969,1970,243],"131 I-Metaiodobenzylguanidine","Potassium iodide solution",{"nctId":1346,"briefTitle":1347,"status":125,"phases":1972,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":1973,"interventions":1974},[94],[1353,1354,1355,1356,1357,1358,1193,1359,1360,1361,1362,1363],[1365,239,1209,243,87,242,496,1343,497,1366,1367,1368],{"intervention":626,"totalTrials":895,"cells":1976},{"EARLY_PHASE1":1977,"PHASE1":1979,"PHASE2":1981,"PHASE3":1999,"PHASE4":2001,"NA":2003},{"trials":1978,"activeCount":102},[],{"trials":1980,"activeCount":102},[],{"trials":1982,"activeCount":158,"soonestReadout":747},[1983,1987,1991,1995],{"nctId":1217,"briefTitle":1218,"status":108,"phases":1984,"primaryCompletion":1220,"completion":1220,"start":1221,"enrollment":1013,"conditions":1985,"interventions":1986},[91],[1223],[1225,120,912],{"nctId":614,"briefTitle":615,"status":229,"phases":1988,"primaryCompletion":617,"completion":618,"start":619,"enrollment":620,"conditions":1989,"interventions":1990},[91],[622,623,624],[626,515,288,42,87,496,97,151,208,420],{"nctId":1276,"briefTitle":1277,"status":125,"phases":1992,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":1993,"interventions":1994},[91],[1283,1284,1285,1286,1287,1288,1289,1290,1291],[561,242,1293,626,1294,1295],{"nctId":744,"briefTitle":745,"status":229,"phases":1996,"primaryCompletion":747,"completion":748,"start":749,"enrollment":8,"conditions":1997,"interventions":1998},[91],[219,509,21,751,752,753,754,755],[483,97,42,302,243,97,285,87,626,242,285],{"trials":2000,"activeCount":102},[],{"trials":2002,"activeCount":102},[],{"trials":2004,"activeCount":102},[2005],{"nctId":858,"briefTitle":859,"status":125,"phases":2006,"primaryCompletion":861,"completion":862,"start":863,"enrollment":864,"conditions":2007,"interventions":2008},[94],[754,822],[626,42,97,867,741],{"intervention":77,"totalTrials":158,"cells":2010},{"EARLY_PHASE1":2011,"PHASE1":2013,"PHASE2":2015,"PHASE3":2049,"PHASE4":2051,"NA":2053},{"trials":2012,"activeCount":102},[],{"trials":2014,"activeCount":102},[],{"trials":2016,"activeCount":1013,"soonestReadout":76},[2017],{"nctId":74,"briefTitle":75,"status":474,"phases":2018,"primaryCompletion":76,"completion":2019,"start":2020,"enrollment":2021,"conditions":2022,"interventions":2042},[91],"2029-07-14","2014-07-10",149,[2023,648,649,2024,583,2025,585,586,2026,587,2027,1285,1284,2028,2029,2030,652,2031,2032,2033,2034,2035,2036,2037,2038,2039,842,2040,2041],"Mucopolysaccharidosis Disorders","Maroteaux Lamy Syndrome","Alpha-Mannosidosis","Glycoprotein Metabolic Disorders","Recessive Leukodystrophies","Niemann-Pick B","Niemann-Pick C Subtype 2","Sphingomyelin Deficiency","Adrenoleukodystrophy With Cerebral Involvement","Zellweger Syndrome","Neonatal Adrenoleukodystrophy","Infantile Refsum Disease","Acyl-CoA Oxidase Deficiency","D-Bifunctional Enzyme Deficiency","Multifunctional Enzyme Deficiency","Alpha-methylacyl-CoA Racmase Deficiency","Mitochondrial Neurogastrointestingal Encephalopathy","Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation)","Inherited Metabolic Disorders",[77,2043,2044,2045,2046,2047,2048,2048],"IMD Preparative Regimen","Osteopetrosis Only Preparative Regimen","Osteopetrosis Haploidentical Only Preparative Regimen","cALD SR-A","cALD SR-B","cALD HR-D",{"trials":2050,"activeCount":102},[],{"trials":2052,"activeCount":102},[],{"trials":2054,"activeCount":1013,"soonestReadout":71},[2055],{"nctId":69,"briefTitle":70,"status":474,"phases":2056,"primaryCompletion":71,"completion":491,"start":951,"enrollment":952,"conditions":2057,"interventions":2058},[94],[954,955,956,957,958,959,960,961,962,963,964,965,966,967],[72,97,87,77,969,242,970,87,971,972],{"intervention":151,"totalTrials":895,"cells":2060},{"EARLY_PHASE1":2061,"PHASE1":2063,"PHASE2":2069,"PHASE3":2083,"PHASE4":2089,"NA":2091},{"trials":2062,"activeCount":102},[],{"trials":2064,"activeCount":102},[2065],{"nctId":138,"briefTitle":139,"status":125,"phases":2066,"primaryCompletion":141,"completion":142,"start":143,"enrollment":144,"conditions":2067,"interventions":2068},[90],[15,18,32,146,21],[148,149,120,97,150,151],{"trials":2070,"activeCount":1013,"soonestReadout":617},[2071,2075,2079],{"nctId":433,"briefTitle":434,"status":125,"phases":2072,"primaryCompletion":436,"completion":437,"start":438,"enrollment":426,"conditions":2073,"interventions":2074},[91],[264,26,440,202,441,192,175,442,237,32,412,443,343,197,198,444,200,445,446,447,448,449,411,450,193],[42,97,209,151,452,207],{"nctId":614,"briefTitle":615,"status":229,"phases":2076,"primaryCompletion":617,"completion":618,"start":619,"enrollment":620,"conditions":2077,"interventions":2078},[91],[622,623,624],[626,515,288,42,87,496,97,151,208,420],{"nctId":703,"briefTitle":704,"status":125,"phases":2080,"primaryCompletion":706,"completion":706,"start":707,"enrollment":708,"conditions":2081,"interventions":2082},[91],[710,15,18,21],[221,118,42,121,151],{"trials":2084,"activeCount":102},[2085],{"nctId":806,"briefTitle":807,"status":125,"phases":2086,"primaryCompletion":809,"completion":809,"start":810,"enrollment":811,"conditions":2087,"interventions":2088},[91,92],[219],[97,42,420,151],{"trials":2090,"activeCount":102},[],{"trials":2092,"activeCount":102},[],{"intervention":1682,"totalTrials":669,"cells":2094},{"EARLY_PHASE1":2095,"PHASE1":2097,"PHASE2":2120,"PHASE3":2165,"PHASE4":2167,"NA":2169},{"trials":2096,"activeCount":102},[],{"trials":2098,"activeCount":102},[2099,2109],{"nctId":2100,"briefTitle":2101,"status":125,"phases":2102,"primaryCompletion":761,"completion":578,"start":1257,"enrollment":986,"conditions":2103,"interventions":2107},"NCT00622674","Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors",[90],[29,2104,671,700,35,2105,1194,2106],"Colorectal Cancer","Pancreatic Cancer","Unspecified Adult Solid Tumor, Protocol Specific",[2108,1682],"cetuximab",{"nctId":2110,"briefTitle":2111,"status":125,"phases":2112,"primaryCompletion":2113,"completion":2114,"start":2115,"enrollment":790,"conditions":2116,"interventions":2118},"NCT00620295","Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors",[90],"2009-02","2009-10","2007-03",[29,2104,671,700,35,24,2105,2117,1194],"Prostate Cancer",[1682,2119],"gemcitabine hydrochloride",{"trials":2121,"activeCount":1013,"soonestReadout":2159},[2122,2134,2143,2147,2155],{"nctId":2123,"briefTitle":2124,"status":108,"phases":2125,"primaryCompletion":894,"completion":894,"start":2126,"enrollment":158,"conditions":2127,"interventions":2128},"NCT01312818","Bortezomib, Vorinostat and Dexamethasone for Relapsed\u002FRefractory Acute Lymphoblastic Leukemia (ALL)",[91],"2011-06",[174],[2129,2130,2131,2132,2133],"Bortezomib","Vorinostat","Dexamethasone","Methotrexate","Imatinib mesylate",{"nctId":2135,"briefTitle":2136,"status":108,"phases":2137,"primaryCompletion":2138,"completion":2138,"start":2139,"enrollment":669,"conditions":2140,"interventions":2141},"NCT01056601","Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy",[91],"2011-02","2010-09",[2105],[2129,2142],"Panobinostat",{"nctId":1675,"briefTitle":1676,"status":108,"phases":2144,"primaryCompletion":1678,"completion":171,"start":1453,"enrollment":112,"conditions":2145,"interventions":2146},[91],[1680],[573,1682],{"nctId":2148,"briefTitle":2149,"status":108,"phases":2150,"primaryCompletion":2151,"completion":2151,"start":250,"enrollment":358,"conditions":2152,"interventions":2153},"NCT00818649","Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia",[91],"2012-05",[15,175],[1682,2154],"vorinostat",{"nctId":2156,"briefTitle":2157,"status":229,"phases":2158,"primaryCompletion":2159,"completion":2160,"start":2161,"enrollment":737,"conditions":2162,"interventions":2163},"NCT07008638","Phase I\u002FII Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)",[90,91],"2027-12-30","2028-01-27","2025-07-07",[26,267],[2129,2164],"CPX-351",{"trials":2166,"activeCount":102},[],{"trials":2168,"activeCount":102},[],{"trials":2170,"activeCount":102},[],{"intervention":392,"totalTrials":460,"cells":2172},{"EARLY_PHASE1":2173,"PHASE1":2175,"PHASE2":2177,"PHASE3":2217,"PHASE4":2219,"NA":2221},{"trials":2174,"activeCount":102},[],{"trials":2176,"activeCount":102},[],{"trials":2178,"activeCount":1013,"soonestReadout":1242},[2179,2183,2187,2191,2195,2204],{"nctId":384,"briefTitle":385,"status":307,"phases":2180,"primaryCompletion":387,"completion":387,"start":388,"enrollment":102,"conditions":2181,"interventions":2182},[91],[18],[391,118,392,393,394,222,395,396],{"nctId":464,"briefTitle":465,"status":125,"phases":2184,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":2185,"interventions":2186},[91],[18],[391,118,394,243,472],{"nctId":1239,"briefTitle":1240,"status":229,"phases":2188,"primaryCompletion":1242,"completion":1243,"start":1244,"enrollment":1245,"conditions":2189,"interventions":2190},[91],[1247,1248],[1250,1251,239,472,242],{"nctId":547,"briefTitle":548,"status":125,"phases":2192,"primaryCompletion":550,"completion":550,"start":329,"enrollment":368,"conditions":2193,"interventions":2194},[91],[18],[222,391,118,392,393,394,395],{"nctId":2196,"briefTitle":2197,"status":108,"phases":2198,"primaryCompletion":2199,"completion":2199,"start":2200,"enrollment":1013,"conditions":2201,"interventions":2202},"NCT00609739","Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation",[90,91],"2010-06","1999-06",[15],[119,392,222,804,224,395,2203],"Cis-Retinoic acid",{"nctId":2205,"briefTitle":2206,"status":108,"phases":2207,"primaryCompletion":894,"completion":894,"start":2208,"enrollment":426,"conditions":2209,"interventions":2210},"NCT00882206","Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia",[91],"2009-04",[15,18],[392,2211,2212,2213,804,2214,2215,2216,2154],"decitabine","doxorubicin hydrochloride","imatinib mesylate","pegaspargase","prednisone","vincristine sulfate",{"trials":2218,"activeCount":102},[],{"trials":2220,"activeCount":102},[],{"trials":2222,"activeCount":102},[],{"intervention":164,"totalTrials":895,"cells":2224},{"EARLY_PHASE1":2225,"PHASE1":2227,"PHASE2":2244,"PHASE3":2258,"PHASE4":2260,"NA":2262},{"trials":2226,"activeCount":102},[],{"trials":2228,"activeCount":102},[2229,2240],{"nctId":2230,"briefTitle":2231,"status":125,"phases":2232,"primaryCompletion":2233,"completion":2233,"start":2234,"enrollment":112,"conditions":2235,"interventions":2237},"NCT04630769","FT516 and IL2 With Enoblituzumab for Ovarian Cancer",[90],"2022-01-01","2021-04-02",[24,2236,1002],"Fallopian Tube Adenocarcinoma",[2238,2239,164],"IP FT516","Enoblituzumab",{"nctId":153,"briefTitle":154,"status":125,"phases":2241,"primaryCompletion":156,"completion":156,"start":157,"enrollment":158,"conditions":2242,"interventions":2243},[90],[24,160,161],[42,97,163,164,165],{"trials":2245,"activeCount":1013,"soonestReadout":631},[2246,2250,2254],{"nctId":290,"briefTitle":291,"status":125,"phases":2247,"primaryCompletion":293,"completion":293,"start":294,"enrollment":295,"conditions":2248,"interventions":2249},[91],[24,297,298,29],[42,97,300,301,164,302,302,303],{"nctId":422,"briefTitle":423,"status":108,"phases":2251,"primaryCompletion":249,"completion":425,"start":294,"enrollment":426,"conditions":2252,"interventions":2253},[91],[428],[430,42,97,431,164],{"nctId":628,"briefTitle":629,"status":229,"phases":2255,"primaryCompletion":631,"completion":632,"start":633,"enrollment":579,"conditions":2256,"interventions":2257},[90,91],[635,636,190],[638,42,97,164],{"trials":2259,"activeCount":102},[],{"trials":2261,"activeCount":102},[],{"trials":2263,"activeCount":102},[],{"intervention":391,"totalTrials":895,"cells":2265},{"EARLY_PHASE1":2266,"PHASE1":2268,"PHASE2":2270,"PHASE3":2292,"PHASE4":2294,"NA":2296},{"trials":2267,"activeCount":102},[],{"trials":2269,"activeCount":102},[],{"trials":2271,"activeCount":1013,"soonestReadout":1242},[2272,2276,2280,2284,2288],{"nctId":384,"briefTitle":385,"status":307,"phases":2273,"primaryCompletion":387,"completion":387,"start":388,"enrollment":102,"conditions":2274,"interventions":2275},[91],[18],[391,118,392,393,394,222,395,396],{"nctId":464,"briefTitle":465,"status":125,"phases":2277,"primaryCompletion":467,"completion":467,"start":468,"enrollment":469,"conditions":2278,"interventions":2279},[91],[18],[391,118,394,243,472],{"nctId":1239,"briefTitle":1240,"status":229,"phases":2281,"primaryCompletion":1242,"completion":1243,"start":1244,"enrollment":1245,"conditions":2282,"interventions":2283},[91],[1247,1248],[1250,1251,239,472,242],{"nctId":547,"briefTitle":548,"status":125,"phases":2285,"primaryCompletion":550,"completion":550,"start":329,"enrollment":368,"conditions":2286,"interventions":2287},[91],[18],[222,391,118,392,393,394,395],{"nctId":656,"briefTitle":657,"status":108,"phases":2289,"primaryCompletion":659,"completion":659,"start":329,"enrollment":660,"conditions":2290,"interventions":2291},[91],[115],[391,118,393,394,222,395,332,663],{"trials":2293,"activeCount":102},[],{"trials":2295,"activeCount":102},[],{"trials":2297,"activeCount":102},[],{"intervention":286,"totalTrials":158,"cells":2299},{"EARLY_PHASE1":2300,"PHASE1":2302,"PHASE2":2304,"PHASE3":2314,"PHASE4":2316,"NA":2318},{"trials":2301,"activeCount":102},[],{"trials":2303,"activeCount":102},[],{"trials":2305,"activeCount":1013,"soonestReadout":258},[2306,2310],{"nctId":255,"briefTitle":256,"status":229,"phases":2307,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":2308,"interventions":2309},[91],[263,264,265,26,174,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,201,283],[42,87,242,285,286,287,288,97],{"nctId":375,"briefTitle":376,"status":108,"phases":2311,"primaryCompletion":378,"completion":378,"start":249,"enrollment":112,"conditions":2312,"interventions":2313},[91],[190,380],[149,42,97,286,87,382,303],{"trials":2315,"activeCount":102},[],{"trials":2317,"activeCount":102},[],{"trials":2319,"activeCount":102},[],{"intervention":484,"totalTrials":158,"cells":2321},{"EARLY_PHASE1":2322,"PHASE1":2324,"PHASE2":2330,"PHASE3":2336,"PHASE4":2338,"NA":2340},{"trials":2323,"activeCount":102},[],{"trials":2325,"activeCount":102},[2326],{"nctId":167,"briefTitle":168,"status":125,"phases":2327,"primaryCompletion":170,"completion":171,"start":172,"enrollment":9,"conditions":2328,"interventions":2329},[90],[174,175,32],[118,119,42,121,177,178],{"trials":2331,"activeCount":1013,"soonestReadout":41},[2332],{"nctId":39,"briefTitle":40,"status":474,"phases":2333,"primaryCompletion":41,"completion":476,"start":477,"enrollment":27,"conditions":2334,"interventions":2335},[91],[26,191,479,192,272,480,481,237,410,411,198],[42,97,483,208,420,484,87,242,485],{"trials":2337,"activeCount":102},[],{"trials":2339,"activeCount":102},[],{"trials":2341,"activeCount":102},[],{"intervention":1702,"totalTrials":158,"cells":2343},{"EARLY_PHASE1":2344,"PHASE1":2346,"PHASE2":2348,"PHASE3":2361,"PHASE4":2363,"NA":2365},{"trials":2345,"activeCount":102},[],{"trials":2347,"activeCount":102},[],{"trials":2349,"activeCount":1013,"soonestReadout":1695},[2350,2357],{"nctId":2351,"briefTitle":2352,"status":108,"phases":2353,"primaryCompletion":930,"completion":930,"start":2208,"enrollment":426,"conditions":2354,"interventions":2355},"NCT00903630","Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer",[90,91],[297,24,763],[1702,2356],"liposomal doxorubicin",{"nctId":1692,"briefTitle":1693,"status":229,"phases":2358,"primaryCompletion":1695,"completion":1696,"start":1697,"enrollment":1698,"conditions":2359,"interventions":2360},[91],[197,413],[1701,285,1702],{"trials":2362,"activeCount":102},[],{"trials":2364,"activeCount":102},[],{"trials":2366,"activeCount":102},[],{"intervention":536,"totalTrials":158,"cells":2368},{"EARLY_PHASE1":2369,"PHASE1":2371,"PHASE2":2373,"PHASE3":2383,"PHASE4":2385,"NA":2387},{"trials":2370,"activeCount":102},[],{"trials":2372,"activeCount":102},[],{"trials":2374,"activeCount":1013,"soonestReadout":1100},[2375,2379],{"nctId":528,"briefTitle":529,"status":125,"phases":2376,"primaryCompletion":531,"completion":532,"start":533,"enrollment":460,"conditions":2377,"interventions":2378},[91],[15,18,115],[223,118,536],{"nctId":1097,"briefTitle":1098,"status":229,"phases":2380,"primaryCompletion":1100,"completion":1101,"start":1102,"enrollment":1103,"conditions":2381,"interventions":2382},[91],[266,371,264,26,21],[1106,42,208,420,1107,1108],{"trials":2384,"activeCount":102},[],{"trials":2386,"activeCount":102},[],{"trials":2388,"activeCount":102},[],{"intervention":52,"totalTrials":1013,"cells":2390},{"EARLY_PHASE1":2391,"PHASE1":2393,"PHASE2":2395,"PHASE3":2415,"PHASE4":2417,"NA":2419},{"trials":2392,"activeCount":102},[],{"trials":2394,"activeCount":102},[],{"trials":2396,"activeCount":1013,"soonestReadout":51},[2397],{"nctId":49,"briefTitle":50,"status":474,"phases":2398,"primaryCompletion":51,"completion":2399,"start":2400,"enrollment":234,"conditions":2401,"interventions":2403},[91],"2028-06-01","2018-12-18",[174,2402],"Large B-cell Lymphoma",[52,2404,2405,2406,2407,2408,2409,2410,2411,2412,2413,2414],"YESCARTA","Fludarabine 30mg\u002Fm2 4 doses","Cyclophosphamide 500 mg\u002Fm2; 2 doses","Fludarabine 30mg\u002Fm2 3 doses","Cyclophosphamide 500 mg\u002Fm2; 3 doses","Fludarabine 25mg\u002Fm2 3 days","Cyclophosphamide 250 mg\u002Fm2; 3 days","Tecartus","Abecma, Intravenous Suspension","Cyclophosphamide 900 mg\u002Fm2; 1 day","Breyanzi Injectable Product",{"trials":2416,"activeCount":102},[],{"trials":2418,"activeCount":102},[],{"trials":2420,"activeCount":102},[],{"intervention":2404,"totalTrials":1013,"cells":2422},{"EARLY_PHASE1":2423,"PHASE1":2425,"PHASE2":2427,"PHASE3":2433,"PHASE4":2435,"NA":2437},{"trials":2424,"activeCount":102},[],{"trials":2426,"activeCount":102},[],{"trials":2428,"activeCount":1013,"soonestReadout":51},[2429],{"nctId":49,"briefTitle":50,"status":474,"phases":2430,"primaryCompletion":51,"completion":2399,"start":2400,"enrollment":234,"conditions":2431,"interventions":2432},[91],[174,2402],[52,2404,2405,2406,2407,2408,2409,2410,2411,2412,2413,2414],{"trials":2434,"activeCount":102},[],{"trials":2436,"activeCount":102},[],{"trials":2438,"activeCount":102},[],{"intervention":2405,"totalTrials":1013,"cells":2440},{"EARLY_PHASE1":2441,"PHASE1":2443,"PHASE2":2445,"PHASE3":2451,"PHASE4":2453,"NA":2455},{"trials":2442,"activeCount":102},[],{"trials":2444,"activeCount":102},[],{"trials":2446,"activeCount":1013,"soonestReadout":51},[2447],{"nctId":49,"briefTitle":50,"status":474,"phases":2448,"primaryCompletion":51,"completion":2399,"start":2400,"enrollment":234,"conditions":2449,"interventions":2450},[91],[174,2402],[52,2404,2405,2406,2407,2408,2409,2410,2411,2412,2413,2414],{"trials":2452,"activeCount":102},[],{"trials":2454,"activeCount":102},[],{"trials":2456,"activeCount":102},[],{"intervention":2406,"totalTrials":1013,"cells":2458},{"EARLY_PHASE1":2459,"PHASE1":2461,"PHASE2":2463,"PHASE3":2469,"PHASE4":2471,"NA":2473},{"trials":2460,"activeCount":102},[],{"trials":2462,"activeCount":102},[],{"trials":2464,"activeCount":1013,"soonestReadout":51},[2465],{"nctId":49,"briefTitle":50,"status":474,"phases":2466,"primaryCompletion":51,"completion":2399,"start":2400,"enrollment":234,"conditions":2467,"interventions":2468},[91],[174,2402],[52,2404,2405,2406,2407,2408,2409,2410,2411,2412,2413,2414],{"trials":2470,"activeCount":102},[],{"trials":2472,"activeCount":102},[],{"trials":2474,"activeCount":102},[],{"intervention":2407,"totalTrials":1013,"cells":2476},{"EARLY_PHASE1":2477,"PHASE1":2479,"PHASE2":2481,"PHASE3":2487,"PHASE4":2489,"NA":2491},{"trials":2478,"activeCount":102},[],{"trials":2480,"activeCount":102},[],{"trials":2482,"activeCount":1013,"soonestReadout":51},[2483],{"nctId":49,"briefTitle":50,"status":474,"phases":2484,"primaryCompletion":51,"completion":2399,"start":2400,"enrollment":234,"conditions":2485,"interventions":2486},[91],[174,2402],[52,2404,2405,2406,2407,2408,2409,2410,2411,2412,2413,2414],{"trials":2488,"activeCount":102},[],{"trials":2490,"activeCount":102},[],{"trials":2492,"activeCount":102},[],{"intervention":2408,"totalTrials":1013,"cells":2494},{"EARLY_PHASE1":2495,"PHASE1":2497,"PHASE2":2499,"PHASE3":2505,"PHASE4":2507,"NA":2509},{"trials":2496,"activeCount":102},[],{"trials":2498,"activeCount":102},[],{"trials":2500,"activeCount":1013,"soonestReadout":51},[2501],{"nctId":49,"briefTitle":50,"status":474,"phases":2502,"primaryCompletion":51,"completion":2399,"start":2400,"enrollment":234,"conditions":2503,"interventions":2504},[91],[174,2402],[52,2404,2405,2406,2407,2408,2409,2410,2411,2412,2413,2414],{"trials":2506,"activeCount":102},[],{"trials":2508,"activeCount":102},[],{"trials":2510,"activeCount":102},[],{"intervention":2409,"totalTrials":1013,"cells":2512},{"EARLY_PHASE1":2513,"PHASE1":2515,"PHASE2":2517,"PHASE3":2523,"PHASE4":2525,"NA":2527},{"trials":2514,"activeCount":102},[],{"trials":2516,"activeCount":102},[],{"trials":2518,"activeCount":1013,"soonestReadout":51},[2519],{"nctId":49,"briefTitle":50,"status":474,"phases":2520,"primaryCompletion":51,"completion":2399,"start":2400,"enrollment":234,"conditions":2521,"interventions":2522},[91],[174,2402],[52,2404,2405,2406,2407,2408,2409,2410,2411,2412,2413,2414],{"trials":2524,"activeCount":102},[],{"trials":2526,"activeCount":102},[],{"trials":2528,"activeCount":102},[],{"intervention":2410,"totalTrials":1013,"cells":2530},{"EARLY_PHASE1":2531,"PHASE1":2533,"PHASE2":2535,"PHASE3":2541,"PHASE4":2543,"NA":2545},{"trials":2532,"activeCount":102},[],{"trials":2534,"activeCount":102},[],{"trials":2536,"activeCount":1013,"soonestReadout":51},[2537],{"nctId":49,"briefTitle":50,"status":474,"phases":2538,"primaryCompletion":51,"completion":2399,"start":2400,"enrollment":234,"conditions":2539,"interventions":2540},[91],[174,2402],[52,2404,2405,2406,2407,2408,2409,2410,2411,2412,2413,2414],{"trials":2542,"activeCount":102},[],{"trials":2544,"activeCount":102},[],{"trials":2546,"activeCount":102},[],{"intervention":2411,"totalTrials":1013,"cells":2548},{"EARLY_PHASE1":2549,"PHASE1":2551,"PHASE2":2553,"PHASE3":2559,"PHASE4":2561,"NA":2563},{"trials":2550,"activeCount":102},[],{"trials":2552,"activeCount":102},[],{"trials":2554,"activeCount":1013,"soonestReadout":51},[2555],{"nctId":49,"briefTitle":50,"status":474,"phases":2556,"primaryCompletion":51,"completion":2399,"start":2400,"enrollment":234,"conditions":2557,"interventions":2558},[91],[174,2402],[52,2404,2405,2406,2407,2408,2409,2410,2411,2412,2413,2414],{"trials":2560,"activeCount":102},[],{"trials":2562,"activeCount":102},[],{"trials":2564,"activeCount":102},[],{"intervention":2412,"totalTrials":1013,"cells":2566},{"EARLY_PHASE1":2567,"PHASE1":2569,"PHASE2":2571,"PHASE3":2577,"PHASE4":2579,"NA":2581},{"trials":2568,"activeCount":102},[],{"trials":2570,"activeCount":102},[],{"trials":2572,"activeCount":1013,"soonestReadout":51},[2573],{"nctId":49,"briefTitle":50,"status":474,"phases":2574,"primaryCompletion":51,"completion":2399,"start":2400,"enrollment":234,"conditions":2575,"interventions":2576},[91],[174,2402],[52,2404,2405,2406,2407,2408,2409,2410,2411,2412,2413,2414],{"trials":2578,"activeCount":102},[],{"trials":2580,"activeCount":102},[],{"trials":2582,"activeCount":102},[],{"intervention":2413,"totalTrials":1013,"cells":2584},{"EARLY_PHASE1":2585,"PHASE1":2587,"PHASE2":2589,"PHASE3":2595,"PHASE4":2597,"NA":2599},{"trials":2586,"activeCount":102},[],{"trials":2588,"activeCount":102},[],{"trials":2590,"activeCount":1013,"soonestReadout":51},[2591],{"nctId":49,"briefTitle":50,"status":474,"phases":2592,"primaryCompletion":51,"completion":2399,"start":2400,"enrollment":234,"conditions":2593,"interventions":2594},[91],[174,2402],[52,2404,2405,2406,2407,2408,2409,2410,2411,2412,2413,2414],{"trials":2596,"activeCount":102},[],{"trials":2598,"activeCount":102},[],{"trials":2600,"activeCount":102},[],{"intervention":2414,"totalTrials":1013,"cells":2602},{"EARLY_PHASE1":2603,"PHASE1":2605,"PHASE2":2607,"PHASE3":2613,"PHASE4":2615,"NA":2617},{"trials":2604,"activeCount":102},[],{"trials":2606,"activeCount":102},[],{"trials":2608,"activeCount":1013,"soonestReadout":51},[2609],{"nctId":49,"briefTitle":50,"status":474,"phases":2610,"primaryCompletion":51,"completion":2399,"start":2400,"enrollment":234,"conditions":2611,"interventions":2612},[91],[174,2402],[52,2404,2405,2406,2407,2408,2409,2410,2411,2412,2413,2414],{"trials":2614,"activeCount":102},[],{"trials":2616,"activeCount":102},[],{"trials":2618,"activeCount":102},[],{"intervention":240,"totalTrials":1013,"cells":2620},{"EARLY_PHASE1":2621,"PHASE1":2623,"PHASE2":2625,"PHASE3":2631,"PHASE4":2633,"NA":2635},{"trials":2622,"activeCount":102},[],{"trials":2624,"activeCount":102},[],{"trials":2626,"activeCount":1013,"soonestReadout":231},[2627],{"nctId":227,"briefTitle":228,"status":229,"phases":2628,"primaryCompletion":231,"completion":232,"start":233,"enrollment":234,"conditions":2629,"interventions":2630},[91],[236,237],[239,240,241,242,243,97],{"trials":2632,"activeCount":102},[],{"trials":2634,"activeCount":102},[],{"trials":2636,"activeCount":102},[],{"intervention":241,"totalTrials":1013,"cells":2638},{"EARLY_PHASE1":2639,"PHASE1":2641,"PHASE2":2643,"PHASE3":2649,"PHASE4":2651,"NA":2653},{"trials":2640,"activeCount":102},[],{"trials":2642,"activeCount":102},[],{"trials":2644,"activeCount":1013,"soonestReadout":231},[2645],{"nctId":227,"briefTitle":228,"status":229,"phases":2646,"primaryCompletion":231,"completion":232,"start":233,"enrollment":234,"conditions":2647,"interventions":2648},[91],[236,237],[239,240,241,242,243,97],{"trials":2650,"activeCount":102},[],{"trials":2652,"activeCount":102},[],{"trials":2654,"activeCount":102},[],{"intervention":287,"totalTrials":1013,"cells":2656},{"EARLY_PHASE1":2657,"PHASE1":2659,"PHASE2":2661,"PHASE3":2667,"PHASE4":2669,"NA":2671},{"trials":2658,"activeCount":102},[],{"trials":2660,"activeCount":102},[],{"trials":2662,"activeCount":1013,"soonestReadout":258},[2663],{"nctId":255,"briefTitle":256,"status":229,"phases":2664,"primaryCompletion":258,"completion":259,"start":260,"enrollment":261,"conditions":2665,"interventions":2666},[91],[263,264,265,26,174,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,201,283],[42,87,242,285,286,287,288,97],{"trials":2668,"activeCount":102},[],{"trials":2670,"activeCount":102},[],{"trials":2672,"activeCount":102},[],{"intervention":2674,"totalTrials":1013,"cells":2675},"Bupivacaine",{"EARLY_PHASE1":2676,"PHASE1":2678,"PHASE2":2680,"PHASE3":2697,"PHASE4":2699,"NA":2701},{"trials":2677,"activeCount":102},[],{"trials":2679,"activeCount":102},[],{"trials":2681,"activeCount":1013,"soonestReadout":747},[2682],{"nctId":2683,"briefTitle":2684,"status":229,"phases":2685,"primaryCompletion":747,"completion":2686,"start":2687,"enrollment":2688,"conditions":2689,"interventions":2692},"NCT06411795","Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy",[91],"2028-01-01","2023-11-10",78,[2690,2691],"Duodenal Neoplasm","Pancreatic Neoplasm",[2674,2693,2694,2695,2696],"Hydromorphone","Iopamidol","Liposomal Bupivacaine","Thoracic Epidural Analgesia",{"trials":2698,"activeCount":102},[],{"trials":2700,"activeCount":102},[],{"trials":2702,"activeCount":102},[],{"intervention":2693,"totalTrials":1013,"cells":2704},{"EARLY_PHASE1":2705,"PHASE1":2707,"PHASE2":2709,"PHASE3":2715,"PHASE4":2717,"NA":2719},{"trials":2706,"activeCount":102},[],{"trials":2708,"activeCount":102},[],{"trials":2710,"activeCount":1013,"soonestReadout":747},[2711],{"nctId":2683,"briefTitle":2684,"status":229,"phases":2712,"primaryCompletion":747,"completion":2686,"start":2687,"enrollment":2688,"conditions":2713,"interventions":2714},[91],[2690,2691],[2674,2693,2694,2695,2696],{"trials":2716,"activeCount":102},[],{"trials":2718,"activeCount":102},[],{"trials":2720,"activeCount":102},[],{"intervention":2694,"totalTrials":1013,"cells":2722},{"EARLY_PHASE1":2723,"PHASE1":2725,"PHASE2":2727,"PHASE3":2733,"PHASE4":2735,"NA":2737},{"trials":2724,"activeCount":102},[],{"trials":2726,"activeCount":102},[],{"trials":2728,"activeCount":1013,"soonestReadout":747},[2729],{"nctId":2683,"briefTitle":2684,"status":229,"phases":2730,"primaryCompletion":747,"completion":2686,"start":2687,"enrollment":2688,"conditions":2731,"interventions":2732},[91],[2690,2691],[2674,2693,2694,2695,2696],{"trials":2734,"activeCount":102},[],{"trials":2736,"activeCount":102},[],{"trials":2738,"activeCount":102},[],{"intervention":2695,"totalTrials":1013,"cells":2740},{"EARLY_PHASE1":2741,"PHASE1":2743,"PHASE2":2745,"PHASE3":2751,"PHASE4":2753,"NA":2755},{"trials":2742,"activeCount":102},[],{"trials":2744,"activeCount":102},[],{"trials":2746,"activeCount":1013,"soonestReadout":747},[2747],{"nctId":2683,"briefTitle":2684,"status":229,"phases":2748,"primaryCompletion":747,"completion":2686,"start":2687,"enrollment":2688,"conditions":2749,"interventions":2750},[91],[2690,2691],[2674,2693,2694,2695,2696],{"trials":2752,"activeCount":102},[],{"trials":2754,"activeCount":102},[],{"trials":2756,"activeCount":102},[],{"intervention":2696,"totalTrials":1013,"cells":2758},{"EARLY_PHASE1":2759,"PHASE1":2761,"PHASE2":2763,"PHASE3":2769,"PHASE4":2771,"NA":2773},{"trials":2760,"activeCount":102},[],{"trials":2762,"activeCount":102},[],{"trials":2764,"activeCount":1013,"soonestReadout":747},[2765],{"nctId":2683,"briefTitle":2684,"status":229,"phases":2766,"primaryCompletion":747,"completion":2686,"start":2687,"enrollment":2688,"conditions":2767,"interventions":2768},[91],[2690,2691],[2674,2693,2694,2695,2696],{"trials":2770,"activeCount":102},[],{"trials":2772,"activeCount":102},[],{"trials":2774,"activeCount":102},[],{"intervention":416,"totalTrials":1013,"cells":2776},{"EARLY_PHASE1":2777,"PHASE1":2779,"PHASE2":2781,"PHASE3":2787,"PHASE4":2789,"NA":2791},{"trials":2778,"activeCount":102},[],{"trials":2780,"activeCount":102},[],{"trials":2782,"activeCount":1013,"soonestReadout":401},[2783],{"nctId":398,"briefTitle":399,"status":229,"phases":2784,"primaryCompletion":401,"completion":402,"start":403,"enrollment":404,"conditions":2785,"interventions":2786},[91],[190,191,406,407,200,192,193,21,408,409,410,411,412,195,413,197,414,370],[416,417,42,97,418,419,420],{"trials":2788,"activeCount":102},[],{"trials":2790,"activeCount":102},[],{"trials":2792,"activeCount":102},[],{"intervention":417,"totalTrials":1013,"cells":2794},{"EARLY_PHASE1":2795,"PHASE1":2797,"PHASE2":2799,"PHASE3":2805,"PHASE4":2807,"NA":2809},{"trials":2796,"activeCount":102},[],{"trials":2798,"activeCount":102},[],{"trials":2800,"activeCount":1013,"soonestReadout":401},[2801],{"nctId":398,"briefTitle":399,"status":229,"phases":2802,"primaryCompletion":401,"completion":402,"start":403,"enrollment":404,"conditions":2803,"interventions":2804},[91],[190,191,406,407,200,192,193,21,408,409,410,411,412,195,413,197,414,370],[416,417,42,97,418,419,420],{"trials":2806,"activeCount":102},[],{"trials":2808,"activeCount":102},[],{"trials":2810,"activeCount":102},[],{"intervention":418,"totalTrials":1013,"cells":2812},{"EARLY_PHASE1":2813,"PHASE1":2815,"PHASE2":2817,"PHASE3":2823,"PHASE4":2825,"NA":2827},{"trials":2814,"activeCount":102},[],{"trials":2816,"activeCount":102},[],{"trials":2818,"activeCount":1013,"soonestReadout":401},[2819],{"nctId":398,"briefTitle":399,"status":229,"phases":2820,"primaryCompletion":401,"completion":402,"start":403,"enrollment":404,"conditions":2821,"interventions":2822},[91],[190,191,406,407,200,192,193,21,408,409,410,411,412,195,413,197,414,370],[416,417,42,97,418,419,420],{"trials":2824,"activeCount":102},[],{"trials":2826,"activeCount":102},[],{"trials":2828,"activeCount":102},[],{"intervention":419,"totalTrials":1013,"cells":2830},{"EARLY_PHASE1":2831,"PHASE1":2833,"PHASE2":2835,"PHASE3":2841,"PHASE4":2843,"NA":2845},{"trials":2832,"activeCount":102},[],{"trials":2834,"activeCount":102},[],{"trials":2836,"activeCount":1013,"soonestReadout":401},[2837],{"nctId":398,"briefTitle":399,"status":229,"phases":2838,"primaryCompletion":401,"completion":402,"start":403,"enrollment":404,"conditions":2839,"interventions":2840},[91],[190,191,406,407,200,192,193,21,408,409,410,411,412,195,413,197,414,370],[416,417,42,97,418,419,420],{"trials":2842,"activeCount":102},[],{"trials":2844,"activeCount":102},[],{"trials":2846,"activeCount":102},[],{"intervention":2848,"totalTrials":1013,"cells":2849},"HSCT with TBI Regimen",{"EARLY_PHASE1":2850,"PHASE1":2852,"PHASE2":2854,"PHASE3":2871,"PHASE4":2873,"NA":2875},{"trials":2851,"activeCount":102},[],{"trials":2853,"activeCount":102},[],{"trials":2855,"activeCount":1013,"soonestReadout":2860},[2856],{"nctId":2857,"briefTitle":2858,"status":229,"phases":2859,"primaryCompletion":2860,"completion":2861,"start":2862,"enrollment":2863,"conditions":2864,"interventions":2869},"NCT03314974","Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders",[91],"2026-06-10","2027-06-10","2018-03-30",300,[264,26,174,18,192,193,2865,370,272,372,2866,194,195,922,197,198,199,200,2867,201,410,283,32,273,447,448,441,2868],"Myeloproliferative Neoplasms","High Risk Anemia","Diffuse Large Cell Non Hodgkins Lymphoma","Acquired Bone Marrow Failure Syndromes",[2848,2870],"HSCT with Non-TBI Regimen",{"trials":2872,"activeCount":102},[],{"trials":2874,"activeCount":102},[],{"trials":2876,"activeCount":102},[],{"intervention":2870,"totalTrials":1013,"cells":2878},{"EARLY_PHASE1":2879,"PHASE1":2881,"PHASE2":2883,"PHASE3":2889,"PHASE4":2891,"NA":2893},{"trials":2880,"activeCount":102},[],{"trials":2882,"activeCount":102},[],{"trials":2884,"activeCount":1013,"soonestReadout":2860},[2885],{"nctId":2857,"briefTitle":2858,"status":229,"phases":2886,"primaryCompletion":2860,"completion":2861,"start":2862,"enrollment":2863,"conditions":2887,"interventions":2888},[91],[264,26,174,18,192,193,2865,370,272,372,2866,194,195,922,197,198,199,200,2867,201,410,283,32,273,447,448,441,2868],[2848,2870],{"trials":2890,"activeCount":102},[],{"trials":2892,"activeCount":102},[],{"trials":2894,"activeCount":102},[],{"intervention":485,"totalTrials":1013,"cells":2896},{"EARLY_PHASE1":2897,"PHASE1":2899,"PHASE2":2901,"PHASE3":2907,"PHASE4":2909,"NA":2911},{"trials":2898,"activeCount":102},[],{"trials":2900,"activeCount":102},[],{"trials":2902,"activeCount":1013,"soonestReadout":41},[2903],{"nctId":39,"briefTitle":40,"status":474,"phases":2904,"primaryCompletion":41,"completion":476,"start":477,"enrollment":27,"conditions":2905,"interventions":2906},[91],[26,191,479,192,272,480,481,237,410,411,198],[42,97,483,208,420,484,87,242,485],{"trials":2908,"activeCount":102},[],{"trials":2910,"activeCount":102},[],{"trials":2912,"activeCount":102},[],{"intervention":1250,"totalTrials":1013,"cells":2914},{"EARLY_PHASE1":2915,"PHASE1":2917,"PHASE2":2919,"PHASE3":2925,"PHASE4":2927,"NA":2929},{"trials":2916,"activeCount":102},[],{"trials":2918,"activeCount":102},[],{"trials":2920,"activeCount":1013,"soonestReadout":1242},[2921],{"nctId":1239,"briefTitle":1240,"status":229,"phases":2922,"primaryCompletion":1242,"completion":1243,"start":1244,"enrollment":1245,"conditions":2923,"interventions":2924},[91],[1247,1248],[1250,1251,239,472,242],{"trials":2926,"activeCount":102},[],{"trials":2928,"activeCount":102},[],{"trials":2930,"activeCount":102},[],{"intervention":514,"totalTrials":1013,"cells":2932},{"EARLY_PHASE1":2933,"PHASE1":2935,"PHASE2":2937,"PHASE3":2943,"PHASE4":2945,"NA":2947},{"trials":2934,"activeCount":102},[],{"trials":2936,"activeCount":102},[],{"trials":2938,"activeCount":1013,"soonestReadout":504},[2939],{"nctId":501,"briefTitle":502,"status":229,"phases":2940,"primaryCompletion":504,"completion":505,"start":506,"enrollment":507,"conditions":2941,"interventions":2942},[91],[509,510,511,512],[285,514,97,42,515,516,208,420],{"trials":2944,"activeCount":102},[],{"trials":2946,"activeCount":102},[],{"trials":2948,"activeCount":102},[],{"intervention":516,"totalTrials":1013,"cells":2950},{"EARLY_PHASE1":2951,"PHASE1":2953,"PHASE2":2955,"PHASE3":2961,"PHASE4":2963,"NA":2965},{"trials":2952,"activeCount":102},[],{"trials":2954,"activeCount":102},[],{"trials":2956,"activeCount":1013,"soonestReadout":504},[2957],{"nctId":501,"briefTitle":502,"status":229,"phases":2958,"primaryCompletion":504,"completion":505,"start":506,"enrollment":507,"conditions":2959,"interventions":2960},[91],[509,510,511,512],[285,514,97,42,515,516,208,420],{"trials":2962,"activeCount":102},[],{"trials":2964,"activeCount":102},[],{"trials":2966,"activeCount":102},[],{"intervention":1701,"totalTrials":1013,"cells":2968},{"EARLY_PHASE1":2969,"PHASE1":2971,"PHASE2":2973,"PHASE3":2979,"PHASE4":2981,"NA":2983},{"trials":2970,"activeCount":102},[],{"trials":2972,"activeCount":102},[],{"trials":2974,"activeCount":1013,"soonestReadout":1695},[2975],{"nctId":1692,"briefTitle":1693,"status":229,"phases":2976,"primaryCompletion":1695,"completion":1696,"start":1697,"enrollment":1698,"conditions":2977,"interventions":2978},[91],[197,413],[1701,285,1702],{"trials":2980,"activeCount":102},[],{"trials":2982,"activeCount":102},[],{"trials":2984,"activeCount":102},[],{"intervention":2986,"totalTrials":1013,"cells":2987},"Oral Restorative Microbiota Therapy (RMT)",{"EARLY_PHASE1":2988,"PHASE1":2990,"PHASE2":2992,"PHASE3":3006,"PHASE4":3008,"NA":3010},{"trials":2989,"activeCount":102},[],{"trials":2991,"activeCount":102},[],{"trials":2993,"activeCount":1013,"soonestReadout":2998},[2994],{"nctId":2995,"briefTitle":2996,"status":229,"phases":2997,"primaryCompletion":2998,"completion":2998,"start":2999,"enrollment":3000,"conditions":3001,"interventions":3003},"NCT04105270","RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial",[91],"2028-01","2022-11-30",82,[3002,35],"Adenocarcinoma of Lung",[2986,3004,3005],"Durvalumab 1500 mg IV","Cisplatin\u002Fpemetrexed or Carboplatin\u002Fpemetrexed",{"trials":3007,"activeCount":102},[],{"trials":3009,"activeCount":102},[],{"trials":3011,"activeCount":102},[],{"intervention":3004,"totalTrials":1013,"cells":3013},{"EARLY_PHASE1":3014,"PHASE1":3016,"PHASE2":3018,"PHASE3":3024,"PHASE4":3026,"NA":3028},{"trials":3015,"activeCount":102},[],{"trials":3017,"activeCount":102},[],{"trials":3019,"activeCount":1013,"soonestReadout":2998},[3020],{"nctId":2995,"briefTitle":2996,"status":229,"phases":3021,"primaryCompletion":2998,"completion":2998,"start":2999,"enrollment":3000,"conditions":3022,"interventions":3023},[91],[3002,35],[2986,3004,3005],{"trials":3025,"activeCount":102},[],{"trials":3027,"activeCount":102},[],{"trials":3029,"activeCount":102},[],{"intervention":3005,"totalTrials":1013,"cells":3031},{"EARLY_PHASE1":3032,"PHASE1":3034,"PHASE2":3036,"PHASE3":3042,"PHASE4":3044,"NA":3046},{"trials":3033,"activeCount":102},[],{"trials":3035,"activeCount":102},[],{"trials":3037,"activeCount":1013,"soonestReadout":2998},[3038],{"nctId":2995,"briefTitle":2996,"status":229,"phases":3039,"primaryCompletion":2998,"completion":2998,"start":2999,"enrollment":3000,"conditions":3040,"interventions":3041},[91],[3002,35],[2986,3004,3005],{"trials":3043,"activeCount":102},[],{"trials":3045,"activeCount":102},[],{"trials":3047,"activeCount":102},[],{"intervention":638,"totalTrials":1013,"cells":3049},{"EARLY_PHASE1":3050,"PHASE1":3052,"PHASE2":3054,"PHASE3":3060,"PHASE4":3062,"NA":3064},{"trials":3051,"activeCount":102},[],{"trials":3053,"activeCount":102},[],{"trials":3055,"activeCount":1013,"soonestReadout":631},[3056],{"nctId":628,"briefTitle":629,"status":229,"phases":3057,"primaryCompletion":631,"completion":632,"start":633,"enrollment":579,"conditions":3058,"interventions":3059},[90,91],[635,636,190],[638,42,97,164],{"trials":3061,"activeCount":102},[],{"trials":3063,"activeCount":102},[],{"trials":3065,"activeCount":102},[],{"intervention":1106,"totalTrials":1013,"cells":3067},{"EARLY_PHASE1":3068,"PHASE1":3070,"PHASE2":3072,"PHASE3":3078,"PHASE4":3080,"NA":3082},{"trials":3069,"activeCount":102},[],{"trials":3071,"activeCount":102},[],{"trials":3073,"activeCount":1013,"soonestReadout":1100},[3074],{"nctId":1097,"briefTitle":1098,"status":229,"phases":3075,"primaryCompletion":1100,"completion":1101,"start":1102,"enrollment":1103,"conditions":3076,"interventions":3077},[91],[266,371,264,26,21],[1106,42,208,420,1107,1108],{"trials":3079,"activeCount":102},[],{"trials":3081,"activeCount":102},[],{"trials":3083,"activeCount":102},[],{"intervention":1107,"totalTrials":1013,"cells":3085},{"EARLY_PHASE1":3086,"PHASE1":3088,"PHASE2":3090,"PHASE3":3096,"PHASE4":3098,"NA":3100},{"trials":3087,"activeCount":102},[],{"trials":3089,"activeCount":102},[],{"trials":3091,"activeCount":1013,"soonestReadout":1100},[3092],{"nctId":1097,"briefTitle":1098,"status":229,"phases":3093,"primaryCompletion":1100,"completion":1101,"start":1102,"enrollment":1103,"conditions":3094,"interventions":3095},[91],[266,371,264,26,21],[1106,42,208,420,1107,1108],{"trials":3097,"activeCount":102},[],{"trials":3099,"activeCount":102},[],{"trials":3101,"activeCount":102},[],{"intervention":2043,"totalTrials":1013,"cells":3103},{"EARLY_PHASE1":3104,"PHASE1":3106,"PHASE2":3108,"PHASE3":3114,"PHASE4":3116,"NA":3118},{"trials":3105,"activeCount":102},[],{"trials":3107,"activeCount":102},[],{"trials":3109,"activeCount":1013,"soonestReadout":76},[3110],{"nctId":74,"briefTitle":75,"status":474,"phases":3111,"primaryCompletion":76,"completion":2019,"start":2020,"enrollment":2021,"conditions":3112,"interventions":3113},[91],[2023,648,649,2024,583,2025,585,586,2026,587,2027,1285,1284,2028,2029,2030,652,2031,2032,2033,2034,2035,2036,2037,2038,2039,842,2040,2041],[77,2043,2044,2045,2046,2047,2048,2048],{"trials":3115,"activeCount":102},[],{"trials":3117,"activeCount":102},[],{"trials":3119,"activeCount":102},[],{"intervention":2044,"totalTrials":1013,"cells":3121},{"EARLY_PHASE1":3122,"PHASE1":3124,"PHASE2":3126,"PHASE3":3132,"PHASE4":3134,"NA":3136},{"trials":3123,"activeCount":102},[],{"trials":3125,"activeCount":102},[],{"trials":3127,"activeCount":1013,"soonestReadout":76},[3128],{"nctId":74,"briefTitle":75,"status":474,"phases":3129,"primaryCompletion":76,"completion":2019,"start":2020,"enrollment":2021,"conditions":3130,"interventions":3131},[91],[2023,648,649,2024,583,2025,585,586,2026,587,2027,1285,1284,2028,2029,2030,652,2031,2032,2033,2034,2035,2036,2037,2038,2039,842,2040,2041],[77,2043,2044,2045,2046,2047,2048,2048],{"trials":3133,"activeCount":102},[],{"trials":3135,"activeCount":102},[],{"trials":3137,"activeCount":102},[],{"intervention":2045,"totalTrials":1013,"cells":3139},{"EARLY_PHASE1":3140,"PHASE1":3142,"PHASE2":3144,"PHASE3":3150,"PHASE4":3152,"NA":3154},{"trials":3141,"activeCount":102},[],{"trials":3143,"activeCount":102},[],{"trials":3145,"activeCount":1013,"soonestReadout":76},[3146],{"nctId":74,"briefTitle":75,"status":474,"phases":3147,"primaryCompletion":76,"completion":2019,"start":2020,"enrollment":2021,"conditions":3148,"interventions":3149},[91],[2023,648,649,2024,583,2025,585,586,2026,587,2027,1285,1284,2028,2029,2030,652,2031,2032,2033,2034,2035,2036,2037,2038,2039,842,2040,2041],[77,2043,2044,2045,2046,2047,2048,2048],{"trials":3151,"activeCount":102},[],{"trials":3153,"activeCount":102},[],{"trials":3155,"activeCount":102},[],{"intervention":2046,"totalTrials":1013,"cells":3157},{"EARLY_PHASE1":3158,"PHASE1":3160,"PHASE2":3162,"PHASE3":3168,"PHASE4":3170,"NA":3172},{"trials":3159,"activeCount":102},[],{"trials":3161,"activeCount":102},[],{"trials":3163,"activeCount":1013,"soonestReadout":76},[3164],{"nctId":74,"briefTitle":75,"status":474,"phases":3165,"primaryCompletion":76,"completion":2019,"start":2020,"enrollment":2021,"conditions":3166,"interventions":3167},[91],[2023,648,649,2024,583,2025,585,586,2026,587,2027,1285,1284,2028,2029,2030,652,2031,2032,2033,2034,2035,2036,2037,2038,2039,842,2040,2041],[77,2043,2044,2045,2046,2047,2048,2048],{"trials":3169,"activeCount":102},[],{"trials":3171,"activeCount":102},[],{"trials":3173,"activeCount":102},[],{"intervention":2047,"totalTrials":1013,"cells":3175},{"EARLY_PHASE1":3176,"PHASE1":3178,"PHASE2":3180,"PHASE3":3186,"PHASE4":3188,"NA":3190},{"trials":3177,"activeCount":102},[],{"trials":3179,"activeCount":102},[],{"trials":3181,"activeCount":1013,"soonestReadout":76},[3182],{"nctId":74,"briefTitle":75,"status":474,"phases":3183,"primaryCompletion":76,"completion":2019,"start":2020,"enrollment":2021,"conditions":3184,"interventions":3185},[91],[2023,648,649,2024,583,2025,585,586,2026,587,2027,1285,1284,2028,2029,2030,652,2031,2032,2033,2034,2035,2036,2037,2038,2039,842,2040,2041],[77,2043,2044,2045,2046,2047,2048,2048],{"trials":3187,"activeCount":102},[],{"trials":3189,"activeCount":102},[],{"trials":3191,"activeCount":102},[],{"intervention":2048,"totalTrials":1013,"cells":3193},{"EARLY_PHASE1":3194,"PHASE1":3196,"PHASE2":3198,"PHASE3":3204,"PHASE4":3206,"NA":3208},{"trials":3195,"activeCount":102},[],{"trials":3197,"activeCount":102},[],{"trials":3199,"activeCount":1013,"soonestReadout":76},[3200],{"nctId":74,"briefTitle":75,"status":474,"phases":3201,"primaryCompletion":76,"completion":2019,"start":2020,"enrollment":2021,"conditions":3202,"interventions":3203},[91],[2023,648,649,2024,583,2025,585,586,2026,587,2027,1285,1284,2028,2029,2030,652,2031,2032,2033,2034,2035,2036,2037,2038,2039,842,2040,2041],[77,2043,2044,2045,2046,2047,2048,2048],{"trials":3205,"activeCount":102},[],{"trials":3207,"activeCount":102},[],{"trials":3209,"activeCount":102},[],{"intervention":2164,"totalTrials":1013,"cells":3211},{"EARLY_PHASE1":3212,"PHASE1":3214,"PHASE2":3216,"PHASE3":3222,"PHASE4":3224,"NA":3226},{"trials":3213,"activeCount":102},[],{"trials":3215,"activeCount":102},[],{"trials":3217,"activeCount":1013,"soonestReadout":2159},[3218],{"nctId":2156,"briefTitle":2157,"status":229,"phases":3219,"primaryCompletion":2159,"completion":2160,"start":2161,"enrollment":737,"conditions":3220,"interventions":3221},[90,91],[26,267],[2129,2164],{"trials":3223,"activeCount":102},[],{"trials":3225,"activeCount":102},[],{"trials":3227,"activeCount":102},[],{"intervention":224,"totalTrials":1454,"cells":3229},{"EARLY_PHASE1":3230,"PHASE1":3232,"PHASE2":3234,"PHASE3":3264,"PHASE4":3274,"NA":3276},{"trials":3231,"activeCount":102},[],{"trials":3233,"activeCount":102},[],{"trials":3235,"activeCount":1013,"soonestReadout":747},[3236,3240,3244,3248,3252,3256,3260],{"nctId":213,"briefTitle":214,"status":125,"phases":3237,"primaryCompletion":216,"completion":216,"start":217,"enrollment":36,"conditions":3238,"interventions":3239},[91],[219],[221,222,223,118,120,224,225],{"nctId":290,"briefTitle":291,"status":125,"phases":3241,"primaryCompletion":293,"completion":293,"start":294,"enrollment":295,"conditions":3242,"interventions":3243},[91],[24,297,298,29],[42,97,300,301,164,302,302,303],{"nctId":352,"briefTitle":353,"status":125,"phases":3245,"primaryCompletion":355,"completion":356,"start":357,"enrollment":358,"conditions":3246,"interventions":3247},[91],[236,194],[285,303,301,97,302,42],{"nctId":518,"briefTitle":519,"status":125,"phases":3249,"primaryCompletion":216,"completion":216,"start":521,"enrollment":522,"conditions":3250,"interventions":3251},[90,91],[219],[525,97,42,302,526,300,420],{"nctId":595,"briefTitle":596,"status":108,"phases":3253,"primaryCompletion":598,"completion":598,"start":599,"enrollment":358,"conditions":3254,"interventions":3255},[91],[15,21],[253,222,602,118,119,120,224,121],{"nctId":2196,"briefTitle":2197,"status":108,"phases":3257,"primaryCompletion":2199,"completion":2199,"start":2200,"enrollment":1013,"conditions":3258,"interventions":3259},[90,91],[15],[119,392,222,804,224,395,2203],{"nctId":744,"briefTitle":745,"status":229,"phases":3261,"primaryCompletion":747,"completion":748,"start":749,"enrollment":8,"conditions":3262,"interventions":3263},[91],[219,509,21,751,752,753,754,755],[483,97,42,302,243,97,285,87,626,242,285],{"trials":3265,"activeCount":102},[3266,3270],{"nctId":797,"briefTitle":798,"status":307,"phases":3267,"primaryCompletion":800,"completion":800,"start":801,"enrollment":102,"conditions":3268,"interventions":3269},[92],[114,15,18],[221,118,119,804,224],{"nctId":815,"briefTitle":816,"status":125,"phases":3271,"primaryCompletion":818,"completion":492,"start":819,"enrollment":820,"conditions":3272,"interventions":3273},[91,92],[754,822],[824,97,42,825,302],{"trials":3275,"activeCount":102},[],{"trials":3277,"activeCount":102},[3278],{"nctId":902,"briefTitle":903,"status":108,"phases":3279,"primaryCompletion":905,"completion":905,"start":906,"enrollment":907,"conditions":3280,"interventions":3281},[94],[886,909,219,114,15,18,115,21,910],[221,223,118,119,222,912,224,121],{"intervention":497,"totalTrials":130,"cells":3283},{"EARLY_PHASE1":3284,"PHASE1":3286,"PHASE2":3288,"PHASE3":3334,"PHASE4":3336,"NA":3338},{"trials":3285,"activeCount":102},[],{"trials":3287,"activeCount":102},[],{"trials":3289,"activeCount":1013,"soonestReadout":490},[3290,3298,3310,3314,3321,3330],{"nctId":3291,"briefTitle":3292,"status":125,"phases":3293,"primaryCompletion":567,"completion":567,"start":1909,"enrollment":144,"conditions":3294,"interventions":3296},"NCT00258362","Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III\u002FIV, or Recurrent Endometrial Cancer",[91],[3295],"Endometrial Cancer",[1790,3297],"docetaxel",{"nctId":3299,"briefTitle":3300,"status":125,"phases":3301,"primaryCompletion":3302,"completion":3303,"start":3304,"enrollment":864,"conditions":3305,"interventions":3306},"NCT03934840","CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone",[91],"2023-06-19","2025-04-03","2019-10-10",[2117],[3307,497,3308,3309],"Cabazitaxel","Abiraterone","Prednisone",{"nctId":487,"briefTitle":488,"status":229,"phases":3311,"primaryCompletion":490,"completion":491,"start":492,"enrollment":9,"conditions":3312,"interventions":3313},[91],[494],[496,97,242,239,497,498,499],{"nctId":3315,"briefTitle":3316,"status":108,"phases":3317,"primaryCompletion":110,"completion":1453,"start":3318,"enrollment":669,"conditions":3319,"interventions":3320},"NCT00331422","Carboplatin, Paclitaxel, and Surgery in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer",[91],"2005-10",[297,24,763],[1790,1791],{"nctId":3322,"briefTitle":3323,"status":108,"phases":3324,"primaryCompletion":110,"completion":3325,"start":3326,"enrollment":27,"conditions":3327,"interventions":3328},"NCT00281827","Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer",[91],"2008-07","2002-05",[35],[1790,2119,3329],"thalidomide",{"nctId":1782,"briefTitle":1783,"status":125,"phases":3331,"primaryCompletion":1785,"completion":1785,"start":1786,"enrollment":1205,"conditions":3332,"interventions":3333},[91],[1190,24,1788],[1790,394,1208,1791,1197,1209,222],{"trials":3335,"activeCount":102},[],{"trials":3337,"activeCount":102},[],{"trials":3339,"activeCount":102},[3340,3351,3355],{"nctId":3341,"briefTitle":3342,"status":108,"phases":3343,"primaryCompletion":3344,"completion":3345,"start":3346,"enrollment":1454,"conditions":3347,"interventions":3349},"NCT01144442","WCC# 59 Hyperthermic Intraperitoneal Chemotherapy Utilizing Carboplatin in First Recurrence Ovarian Cancer",[94],"2013-09-25","2015-05-01","2010-07-27",[24,297,3348],"Peritoneal Carcinoma",[3350,497,1366],"Hyperthermic intraperitoneal chemotherapy with Carboplatin",{"nctId":1336,"briefTitle":1337,"status":125,"phases":3352,"primaryCompletion":1339,"completion":1339,"start":1340,"enrollment":295,"conditions":3353,"interventions":3354},[94],[494],[497,1343,499,1344,242,239],{"nctId":1346,"briefTitle":1347,"status":125,"phases":3356,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":3357,"interventions":3358},[94],[1353,1354,1355,1356,1357,1358,1193,1359,1360,1361,1362,1363],[1365,239,1209,243,87,242,496,1343,497,1366,1367,1368],{"intervention":1343,"totalTrials":112,"cells":3360},{"EARLY_PHASE1":3361,"PHASE1":3363,"PHASE2":3365,"PHASE3":3371,"PHASE4":3373,"NA":3375},{"trials":3362,"activeCount":102},[],{"trials":3364,"activeCount":102},[],{"trials":3366,"activeCount":1013,"soonestReadout":490},[3367],{"nctId":487,"briefTitle":488,"status":229,"phases":3368,"primaryCompletion":490,"completion":491,"start":492,"enrollment":9,"conditions":3369,"interventions":3370},[91],[494],[496,97,242,239,497,498,499],{"trials":3372,"activeCount":102},[],{"trials":3374,"activeCount":102},[],{"trials":3376,"activeCount":102},[3377,3381],{"nctId":1336,"briefTitle":1337,"status":125,"phases":3378,"primaryCompletion":1339,"completion":1339,"start":1340,"enrollment":295,"conditions":3379,"interventions":3380},[94],[494],[497,1343,499,1344,242,239],{"nctId":1346,"briefTitle":1347,"status":125,"phases":3382,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":3383,"interventions":3384},[94],[1353,1354,1355,1356,1357,1358,1193,1359,1360,1361,1362,1363],[1365,239,1209,243,87,242,496,1343,497,1366,1367,1368],{"intervention":499,"totalTrials":158,"cells":3386},{"EARLY_PHASE1":3387,"PHASE1":3389,"PHASE2":3391,"PHASE3":3397,"PHASE4":3399,"NA":3401},{"trials":3388,"activeCount":102},[],{"trials":3390,"activeCount":102},[],{"trials":3392,"activeCount":1013,"soonestReadout":490},[3393],{"nctId":487,"briefTitle":488,"status":229,"phases":3394,"primaryCompletion":490,"completion":491,"start":492,"enrollment":9,"conditions":3395,"interventions":3396},[91],[494],[496,97,242,239,497,498,499],{"trials":3398,"activeCount":102},[],{"trials":3400,"activeCount":102},[],{"trials":3402,"activeCount":102},[3403],{"nctId":1336,"briefTitle":1337,"status":125,"phases":3404,"primaryCompletion":1339,"completion":1339,"start":1340,"enrollment":295,"conditions":3405,"interventions":3406},[94],[494],[497,1343,499,1344,242,239],{"intervention":82,"totalTrials":158,"cells":3408},{"EARLY_PHASE1":3409,"PHASE1":3411,"PHASE2":3428,"PHASE3":3430,"PHASE4":3432,"NA":3434},{"trials":3410,"activeCount":102},[],{"trials":3412,"activeCount":158,"soonestReadout":81},[3413,3424],{"nctId":3414,"briefTitle":3415,"status":229,"phases":3416,"primaryCompletion":2399,"completion":3417,"start":3418,"enrollment":130,"conditions":3419,"interventions":3423},"NCT07560865","First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma",[90],"2029-06-01","2026-04-23",[3420,3421,3422],"Astrocytoma","Glioblastoma","Progressive Disease",[82],{"nctId":79,"briefTitle":80,"status":474,"phases":3425,"primaryCompletion":81,"completion":998,"start":999,"enrollment":112,"conditions":3426,"interventions":3427},[90],[1001,24,297,1002],[82,42,1004],{"trials":3429,"activeCount":102},[],{"trials":3431,"activeCount":102},[],{"trials":3433,"activeCount":102},[],{"trials":3435,"activeCount":102},[],{"intervention":3437,"totalTrials":1013,"cells":3438},"Peptide Alarm Therapy",{"EARLY_PHASE1":3439,"PHASE1":3441,"PHASE2":3453,"PHASE3":3455,"PHASE4":3457,"NA":3459},{"trials":3440,"activeCount":102},[],{"trials":3442,"activeCount":1013,"soonestReadout":3447},[3443],{"nctId":3444,"briefTitle":3445,"status":229,"phases":3446,"primaryCompletion":3447,"completion":3447,"start":3448,"enrollment":30,"conditions":3449,"interventions":3452},"NCT05338658","Study of PAT in Patients With Solid Tumor Cancers",[90],"2027-01","2023-05-19",[3450,3451],"Metastasis","Solid Tumor",[3437],{"trials":3454,"activeCount":102},[],{"trials":3456,"activeCount":102},[],{"trials":3458,"activeCount":102},[],{"trials":3460,"activeCount":102},[],{"intervention":3462,"totalTrials":1013,"cells":3463},"GTB-5550",{"EARLY_PHASE1":3464,"PHASE1":3466,"PHASE2":3480,"PHASE3":3482,"PHASE4":3484,"NA":3486},{"trials":3465,"activeCount":102},[],{"trials":3467,"activeCount":1013,"soonestReadout":3472},[3468],{"nctId":3469,"briefTitle":3470,"status":229,"phases":3471,"primaryCompletion":3472,"completion":3473,"start":3474,"enrollment":3475,"conditions":3476,"interventions":3479},"NCT07541573","GTB-5550 in Advanced Solid Tumors",[90],"2031-01","2032-01","2026-04-08",175,[3477,3451,3478],"Tri-specific Killer Engager","Advanced Solid Tumor",[3462],{"trials":3481,"activeCount":102},[],{"trials":3483,"activeCount":102},[],{"trials":3485,"activeCount":102},[],{"trials":3487,"activeCount":102},[],{"intervention":1613,"totalTrials":1013,"cells":3489},{"EARLY_PHASE1":3490,"PHASE1":3492,"PHASE2":3498,"PHASE3":3500,"PHASE4":3502,"NA":3504},{"trials":3491,"activeCount":102},[],{"trials":3493,"activeCount":1013,"soonestReadout":1608},[3494],{"nctId":1605,"briefTitle":1606,"status":229,"phases":3495,"primaryCompletion":1608,"completion":1608,"start":1609,"enrollment":1137,"conditions":3496,"interventions":3497},[90],[1611],[1613,208],{"trials":3499,"activeCount":102},[],{"trials":3501,"activeCount":102},[],{"trials":3503,"activeCount":102},[],{"trials":3505,"activeCount":102},[],{"intervention":3507,"totalTrials":1013,"cells":3508},"GTB-360",{"EARLY_PHASE1":3509,"PHASE1":3511,"PHASE2":3523,"PHASE3":3525,"PHASE4":3527,"NA":3529},{"trials":3510,"activeCount":102},[],{"trials":3512,"activeCount":1013,"soonestReadout":3517},[3513],{"nctId":3514,"briefTitle":3515,"status":229,"phases":3516,"primaryCompletion":3517,"completion":3518,"start":619,"enrollment":3519,"conditions":3520,"interventions":3522},"NCT06594445","HM2023-05: GTB-3650 Trike for High Risk MDS and R\u002FR AML",[90],"2027-03-30","2027-10-30",45,[3521,26,21],"Myeloid Malignancy",[3507],{"trials":3524,"activeCount":102},[],{"trials":3526,"activeCount":102},[],{"trials":3528,"activeCount":102},[],{"trials":3530,"activeCount":102},[],{"intervention":62,"totalTrials":1013,"cells":3532},{"EARLY_PHASE1":3533,"PHASE1":3535,"PHASE2":3545,"PHASE3":3547,"PHASE4":3549,"NA":3551},{"trials":3534,"activeCount":102},[],{"trials":3536,"activeCount":1013,"soonestReadout":61},[3537],{"nctId":59,"briefTitle":60,"status":474,"phases":3538,"primaryCompletion":61,"completion":3539,"start":3540,"enrollment":3541,"conditions":3542,"interventions":3544},[90],"2026-08","2021-10-19",55,[3543],"Smokeless Tobacco",[62],{"trials":3546,"activeCount":102},[],{"trials":3548,"activeCount":102},[],{"trials":3550,"activeCount":102},[],{"trials":3552,"activeCount":102},[],{"intervention":57,"totalTrials":1013,"cells":3554},{"EARLY_PHASE1":3555,"PHASE1":3557,"PHASE2":3567,"PHASE3":3569,"PHASE4":3571,"NA":3573},{"trials":3556,"activeCount":102},[],{"trials":3558,"activeCount":1013,"soonestReadout":56},[3559],{"nctId":54,"briefTitle":55,"status":474,"phases":3560,"primaryCompletion":56,"completion":3561,"start":3562,"enrollment":3563,"conditions":3564,"interventions":3566},[90],"2026-05-20","2022-05-11",47,[3565],"Smoking, Cigarette",[57],{"trials":3568,"activeCount":102},[],{"trials":3570,"activeCount":102},[],{"trials":3572,"activeCount":102},[],{"trials":3574,"activeCount":102},[],{"intervention":1004,"totalTrials":1013,"cells":3576},{"EARLY_PHASE1":3577,"PHASE1":3579,"PHASE2":3585,"PHASE3":3587,"PHASE4":3589,"NA":3591},{"trials":3578,"activeCount":102},[],{"trials":3580,"activeCount":1013,"soonestReadout":81},[3581],{"nctId":79,"briefTitle":80,"status":474,"phases":3582,"primaryCompletion":81,"completion":998,"start":999,"enrollment":112,"conditions":3583,"interventions":3584},[90],[1001,24,297,1002],[82,42,1004],{"trials":3586,"activeCount":102},[],{"trials":3588,"activeCount":102},[],{"trials":3590,"activeCount":102},[],{"trials":3592,"activeCount":102},[],{"intervention":3594,"totalTrials":1013,"cells":3595},"Replicative Adenovirus Vector",{"EARLY_PHASE1":3596,"PHASE1":3598,"PHASE2":3610,"PHASE3":3612,"PHASE4":3614,"NA":3616},{"trials":3597,"activeCount":102},[],{"trials":3599,"activeCount":1013,"soonestReadout":3604},[3600],{"nctId":3601,"briefTitle":3602,"status":229,"phases":3603,"primaryCompletion":3604,"completion":3605,"start":3606,"enrollment":579,"conditions":3607,"interventions":3609},"NCT06693986","Adenovirus (RGDCRAdCOX2F)",[90],"2028-10-15","2029-10-15","2024-12-27",[3608],"Adenocarcinoma of Pancreas",[3594],{"trials":3611,"activeCount":102},[],{"trials":3613,"activeCount":102},[],{"trials":3615,"activeCount":102},[],{"trials":3617,"activeCount":102},[],{"intervention":393,"totalTrials":460,"cells":3619},{"EARLY_PHASE1":3620,"PHASE1":3627,"PHASE2":3629,"PHASE3":3647,"PHASE4":3653,"NA":3655},{"trials":3621,"activeCount":1013,"soonestReadout":46},[3622],{"nctId":44,"briefTitle":45,"status":474,"phases":3623,"primaryCompletion":46,"completion":491,"start":3624,"enrollment":986,"conditions":3625,"interventions":3626},[89],"2020-08-06",[18],[47,2131],{"trials":3628,"activeCount":102},[],{"trials":3630,"activeCount":102},[3631,3635,3639,3643],{"nctId":2123,"briefTitle":2124,"status":108,"phases":3632,"primaryCompletion":894,"completion":894,"start":2126,"enrollment":158,"conditions":3633,"interventions":3634},[91],[174],[2129,2130,2131,2132,2133],{"nctId":384,"briefTitle":385,"status":307,"phases":3636,"primaryCompletion":387,"completion":387,"start":388,"enrollment":102,"conditions":3637,"interventions":3638},[91],[18],[391,118,392,393,394,222,395,396],{"nctId":547,"briefTitle":548,"status":125,"phases":3640,"primaryCompletion":550,"completion":550,"start":329,"enrollment":368,"conditions":3641,"interventions":3642},[91],[18],[222,391,118,392,393,394,395],{"nctId":656,"briefTitle":657,"status":108,"phases":3644,"primaryCompletion":659,"completion":659,"start":329,"enrollment":660,"conditions":3645,"interventions":3646},[91],[115],[391,118,393,394,222,395,332,663],{"trials":3648,"activeCount":102},[3649],{"nctId":846,"briefTitle":847,"status":108,"phases":3650,"primaryCompletion":849,"completion":849,"start":850,"enrollment":9,"conditions":3651,"interventions":3652},[91,92],[15],[663,223,118,393,394],{"trials":3654,"activeCount":102},[],{"trials":3656,"activeCount":102},[],{"intervention":47,"totalTrials":1013,"cells":3658},{"EARLY_PHASE1":3659,"PHASE1":3665,"PHASE2":3667,"PHASE3":3669,"PHASE4":3671,"NA":3673},{"trials":3660,"activeCount":1013,"soonestReadout":46},[3661],{"nctId":44,"briefTitle":45,"status":474,"phases":3662,"primaryCompletion":46,"completion":491,"start":3624,"enrollment":986,"conditions":3663,"interventions":3664},[89],[18],[47,2131],{"trials":3666,"activeCount":102},[],{"trials":3668,"activeCount":102},[],{"trials":3670,"activeCount":102},[],{"trials":3672,"activeCount":102},[],{"trials":3674,"activeCount":102},[],{"intervention":867,"totalTrials":1438,"cells":3676},{"EARLY_PHASE1":3677,"PHASE1":3679,"PHASE2":3681,"PHASE3":3693,"PHASE4":3695,"NA":3697},{"trials":3678,"activeCount":102},[],{"trials":3680,"activeCount":102},[],{"trials":3682,"activeCount":102},[3683],{"nctId":3684,"briefTitle":3685,"status":125,"phases":3686,"primaryCompletion":3687,"completion":3688,"start":3689,"enrollment":426,"conditions":3690,"interventions":3691},"NCT00167219","Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)",[90,91],"2022-07-12","2023-08-09","1999-11-18",[273],[867,3692],"Preparative Regimen",{"trials":3694,"activeCount":102},[],{"trials":3696,"activeCount":102},[],{"trials":3698,"activeCount":1013,"soonestReadout":86},[3699,3703,3707],{"nctId":858,"briefTitle":859,"status":125,"phases":3700,"primaryCompletion":861,"completion":862,"start":863,"enrollment":864,"conditions":3701,"interventions":3702},[94],[754,822],[626,42,97,867,741],{"nctId":934,"briefTitle":935,"status":108,"phases":3704,"primaryCompletion":937,"completion":937,"start":938,"enrollment":939,"conditions":3705,"interventions":3706},[94],[941,266,834,371,942,943,944,945,32],[867,97,87,947,948],{"nctId":84,"briefTitle":85,"status":229,"phases":3708,"primaryCompletion":86,"completion":1166,"start":172,"enrollment":16,"conditions":3709,"interventions":3710},[94],[1168,624,1169],[87,42,1171,898],{"intervention":1209,"totalTrials":1438,"cells":3712},{"EARLY_PHASE1":3713,"PHASE1":3715,"PHASE2":3721,"PHASE3":3727,"PHASE4":3729,"NA":3731},{"trials":3714,"activeCount":102},[],{"trials":3716,"activeCount":102},[3717],{"nctId":1199,"briefTitle":1200,"status":108,"phases":3718,"primaryCompletion":1202,"completion":1203,"start":1204,"enrollment":1205,"conditions":3719,"interventions":3720},[90],[1189,700,1192,1193,1194],[222,223,394,1208,912,1197,1209],{"trials":3722,"activeCount":102},[3723],{"nctId":1782,"briefTitle":1783,"status":125,"phases":3724,"primaryCompletion":1785,"completion":1785,"start":1786,"enrollment":1205,"conditions":3725,"interventions":3726},[91],[1190,24,1788],[1790,394,1208,1791,1197,1209,222],{"trials":3728,"activeCount":102},[],{"trials":3730,"activeCount":102},[],{"trials":3732,"activeCount":1013,"soonestReadout":71},[3733,3737],{"nctId":1346,"briefTitle":1347,"status":125,"phases":3734,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":3735,"interventions":3736},[94],[1353,1354,1355,1356,1357,1358,1193,1359,1360,1361,1362,1363],[1365,239,1209,243,87,242,496,1343,497,1366,1367,1368],{"nctId":69,"briefTitle":70,"status":474,"phases":3738,"primaryCompletion":71,"completion":491,"start":951,"enrollment":952,"conditions":3739,"interventions":3740},[94],[954,955,956,957,958,959,960,961,962,963,964,965,966,967],[72,97,87,77,969,242,970,87,971,972],{"intervention":3742,"totalTrials":158,"cells":3743},"Umbilical Cord Blood",{"EARLY_PHASE1":3744,"PHASE1":3746,"PHASE2":3748,"PHASE3":3750,"PHASE4":3752,"NA":3754},{"trials":3745,"activeCount":102},[],{"trials":3747,"activeCount":102},[],{"trials":3749,"activeCount":102},[],{"trials":3751,"activeCount":102},[],{"trials":3753,"activeCount":102},[],{"trials":3755,"activeCount":1013,"soonestReadout":680},[3756,3766],{"nctId":3757,"briefTitle":3758,"status":229,"phases":3759,"primaryCompletion":680,"completion":3760,"start":1350,"enrollment":3761,"conditions":3762,"interventions":3765},"NCT01451502","Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units",[94],"2027-02",250,[3763,3764],"Lymphatic Diseases","Hematopoietic Malignancy",[3742],{"nctId":914,"briefTitle":915,"status":108,"phases":3767,"primaryCompletion":917,"completion":917,"start":171,"enrollment":918,"conditions":3768,"interventions":3769},[94],[920,921,192,193,370,272,194,195,922,197,198,199,200,684,201,202,236,32],[42,97,654,924,925],{"intervention":898,"totalTrials":158,"cells":3771},{"EARLY_PHASE1":3772,"PHASE1":3774,"PHASE2":3776,"PHASE3":3778,"PHASE4":3780,"NA":3782},{"trials":3773,"activeCount":102},[],{"trials":3775,"activeCount":102},[],{"trials":3777,"activeCount":102},[],{"trials":3779,"activeCount":102},[],{"trials":3781,"activeCount":102},[],{"trials":3783,"activeCount":1013,"soonestReadout":86},[3784,3788],{"nctId":890,"briefTitle":891,"status":108,"phases":3785,"primaryCompletion":893,"completion":893,"start":894,"enrollment":895,"conditions":3786,"interventions":3787},[94],[174,26,175],[149,898,87,97,208,899,900,526,825],{"nctId":84,"briefTitle":85,"status":229,"phases":3789,"primaryCompletion":86,"completion":1166,"start":172,"enrollment":16,"conditions":3790,"interventions":3791},[94],[1168,624,1169],[87,42,1171,898],{"intervention":3793,"totalTrials":1013,"cells":3794},"Alcohol",{"EARLY_PHASE1":3795,"PHASE1":3797,"PHASE2":3799,"PHASE3":3801,"PHASE4":3803,"NA":3805},{"trials":3796,"activeCount":102},[],{"trials":3798,"activeCount":102},[],{"trials":3800,"activeCount":102},[],{"trials":3802,"activeCount":102},[],{"trials":3804,"activeCount":102},[],{"trials":3806,"activeCount":1013,"soonestReadout":3811},[3807],{"nctId":3808,"briefTitle":3809,"status":229,"phases":3810,"primaryCompletion":3811,"completion":3812,"start":3813,"enrollment":3814,"conditions":3815,"interventions":3818},"NCT05973656","Role of Acetaldehyde in the Development of Oral Cancer",[94],"2026-11-30","2027-09-30","2022-07-08",170,[3816,219,3817],"Alcohol-Related Carcinoma","Oral Cavity Carcinoma",[3793],{"intervention":67,"totalTrials":1013,"cells":3820},{"EARLY_PHASE1":3821,"PHASE1":3823,"PHASE2":3825,"PHASE3":3827,"PHASE4":3829,"NA":3831},{"trials":3822,"activeCount":102},[],{"trials":3824,"activeCount":102},[],{"trials":3826,"activeCount":102},[],{"trials":3828,"activeCount":102},[],{"trials":3830,"activeCount":102},[],{"trials":3832,"activeCount":1013,"soonestReadout":66},[3833],{"nctId":64,"briefTitle":65,"status":474,"phases":3834,"primaryCompletion":66,"completion":490,"start":3835,"enrollment":295,"conditions":3836,"interventions":3839},[],"2022-11-17",[3837,3838],"Hematopoietic Cell Transplantation","Mucopolysaccharidosis Type I",[67],{"intervention":3841,"totalTrials":1013,"cells":3842},"Nicoderm CQ nicotine patch",{"EARLY_PHASE1":3843,"PHASE1":3845,"PHASE2":3847,"PHASE3":3849,"PHASE4":3851,"NA":3853},{"trials":3844,"activeCount":102},[],{"trials":3846,"activeCount":102},[],{"trials":3848,"activeCount":102},[],{"trials":3850,"activeCount":102},[],{"trials":3852,"activeCount":102},[],{"trials":3854,"activeCount":1013,"soonestReadout":3860},[3855],{"nctId":3856,"briefTitle":3857,"status":3858,"phases":3859,"primaryCompletion":3860,"completion":3861,"start":3862,"enrollment":3863,"conditions":3864,"interventions":3866},"NCT06584929","Rural Smoking Cessation","NOT_YET_RECRUITING",[94],"2028-10-01","2029-08-31","2026-05-01",272,[3865],"Smoking Cessation",[3841,3867],"Nicorette Nicotine Lozenges",{"intervention":3867,"totalTrials":1013,"cells":3869},{"EARLY_PHASE1":3870,"PHASE1":3872,"PHASE2":3874,"PHASE3":3876,"PHASE4":3878,"NA":3880},{"trials":3871,"activeCount":102},[],{"trials":3873,"activeCount":102},[],{"trials":3875,"activeCount":102},[],{"trials":3877,"activeCount":102},[],{"trials":3879,"activeCount":102},[],{"trials":3881,"activeCount":1013,"soonestReadout":3860},[3882],{"nctId":3856,"briefTitle":3857,"status":3858,"phases":3883,"primaryCompletion":3860,"completion":3861,"start":3862,"enrollment":3863,"conditions":3884,"interventions":3885},[94],[3865],[3841,3867],{"intervention":3887,"totalTrials":1013,"cells":3888},"Lactobacillus and Bifidobacterium",{"EARLY_PHASE1":3889,"PHASE1":3891,"PHASE2":3893,"PHASE3":3895,"PHASE4":3897,"NA":3899},{"trials":3890,"activeCount":102},[],{"trials":3892,"activeCount":102},[],{"trials":3894,"activeCount":102},[],{"trials":3896,"activeCount":102},[],{"trials":3898,"activeCount":102},[],{"trials":3900,"activeCount":1013,"soonestReadout":3905},[3901],{"nctId":3902,"briefTitle":3903,"status":3858,"phases":3904,"primaryCompletion":3905,"completion":3906,"start":3907,"enrollment":3908,"conditions":3909,"interventions":3912},"NCT06772090","Probiotic Supplementation During Cytotoxic Chemotherapy for Solid Tumor Malignancies",[94],"2027-12-31","2028-12-31","2026-12-25",40,[3910,3911],"Solid Tumor, Adult","Cytotoxicity",[3887],{"intervention":72,"totalTrials":1013,"cells":3914},{"EARLY_PHASE1":3915,"PHASE1":3917,"PHASE2":3919,"PHASE3":3921,"PHASE4":3923,"NA":3925},{"trials":3916,"activeCount":102},[],{"trials":3918,"activeCount":102},[],{"trials":3920,"activeCount":102},[],{"trials":3922,"activeCount":102},[],{"trials":3924,"activeCount":102},[],{"trials":3926,"activeCount":1013,"soonestReadout":71},[3927],{"nctId":69,"briefTitle":70,"status":474,"phases":3928,"primaryCompletion":71,"completion":491,"start":951,"enrollment":952,"conditions":3929,"interventions":3930},[94],[954,955,956,957,958,959,960,961,962,963,964,965,966,967],[72,97,87,77,969,242,970,87,971,972],{"intervention":969,"totalTrials":1013,"cells":3932},{"EARLY_PHASE1":3933,"PHASE1":3935,"PHASE2":3937,"PHASE3":3939,"PHASE4":3941,"NA":3943},{"trials":3934,"activeCount":102},[],{"trials":3936,"activeCount":102},[],{"trials":3938,"activeCount":102},[],{"trials":3940,"activeCount":102},[],{"trials":3942,"activeCount":102},[],{"trials":3944,"activeCount":1013,"soonestReadout":71},[3945],{"nctId":69,"briefTitle":70,"status":474,"phases":3946,"primaryCompletion":71,"completion":491,"start":951,"enrollment":952,"conditions":3947,"interventions":3948},[94],[954,955,956,957,958,959,960,961,962,963,964,965,966,967],[72,97,87,77,969,242,970,87,971,972],{"intervention":970,"totalTrials":1013,"cells":3950},{"EARLY_PHASE1":3951,"PHASE1":3953,"PHASE2":3955,"PHASE3":3957,"PHASE4":3959,"NA":3961},{"trials":3952,"activeCount":102},[],{"trials":3954,"activeCount":102},[],{"trials":3956,"activeCount":102},[],{"trials":3958,"activeCount":102},[],{"trials":3960,"activeCount":102},[],{"trials":3962,"activeCount":1013,"soonestReadout":71},[3963],{"nctId":69,"briefTitle":70,"status":474,"phases":3964,"primaryCompletion":71,"completion":491,"start":951,"enrollment":952,"conditions":3965,"interventions":3966},[94],[954,955,956,957,958,959,960,961,962,963,964,965,966,967],[72,97,87,77,969,242,970,87,971,972],{"intervention":971,"totalTrials":1013,"cells":3968},{"EARLY_PHASE1":3969,"PHASE1":3971,"PHASE2":3973,"PHASE3":3975,"PHASE4":3977,"NA":3979},{"trials":3970,"activeCount":102},[],{"trials":3972,"activeCount":102},[],{"trials":3974,"activeCount":102},[],{"trials":3976,"activeCount":102},[],{"trials":3978,"activeCount":102},[],{"trials":3980,"activeCount":1013,"soonestReadout":71},[3981],{"nctId":69,"briefTitle":70,"status":474,"phases":3982,"primaryCompletion":71,"completion":491,"start":951,"enrollment":952,"conditions":3983,"interventions":3984},[94],[954,955,956,957,958,959,960,961,962,963,964,965,966,967],[72,97,87,77,969,242,970,87,971,972],{"intervention":984,"totalTrials":1013,"cells":3986},{"EARLY_PHASE1":3987,"PHASE1":3989,"PHASE2":3991,"PHASE3":3993,"PHASE4":3995,"NA":3997},{"trials":3988,"activeCount":102},[],{"trials":3990,"activeCount":102},[],{"trials":3992,"activeCount":102},[],{"trials":3994,"activeCount":102},[],{"trials":3996,"activeCount":102},[],{"trials":3998,"activeCount":1013,"soonestReadout":977},[3999],{"nctId":974,"briefTitle":975,"status":229,"phases":4000,"primaryCompletion":977,"completion":978,"start":979,"enrollment":727,"conditions":4001,"interventions":4002},[],[981,982],[42,97,984],{"intervention":804,"totalTrials":1438,"cells":4004},{"EARLY_PHASE1":4005,"PHASE1":4007,"PHASE2":4009,"PHASE3":4023,"PHASE4":4029,"NA":4031},{"trials":4006,"activeCount":102},[],{"trials":4008,"activeCount":102},[],{"trials":4010,"activeCount":102},[4011,4015,4019],{"nctId":2123,"briefTitle":2124,"status":108,"phases":4012,"primaryCompletion":894,"completion":894,"start":2126,"enrollment":158,"conditions":4013,"interventions":4014},[91],[174],[2129,2130,2131,2132,2133],{"nctId":2196,"briefTitle":2197,"status":108,"phases":4016,"primaryCompletion":2199,"completion":2199,"start":2200,"enrollment":1013,"conditions":4017,"interventions":4018},[90,91],[15],[119,392,222,804,224,395,2203],{"nctId":2205,"briefTitle":2206,"status":108,"phases":4020,"primaryCompletion":894,"completion":894,"start":2208,"enrollment":426,"conditions":4021,"interventions":4022},[91],[15,18],[392,2211,2212,2213,804,2214,2215,2216,2154],{"trials":4024,"activeCount":102},[4025],{"nctId":797,"briefTitle":798,"status":307,"phases":4026,"primaryCompletion":800,"completion":800,"start":801,"enrollment":102,"conditions":4027,"interventions":4028},[92],[114,15,18],[221,118,119,804,224],{"trials":4030,"activeCount":102},[],{"trials":4032,"activeCount":102},[],{"intervention":207,"totalTrials":112,"cells":4034},{"EARLY_PHASE1":4035,"PHASE1":4037,"PHASE2":4039,"PHASE3":4049,"PHASE4":4055,"NA":4057},{"trials":4036,"activeCount":102},[],{"trials":4038,"activeCount":102},[],{"trials":4040,"activeCount":102},[4041,4045],{"nctId":182,"briefTitle":183,"status":125,"phases":4042,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":4043,"interventions":4044},[91],[190,191,192,193,21,194,195,196,197,198,199,200,201,202,203,32,204,205],[149,42,97,207,208,209,210,211],{"nctId":433,"briefTitle":434,"status":125,"phases":4046,"primaryCompletion":436,"completion":437,"start":438,"enrollment":426,"conditions":4047,"interventions":4048},[91],[264,26,440,202,441,192,175,442,237,32,412,443,343,197,198,444,200,445,446,447,448,449,411,450,193],[42,97,209,151,452,207],{"trials":4050,"activeCount":102},[4051],{"nctId":827,"briefTitle":828,"status":108,"phases":4052,"primaryCompletion":830,"completion":830,"start":831,"enrollment":832,"conditions":4053,"interventions":4054},[91,92],[834,266,371],[87,97,242,243,207],{"trials":4056,"activeCount":102},[],{"trials":4058,"activeCount":102},[],{"intervention":824,"totalTrials":158,"cells":4060},{"EARLY_PHASE1":4061,"PHASE1":4063,"PHASE2":4065,"PHASE3":4071,"PHASE4":4077,"NA":4079},{"trials":4062,"activeCount":102},[],{"trials":4064,"activeCount":102},[],{"trials":4066,"activeCount":102},[4067],{"nctId":1073,"briefTitle":1074,"status":125,"phases":4068,"primaryCompletion":172,"completion":1076,"start":1077,"enrollment":33,"conditions":4069,"interventions":4070},[91],[964,1079,966,965,1080,1081],[42,242,741,824,731,899,1083],{"trials":4072,"activeCount":102},[4073],{"nctId":815,"briefTitle":816,"status":125,"phases":4074,"primaryCompletion":818,"completion":492,"start":819,"enrollment":820,"conditions":4075,"interventions":4076},[91,92],[754,822],[824,97,42,825,302],{"trials":4078,"activeCount":102},[],{"trials":4080,"activeCount":102},[],{"intervention":844,"totalTrials":158,"cells":4082},{"EARLY_PHASE1":4083,"PHASE1":4085,"PHASE2":4087,"PHASE3":4089,"PHASE4":4099,"NA":4101},{"trials":4084,"activeCount":102},[],{"trials":4086,"activeCount":102},[],{"trials":4088,"activeCount":102},[],{"trials":4090,"activeCount":102},[4091,4095],{"nctId":837,"briefTitle":838,"status":125,"phases":4092,"primaryCompletion":840,"completion":840,"start":598,"enrollment":669,"conditions":4093,"interventions":4094},[91,92],[842],[593,97,87,844],{"nctId":1450,"briefTitle":1451,"status":125,"phases":4096,"primaryCompletion":1453,"completion":1453,"start":697,"enrollment":1454,"conditions":4097,"interventions":4098},[91,92],[1456,1457,1458],[844,87,221],{"trials":4100,"activeCount":102},[],{"trials":4102,"activeCount":102},[],{"intervention":663,"totalTrials":158,"cells":4104},{"EARLY_PHASE1":4105,"PHASE1":4107,"PHASE2":4109,"PHASE3":4115,"PHASE4":4121,"NA":4123},{"trials":4106,"activeCount":102},[],{"trials":4108,"activeCount":102},[],{"trials":4110,"activeCount":102},[4111],{"nctId":656,"briefTitle":657,"status":108,"phases":4112,"primaryCompletion":659,"completion":659,"start":329,"enrollment":660,"conditions":4113,"interventions":4114},[91],[115],[391,118,393,394,222,395,332,663],{"trials":4116,"activeCount":102},[4117],{"nctId":846,"briefTitle":847,"status":108,"phases":4118,"primaryCompletion":849,"completion":849,"start":850,"enrollment":9,"conditions":4119,"interventions":4120},[91,92],[15],[663,223,118,393,394],{"trials":4122,"activeCount":102},[],{"trials":4124,"activeCount":102},[],{"intervention":1311,"totalTrials":1013,"cells":4126},{"EARLY_PHASE1":4127,"PHASE1":4129,"PHASE2":4131,"PHASE3":4133,"PHASE4":4139,"NA":4141},{"trials":4128,"activeCount":102},[],{"trials":4130,"activeCount":102},[],{"trials":4132,"activeCount":102},[],{"trials":4134,"activeCount":102},[4135],{"nctId":1303,"briefTitle":1304,"status":125,"phases":4136,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1308,"conditions":4137,"interventions":4138},[91,92],[32],[1311,242,1312],{"trials":4140,"activeCount":102},[],{"trials":4142,"activeCount":102},[],{"intervention":1312,"totalTrials":1013,"cells":4144},{"EARLY_PHASE1":4145,"PHASE1":4147,"PHASE2":4149,"PHASE3":4151,"PHASE4":4157,"NA":4159},{"trials":4146,"activeCount":102},[],{"trials":4148,"activeCount":102},[],{"trials":4150,"activeCount":102},[],{"trials":4152,"activeCount":102},[4153],{"nctId":1303,"briefTitle":1304,"status":125,"phases":4154,"primaryCompletion":1306,"completion":1306,"start":1307,"enrollment":1308,"conditions":4155,"interventions":4156},[91,92],[32],[1311,242,1312],{"trials":4158,"activeCount":102},[],{"trials":4160,"activeCount":102},[],{"intervention":4162,"totalTrials":1013,"cells":4163},"Busulfan, Fludarabine, ATG, TLI",{"EARLY_PHASE1":4164,"PHASE1":4166,"PHASE2":4168,"PHASE3":4170,"PHASE4":4185,"NA":4187},{"trials":4165,"activeCount":102},[],{"trials":4167,"activeCount":102},[],{"trials":4169,"activeCount":102},[],{"trials":4171,"activeCount":102},[4172],{"nctId":4173,"briefTitle":4174,"status":125,"phases":4175,"primaryCompletion":4176,"completion":4177,"start":4178,"enrollment":27,"conditions":4179,"interventions":4182},"NCT00176852","Stem Cell Transplant for Hemoglobinopathy",[91,92],"2014-03","2020-01","2002-06",[623,4180,4181,1456,1458],"Thalassemia","Severe Congenital Neutropenia",[4162,4183,4184],"Busulfan, Cyclophosphamide, ATG, GCSF","Campath, Fludarabine, Cyclophosphamide",{"trials":4186,"activeCount":102},[],{"trials":4188,"activeCount":102},[],{"intervention":4183,"totalTrials":1013,"cells":4190},{"EARLY_PHASE1":4191,"PHASE1":4193,"PHASE2":4195,"PHASE3":4197,"PHASE4":4203,"NA":4205},{"trials":4192,"activeCount":102},[],{"trials":4194,"activeCount":102},[],{"trials":4196,"activeCount":102},[],{"trials":4198,"activeCount":102},[4199],{"nctId":4173,"briefTitle":4174,"status":125,"phases":4200,"primaryCompletion":4176,"completion":4177,"start":4178,"enrollment":27,"conditions":4201,"interventions":4202},[91,92],[623,4180,4181,1456,1458],[4162,4183,4184],{"trials":4204,"activeCount":102},[],{"trials":4206,"activeCount":102},[],{"intervention":4184,"totalTrials":1013,"cells":4208},{"EARLY_PHASE1":4209,"PHASE1":4211,"PHASE2":4213,"PHASE3":4215,"PHASE4":4221,"NA":4223},{"trials":4210,"activeCount":102},[],{"trials":4212,"activeCount":102},[],{"trials":4214,"activeCount":102},[],{"trials":4216,"activeCount":102},[4217],{"nctId":4173,"briefTitle":4174,"status":125,"phases":4218,"primaryCompletion":4176,"completion":4177,"start":4178,"enrollment":27,"conditions":4219,"interventions":4220},[91,92],[623,4180,4181,1456,1458],[4162,4183,4184],{"trials":4222,"activeCount":102},[],{"trials":4224,"activeCount":102},[],{"intervention":4226,"totalTrials":1013,"cells":4227},"Myeloablative conditioning regimen",{"EARLY_PHASE1":4228,"PHASE1":4230,"PHASE2":4232,"PHASE3":4234,"PHASE4":4246,"NA":4248},{"trials":4229,"activeCount":102},[],{"trials":4231,"activeCount":102},[],{"trials":4233,"activeCount":102},[],{"trials":4235,"activeCount":102},[4236],{"nctId":4237,"briefTitle":4238,"status":108,"phases":4239,"primaryCompletion":172,"completion":4240,"start":4241,"enrollment":27,"conditions":4242,"interventions":4245},"NCT00176826","T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders",[91,92],"2015-08","2000-09",[964,1079,966,965,4243,1081,4244],"Immunologic Diseases","Hematologic Diseases",[4226],{"trials":4247,"activeCount":102},[],{"trials":4249,"activeCount":102},[],{"intervention":4251,"totalTrials":1013,"cells":4252},"Busulfan, Cyclophosphamide, Antithymocyte Globulin",{"EARLY_PHASE1":4253,"PHASE1":4255,"PHASE2":4257,"PHASE3":4259,"PHASE4":4273,"NA":4275},{"trials":4254,"activeCount":102},[],{"trials":4256,"activeCount":102},[],{"trials":4258,"activeCount":102},[],{"trials":4260,"activeCount":102},[4261],{"nctId":4262,"briefTitle":4263,"status":125,"phases":4264,"primaryCompletion":2199,"completion":2199,"start":4265,"enrollment":4266,"conditions":4267,"interventions":4272},"NCT00176904","Stem Cell Transplant for Inborn Errors of Metabolism",[91,92],"1995-01",135,[1283,1284,1285,4268,585,1288,4269,4270,1291,1286,4271],"Gaucher's Disease","Niemann-Pick Disease","Batten Disease","Sandhoff Disease",[4251],{"trials":4274,"activeCount":102},[],{"trials":4276,"activeCount":102},[],{"intervention":253,"totalTrials":1454,"cells":4278},{"EARLY_PHASE1":4279,"PHASE1":4281,"PHASE2":4291,"PHASE3":4338,"PHASE4":4340,"NA":4342},{"trials":4280,"activeCount":102},[],{"trials":4282,"activeCount":102},[4283],{"nctId":4284,"briefTitle":4285,"status":108,"phases":4286,"primaryCompletion":1909,"completion":1909,"start":4287,"conditions":4288,"interventions":4289},"NCT00005993","Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer",[90],"1999-05",[29,18],[253,222,4290],"recombinant human stem cell factor",{"trials":4292,"activeCount":102},[4293,4297,4301,4310,4314,4318,4322,4326,4330],{"nctId":245,"briefTitle":246,"status":108,"phases":4294,"primaryCompletion":248,"completion":249,"start":250,"enrollment":158,"conditions":4295,"interventions":4296},[91],[15],[253,118,120],{"nctId":316,"briefTitle":317,"status":125,"phases":4298,"primaryCompletion":319,"completion":319,"start":320,"enrollment":30,"conditions":4299,"interventions":4300},[91],[15],[253,323,118,120],{"nctId":4302,"briefTitle":4303,"status":108,"phases":4304,"primaryCompletion":4305,"completion":4305,"start":4306,"enrollment":36,"conditions":4307,"interventions":4308},"NCT00784524","Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca",[91],"2014-07","2008-09",[29],[4309,253],"allogeneic large multivalent immunogen breast cancer vaccine",{"nctId":564,"briefTitle":565,"status":108,"phases":4311,"primaryCompletion":567,"completion":568,"start":569,"enrollment":460,"conditions":4312,"interventions":4313},[90,91],[15,18],[253,572,573,118,120],{"nctId":595,"briefTitle":596,"status":108,"phases":4315,"primaryCompletion":598,"completion":598,"start":599,"enrollment":358,"conditions":4316,"interventions":4317},[91],[15,21],[253,222,602,118,119,120,224,121],{"nctId":604,"briefTitle":605,"status":307,"phases":4319,"primaryCompletion":607,"completion":607,"start":378,"enrollment":102,"conditions":4320,"interventions":4321},[91],[190],[610,611,97,42,612],{"nctId":722,"briefTitle":723,"status":125,"phases":4323,"primaryCompletion":725,"completion":725,"start":726,"enrollment":727,"conditions":4324,"interventions":4325},[90,91],[190],[253,730,118,120,288,731,118,120],{"nctId":758,"briefTitle":759,"status":108,"phases":4327,"primaryCompletion":761,"completion":761,"start":110,"enrollment":36,"conditions":4328,"interventions":4329},[91],[297,24,763],[149,97,765,766,612],{"nctId":4331,"briefTitle":4332,"status":125,"phases":4333,"primaryCompletion":2126,"completion":2126,"start":319,"enrollment":30,"conditions":4334,"interventions":4336},"NCT00726739","Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma",[91],[4335],"Stage IV Melanoma",[253,4337],"allogeneic large multivalent immunogen vaccine",{"trials":4339,"activeCount":102},[],{"trials":4341,"activeCount":102},[],{"trials":4343,"activeCount":102},[],{"intervention":303,"totalTrials":669,"cells":4345},{"EARLY_PHASE1":4346,"PHASE1":4348,"PHASE2":4360,"PHASE3":4398,"PHASE4":4400,"NA":4402},{"trials":4347,"activeCount":102},[],{"trials":4349,"activeCount":102},[4350],{"nctId":4351,"briefTitle":4352,"status":125,"phases":4353,"primaryCompletion":4354,"completion":4354,"start":4355,"enrollment":1454,"conditions":4356,"interventions":4358},"NCT03213964","Intraperitoneal Delivery of Adaptive Natural Killer (NK) Cells (FATE-NK100) With Intraperitoneal Int",[90],"2021-03-10","2017-10-19",[4357,297,298],"Epithelial Ovarian Cancer",[4359,303],"FATE-NK100",{"trials":4361,"activeCount":102},[4362,4366,4370,4374,4386,4390],{"nctId":290,"briefTitle":291,"status":125,"phases":4363,"primaryCompletion":293,"completion":293,"start":294,"enrollment":295,"conditions":4364,"interventions":4365},[91],[24,297,298,29],[42,97,300,301,164,302,302,303],{"nctId":352,"briefTitle":353,"status":125,"phases":4367,"primaryCompletion":355,"completion":356,"start":357,"enrollment":358,"conditions":4368,"interventions":4369},[91],[236,194],[285,303,301,97,302,42],{"nctId":375,"briefTitle":376,"status":108,"phases":4371,"primaryCompletion":378,"completion":378,"start":249,"enrollment":112,"conditions":4372,"interventions":4373},[91],[190,380],[149,42,97,286,87,382,303],{"nctId":4375,"briefTitle":4376,"status":125,"phases":4377,"primaryCompletion":4378,"completion":4379,"start":4380,"enrollment":1374,"conditions":4381,"interventions":4382},"NCT01370213","NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases",[91],"2016-04","2017-04","2011-09",[26,175],[3692,4383,303,4384,4385],"NK Cells","CD34 Graft\u002FAnti-thymocyte globulin","Donor TCR α\u002Fβ-depleted Graft\u002FATG",{"nctId":454,"briefTitle":455,"status":108,"phases":4387,"primaryCompletion":457,"completion":458,"start":459,"enrollment":460,"conditions":4388,"interventions":4389},[91],[29],[42,97,303],{"nctId":4391,"briefTitle":4392,"status":125,"phases":4393,"primaryCompletion":4394,"completion":4394,"start":1678,"enrollment":130,"conditions":4395,"interventions":4396},"NCT01593670","Decitabine and Vorinostat Conditioning Followed by CD3-\u002FCD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes",[91],"2018-10-23",[175],[4397,2130,303],"Decitabine",{"trials":4399,"activeCount":102},[],{"trials":4401,"activeCount":102},[],{"trials":4403,"activeCount":102},[],{"intervention":4405,"totalTrials":460,"cells":4406},"cisplatin",{"EARLY_PHASE1":4407,"PHASE1":4409,"PHASE2":4438,"PHASE3":4470,"PHASE4":4472,"NA":4474},{"trials":4408,"activeCount":102},[],{"trials":4410,"activeCount":102},[4411,4419,4430],{"nctId":4412,"briefTitle":4413,"status":307,"phases":4414,"primaryCompletion":110,"completion":110,"start":1221,"enrollment":102,"conditions":4415,"interventions":4417},"NCT00428194","Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer",[90],[4416],"Cervical Cancer",[4405,4418],"erlotinib hydrochloride",{"nctId":4420,"briefTitle":4421,"status":125,"phases":4422,"primaryCompletion":2139,"completion":4423,"start":4424,"enrollment":358,"conditions":4425,"interventions":4427},"NCT00703638","Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors",[90],"2010-11","2008-05",[29,2104,671,35,4426,2105,2117,1194],"Mesothelioma",[4405,4428,4429],"pemetrexed disodium","sorafenib",{"nctId":4431,"briefTitle":4432,"status":125,"phases":4433,"primaryCompletion":567,"completion":567,"start":4434,"enrollment":579,"conditions":4435,"interventions":4436},"NCT00287911","Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer",[90],"2005-02",[4416],[4405,4437],"topotecan hydrochloride",{"trials":4439,"activeCount":102},[4440,4448,4461],{"nctId":4441,"briefTitle":4442,"status":108,"phases":4443,"primaryCompletion":4444,"completion":930,"start":726,"enrollment":1205,"conditions":4445,"interventions":4446},"NCT00262951","Chemoradiation in Locally Advanced Pancreatic Cancer",[91],"2011-04",[2105],[332,4405,4447],"fluorouracil",{"nctId":4449,"briefTitle":4450,"status":125,"phases":4451,"primaryCompletion":4452,"completion":4453,"start":4454,"enrollment":907,"conditions":4455,"interventions":4457},"NCT03294304","BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy",[91],"2020-06-05","2021-07-01","2018-01-29",[4456],"Muscle Invasive Bladder Cancer",[4458,4459,4460],"Nivolumab","Cisplatin","Gemcitabine",{"nctId":4462,"briefTitle":4463,"status":108,"phases":4464,"primaryCompletion":4465,"completion":4465,"start":4466,"enrollment":1438,"conditions":4467,"interventions":4468},"NCT00352118","Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer",[91],"2008-04","2006-03",[671],[222,4469,4405,3297,4447],"pegfilgrastim",{"trials":4471,"activeCount":102},[],{"trials":4473,"activeCount":102},[],{"trials":4475,"activeCount":102},[],{"intervention":2130,"totalTrials":895,"cells":4477},{"EARLY_PHASE1":4478,"PHASE1":4480,"PHASE2":4496,"PHASE3":4514,"PHASE4":4516,"NA":4518},{"trials":4479,"activeCount":102},[],{"trials":4481,"activeCount":102},[4482],{"nctId":4483,"briefTitle":4484,"status":307,"phases":4485,"primaryCompletion":4486,"completion":4487,"start":4488,"enrollment":102,"conditions":4489,"interventions":4495},"NCT05700630","Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia",[90],"2024-07-26","2024-08-21","2024-07-15",[4490,4491,4492,4493,4494],"HIV-1-infection","ART","Cd4+ Lymphocyte Deficiency","Lymphoid Tissue; Infection","Interleukin",[136,2130],{"trials":4497,"activeCount":102},[4498,4502,4506,4510],{"nctId":2123,"briefTitle":2124,"status":108,"phases":4499,"primaryCompletion":894,"completion":894,"start":2126,"enrollment":158,"conditions":4500,"interventions":4501},[91],[174],[2129,2130,2131,2132,2133],{"nctId":2148,"briefTitle":2149,"status":108,"phases":4503,"primaryCompletion":2151,"completion":2151,"start":250,"enrollment":358,"conditions":4504,"interventions":4505},[91],[15,175],[1682,2154],{"nctId":4391,"briefTitle":4392,"status":125,"phases":4507,"primaryCompletion":4394,"completion":4394,"start":1678,"enrollment":130,"conditions":4508,"interventions":4509},[91],[175],[4397,2130,303],{"nctId":2205,"briefTitle":2206,"status":108,"phases":4511,"primaryCompletion":894,"completion":894,"start":2208,"enrollment":426,"conditions":4512,"interventions":4513},[91],[15,18],[392,2211,2212,2213,804,2214,2215,2216,2154],{"trials":4515,"activeCount":102},[],{"trials":4517,"activeCount":102},[],{"trials":4519,"activeCount":102},[],{"intervention":301,"totalTrials":1438,"cells":4521},{"EARLY_PHASE1":4522,"PHASE1":4524,"PHASE2":4526,"PHASE3":4544,"PHASE4":4546,"NA":4548},{"trials":4523,"activeCount":102},[],{"trials":4525,"activeCount":102},[],{"trials":4527,"activeCount":102},[4528,4532,4536,4540],{"nctId":290,"briefTitle":291,"status":125,"phases":4529,"primaryCompletion":293,"completion":293,"start":294,"enrollment":295,"conditions":4530,"interventions":4531},[91],[24,297,298,29],[42,97,300,301,164,302,302,303],{"nctId":352,"briefTitle":353,"status":125,"phases":4533,"primaryCompletion":355,"completion":356,"start":357,"enrollment":358,"conditions":4534,"interventions":4535},[91],[236,194],[285,303,301,97,302,42],{"nctId":422,"briefTitle":423,"status":108,"phases":4537,"primaryCompletion":249,"completion":425,"start":294,"enrollment":426,"conditions":4538,"interventions":4539},[91],[428],[430,42,97,431,164],{"nctId":722,"briefTitle":723,"status":125,"phases":4541,"primaryCompletion":725,"completion":725,"start":726,"enrollment":727,"conditions":4542,"interventions":4543},[90,91],[190],[253,730,118,120,288,731,118,120],{"trials":4545,"activeCount":102},[],{"trials":4547,"activeCount":102},[],{"trials":4549,"activeCount":102},[],{"intervention":332,"totalTrials":1438,"cells":4551},{"EARLY_PHASE1":4552,"PHASE1":4554,"PHASE2":4556,"PHASE3":4574,"PHASE4":4576,"NA":4578},{"trials":4553,"activeCount":102},[],{"trials":4555,"activeCount":102},[],{"trials":4557,"activeCount":102},[4558,4562,4566,4570],{"nctId":325,"briefTitle":326,"status":108,"phases":4559,"primaryCompletion":328,"start":329,"conditions":4560,"interventions":4561},[91],[15],[223,118,222,332],{"nctId":4441,"briefTitle":4442,"status":108,"phases":4563,"primaryCompletion":4444,"completion":930,"start":726,"enrollment":1205,"conditions":4564,"interventions":4565},[91],[2105],[332,4405,4447],{"nctId":656,"briefTitle":657,"status":108,"phases":4567,"primaryCompletion":659,"completion":659,"start":329,"enrollment":660,"conditions":4568,"interventions":4569},[91],[115],[391,118,393,394,222,395,332,663],{"nctId":777,"briefTitle":778,"status":108,"phases":4571,"primaryCompletion":780,"completion":780,"start":329,"enrollment":27,"conditions":4572,"interventions":4573},[91],[15],[118,222,332],{"trials":4575,"activeCount":102},[],{"trials":4577,"activeCount":102},[],{"trials":4579,"activeCount":102},[],{"intervention":3297,"totalTrials":1438,"cells":4581},{"EARLY_PHASE1":4582,"PHASE1":4584,"PHASE2":4603,"PHASE3":4613,"PHASE4":4615,"NA":4617},{"trials":4583,"activeCount":102},[],{"trials":4585,"activeCount":102},[4586,4593],{"nctId":4587,"briefTitle":4588,"status":108,"phases":4589,"primaryCompletion":111,"completion":111,"start":459,"enrollment":1438,"conditions":4590,"interventions":4591},"NCT00356941","Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II\u002FIII or Recurrent NSCLC",[90],[35],[3297,4592],"oxaliplatin",{"nctId":4594,"briefTitle":4595,"status":125,"phases":4596,"primaryCompletion":4597,"completion":4597,"start":4598,"enrollment":579,"conditions":4599,"interventions":4602},"NCT00287885","Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer",[90],"2008-12","2004-03",[4416,3295,297,24,763,1194,4600,4601],"Vaginal Cancer","Vulvar Cancer",[3297],{"trials":4604,"activeCount":102},[4605,4609],{"nctId":3291,"briefTitle":3292,"status":125,"phases":4606,"primaryCompletion":567,"completion":567,"start":1909,"enrollment":144,"conditions":4607,"interventions":4608},[91],[3295],[1790,3297],{"nctId":4462,"briefTitle":4463,"status":108,"phases":4610,"primaryCompletion":4465,"completion":4465,"start":4466,"enrollment":1438,"conditions":4611,"interventions":4612},[91],[671],[222,4469,4405,3297,4447],{"trials":4614,"activeCount":102},[],{"trials":4616,"activeCount":102},[],{"trials":4618,"activeCount":102},[],{"intervention":395,"totalTrials":1438,"cells":4620},{"EARLY_PHASE1":4621,"PHASE1":4623,"PHASE2":4625,"PHASE3":4643,"PHASE4":4645,"NA":4647},{"trials":4622,"activeCount":102},[],{"trials":4624,"activeCount":102},[],{"trials":4626,"activeCount":102},[4627,4631,4635,4639],{"nctId":384,"briefTitle":385,"status":307,"phases":4628,"primaryCompletion":387,"completion":387,"start":388,"enrollment":102,"conditions":4629,"interventions":4630},[91],[18],[391,118,392,393,394,222,395,396],{"nctId":547,"briefTitle":548,"status":125,"phases":4632,"primaryCompletion":550,"completion":550,"start":329,"enrollment":368,"conditions":4633,"interventions":4634},[91],[18],[222,391,118,392,393,394,395],{"nctId":656,"briefTitle":657,"status":108,"phases":4636,"primaryCompletion":659,"completion":659,"start":329,"enrollment":660,"conditions":4637,"interventions":4638},[91],[115],[391,118,393,394,222,395,332,663],{"nctId":2196,"briefTitle":2197,"status":108,"phases":4640,"primaryCompletion":2199,"completion":2199,"start":2200,"enrollment":1013,"conditions":4641,"interventions":4642},[90,91],[15],[119,392,222,804,224,395,2203],{"trials":4644,"activeCount":102},[],{"trials":4646,"activeCount":102},[],{"trials":4648,"activeCount":102},[],{"intervention":4397,"totalTrials":112,"cells":4650},{"EARLY_PHASE1":4651,"PHASE1":4653,"PHASE2":4655,"PHASE3":4676,"PHASE4":4678,"NA":4680},{"trials":4652,"activeCount":102},[],{"trials":4654,"activeCount":102},[],{"trials":4656,"activeCount":102},[4657,4668,4672],{"nctId":4658,"briefTitle":4659,"status":125,"phases":4660,"primaryCompletion":4661,"completion":4661,"start":4662,"enrollment":36,"conditions":4663,"interventions":4665},"NCT04055844","Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML\u002FMDS",[91],"2022-09-06","2020-02-17",[26,4664,21],"Myeloid and Monocytic Leukemia",[4397,4666,4667],"Ruxolitinib","Donor Lymphocyte",{"nctId":4391,"briefTitle":4392,"status":125,"phases":4669,"primaryCompletion":4394,"completion":4394,"start":1678,"enrollment":130,"conditions":4670,"interventions":4671},[91],[175],[4397,2130,303],{"nctId":2205,"briefTitle":2206,"status":108,"phases":4673,"primaryCompletion":894,"completion":894,"start":2208,"enrollment":426,"conditions":4674,"interventions":4675},[91],[15,18],[392,2211,2212,2213,804,2214,2215,2216,2154],{"trials":4677,"activeCount":102},[],{"trials":4679,"activeCount":102},[],{"trials":4681,"activeCount":102},[],{"intervention":4683,"totalTrials":112,"cells":4684},"ALT-803",{"EARLY_PHASE1":4685,"PHASE1":4687,"PHASE2":4689,"PHASE3":4724,"PHASE4":4726,"NA":4728},{"trials":4686,"activeCount":102},[],{"trials":4688,"activeCount":102},[],{"trials":4690,"activeCount":102},[4691,4698,4714],{"nctId":4692,"briefTitle":4693,"status":125,"phases":4694,"primaryCompletion":532,"completion":532,"start":4695,"enrollment":1137,"conditions":4696,"interventions":4697},"NCT03050216","QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML",[91],"2017-05-16",[26],[4683],{"nctId":4699,"briefTitle":4700,"status":125,"phases":4701,"primaryCompletion":4702,"completion":4703,"start":4704,"enrollment":4705,"conditions":4706,"interventions":4713},"NCT01885897","IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT",[90,91],"2019-07","2020-07","2013-11-11",33,[4707,4708,4709,18,4710,4711,4712],"Acute Myelogenous Leukemia (AML)","Acute Lymphoblastic Leukemia (ALL)","Myelodysplastic Syndromes (MDS)","Myeloma","Chronic Lymphocytic Leukemia (CLL)","Chronic Myelogenous Leukemia (CML)",[4683],{"nctId":4715,"briefTitle":4716,"status":307,"phases":4717,"primaryCompletion":4718,"completion":4718,"start":4719,"enrollment":102,"conditions":4720,"interventions":4723},"NCT03365661","QUILT-3.034: Non-Myeloablative TCRa\u002Fb Deplete Haplo HSCT With Post ALT-803 for AML",[91],"2023-01-01","2018-10-30",[4721,4722,1262,175],"High-Risk Acute Myeloid Leukemia","Treatment-Related Acute Myeloid Leukemia",[4683],{"trials":4725,"activeCount":102},[],{"trials":4727,"activeCount":102},[],{"trials":4729,"activeCount":102},[],{"intervention":350,"totalTrials":112,"cells":4731},{"EARLY_PHASE1":4732,"PHASE1":4734,"PHASE2":4740,"PHASE3":4750,"PHASE4":4752,"NA":4754},{"trials":4733,"activeCount":102},[],{"trials":4735,"activeCount":102},[4736],{"nctId":138,"briefTitle":139,"status":125,"phases":4737,"primaryCompletion":141,"completion":142,"start":143,"enrollment":144,"conditions":4738,"interventions":4739},[90],[15,18,32,146,21],[148,149,120,97,150,151],{"trials":4741,"activeCount":102},[4742,4746],{"nctId":334,"briefTitle":335,"status":307,"phases":4743,"primaryCompletion":337,"completion":337,"start":338,"enrollment":102,"conditions":4744,"interventions":4745},[90,91],[263,26,191,340,341,342,194,195,343,197,198,199,344,345,201,202,346],[348,349,42,97,350],{"nctId":375,"briefTitle":376,"status":108,"phases":4747,"primaryCompletion":378,"completion":378,"start":249,"enrollment":112,"conditions":4748,"interventions":4749},[91],[190,380],[149,42,97,286,87,382,303],{"trials":4751,"activeCount":102},[],{"trials":4753,"activeCount":102},[],{"trials":4755,"activeCount":102},[],{"intervention":4437,"totalTrials":112,"cells":4757},{"EARLY_PHASE1":4758,"PHASE1":4760,"PHASE2":4774,"PHASE3":4783,"PHASE4":4785,"NA":4787},{"trials":4759,"activeCount":102},[],{"trials":4761,"activeCount":102},[4762,4770],{"nctId":4763,"briefTitle":4764,"status":108,"phases":4765,"primaryCompletion":4766,"completion":4766,"start":4767,"enrollment":895,"conditions":4768,"interventions":4769},"NCT00287859","Topotecan in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer",[90],"2006-12","2004-08",[297,24,763],[4437],{"nctId":4431,"briefTitle":4432,"status":125,"phases":4771,"primaryCompletion":567,"completion":567,"start":4434,"enrollment":579,"conditions":4772,"interventions":4773},[90],[4416],[4405,4437],{"trials":4775,"activeCount":102},[4776],{"nctId":4777,"briefTitle":4778,"status":125,"phases":4779,"primaryCompletion":4380,"completion":4380,"start":1280,"enrollment":645,"conditions":4780,"interventions":4781},"NCT00365547","Topotecan and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Did Not Respond to Previous Systemic Chemotherapy",[91],[35],[4782,4437],"bevacizumab",{"trials":4784,"activeCount":102},[],{"trials":4786,"activeCount":102},[],{"trials":4788,"activeCount":102},[],{"intervention":2119,"totalTrials":112,"cells":4790},{"EARLY_PHASE1":4791,"PHASE1":4793,"PHASE2":4806,"PHASE3":4812,"PHASE4":4814,"NA":4816},{"trials":4792,"activeCount":102},[],{"trials":4794,"activeCount":102},[4795,4799],{"nctId":2110,"briefTitle":2111,"status":125,"phases":4796,"primaryCompletion":2113,"completion":2114,"start":2115,"enrollment":790,"conditions":4797,"interventions":4798},[90],[29,2104,671,700,35,24,2105,2117,1194],[1682,2119],{"nctId":4800,"briefTitle":4801,"status":108,"phases":4802,"primaryCompletion":250,"completion":250,"start":4803,"enrollment":1438,"conditions":4804,"interventions":4805},"NCT00619021","Bronchial Artery Infusion of Gemcitabine in Treating Patients With Recurrent or Progressive Non-Small Cell Lung Cancer",[90],"2003-01",[35],[2119],{"trials":4807,"activeCount":102},[4808],{"nctId":3322,"briefTitle":3323,"status":108,"phases":4809,"primaryCompletion":110,"completion":3325,"start":3326,"enrollment":27,"conditions":4810,"interventions":4811},[91],[35],[1790,2119,3329],{"trials":4813,"activeCount":102},[],{"trials":4815,"activeCount":102},[],{"trials":4817,"activeCount":102},[],{"intervention":3692,"totalTrials":112,"cells":4819},{"EARLY_PHASE1":4820,"PHASE1":4822,"PHASE2":4832,"PHASE3":4842,"PHASE4":4844,"NA":4846},{"trials":4821,"activeCount":102},[],{"trials":4823,"activeCount":102},[4824],{"nctId":4825,"briefTitle":4826,"status":125,"phases":4827,"primaryCompletion":818,"completion":818,"start":4380,"enrollment":4828,"conditions":4829,"interventions":4830},"NCT01385423","Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)",[90],26,[190,175],[3692,4831],"Intravenous Recombinant Human IL-15",{"trials":4833,"activeCount":102},[4834,4838],{"nctId":3684,"briefTitle":3685,"status":125,"phases":4835,"primaryCompletion":3687,"completion":3688,"start":3689,"enrollment":426,"conditions":4836,"interventions":4837},[90,91],[273],[867,3692],{"nctId":4375,"briefTitle":4376,"status":125,"phases":4839,"primaryCompletion":4378,"completion":4379,"start":4380,"enrollment":1374,"conditions":4840,"interventions":4841},[91],[26,175],[3692,4383,303,4384,4385],{"trials":4843,"activeCount":102},[],{"trials":4845,"activeCount":102},[],{"trials":4847,"activeCount":102},[],{"intervention":4849,"totalTrials":112,"cells":4850},"852A",{"EARLY_PHASE1":4851,"PHASE1":4853,"PHASE2":4864,"PHASE3":4881,"PHASE4":4883,"NA":4885},{"trials":4852,"activeCount":102},[],{"trials":4854,"activeCount":102},[4855],{"nctId":4856,"briefTitle":4857,"status":125,"phases":4858,"primaryCompletion":883,"completion":883,"start":4859,"enrollment":4860,"conditions":4861,"interventions":4863},"NCT00095160","Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors",[90],"2003-10",42,[4862],"Neoplasms",[4849],{"trials":4865,"activeCount":102},[4866,4874],{"nctId":4867,"briefTitle":4868,"status":108,"phases":4869,"primaryCompletion":4870,"completion":4870,"start":883,"enrollment":460,"conditions":4871,"interventions":4873},"NCT00276159","Study of Immune Response Modifier in the Treatment of Hematologic Malignancies",[91],"2008-11",[174,26,203,4872,32,194],"Hodgkin's Lymphoma",[4849],{"nctId":4875,"briefTitle":4876,"status":125,"phases":4877,"primaryCompletion":4878,"completion":4597,"start":459,"enrollment":426,"conditions":4879,"interventions":4880},"NCT00319748","Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers",[91],"2007-12",[29,24,3295,4416],[4849],{"trials":4882,"activeCount":102},[],{"trials":4884,"activeCount":102},[],{"trials":4886,"activeCount":102},[],{"intervention":4447,"totalTrials":112,"cells":4888},{"EARLY_PHASE1":4889,"PHASE1":4891,"PHASE2":4901,"PHASE3":4911,"PHASE4":4913,"NA":4915},{"trials":4890,"activeCount":102},[],{"trials":4892,"activeCount":102},[4893],{"nctId":4894,"briefTitle":4895,"status":125,"phases":4896,"primaryCompletion":458,"completion":4380,"start":4897,"enrollment":790,"conditions":4898,"interventions":4899},"NCT00625092","Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies",[90],"2007-10",[763],[4447,4900,4592],"leucovorin calcium",{"trials":4902,"activeCount":102},[4903,4907],{"nctId":4441,"briefTitle":4442,"status":108,"phases":4904,"primaryCompletion":4444,"completion":930,"start":726,"enrollment":1205,"conditions":4905,"interventions":4906},[91],[2105],[332,4405,4447],{"nctId":4462,"briefTitle":4463,"status":108,"phases":4908,"primaryCompletion":4465,"completion":4465,"start":4466,"enrollment":1438,"conditions":4909,"interventions":4910},[91],[671],[222,4469,4405,3297,4447],{"trials":4912,"activeCount":102},[],{"trials":4914,"activeCount":102},[],{"trials":4916,"activeCount":102},[],{"intervention":209,"totalTrials":158,"cells":4918},{"EARLY_PHASE1":4919,"PHASE1":4921,"PHASE2":4923,"PHASE3":4933,"PHASE4":4935,"NA":4937},{"trials":4920,"activeCount":102},[],{"trials":4922,"activeCount":102},[],{"trials":4924,"activeCount":102},[4925,4929],{"nctId":182,"briefTitle":183,"status":125,"phases":4926,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":4927,"interventions":4928},[91],[190,191,192,193,21,194,195,196,197,198,199,200,201,202,203,32,204,205],[149,42,97,207,208,209,210,211],{"nctId":433,"briefTitle":434,"status":125,"phases":4930,"primaryCompletion":436,"completion":437,"start":438,"enrollment":426,"conditions":4931,"interventions":4932},[91],[264,26,440,202,441,192,175,442,237,32,412,443,343,197,198,444,200,445,446,447,448,449,411,450,193],[42,97,209,151,452,207],{"trials":4934,"activeCount":102},[],{"trials":4936,"activeCount":102},[],{"trials":4938,"activeCount":102},[],{"intervention":2133,"totalTrials":158,"cells":4940},{"EARLY_PHASE1":4941,"PHASE1":4943,"PHASE2":4945,"PHASE3":4955,"PHASE4":4957,"NA":4959},{"trials":4942,"activeCount":102},[],{"trials":4944,"activeCount":102},[],{"trials":4946,"activeCount":102},[4947,4951],{"nctId":2123,"briefTitle":2124,"status":108,"phases":4948,"primaryCompletion":894,"completion":894,"start":2126,"enrollment":158,"conditions":4949,"interventions":4950},[91],[174],[2129,2130,2131,2132,2133],{"nctId":2205,"briefTitle":2206,"status":108,"phases":4952,"primaryCompletion":894,"completion":894,"start":2208,"enrollment":426,"conditions":4953,"interventions":4954},[91],[15,18],[392,2211,2212,2213,804,2214,2215,2216,2154],{"trials":4956,"activeCount":102},[],{"trials":4958,"activeCount":102},[],{"trials":4960,"activeCount":102},[],{"intervention":2108,"totalTrials":158,"cells":4962},{"EARLY_PHASE1":4963,"PHASE1":4965,"PHASE2":4971,"PHASE3":4977,"PHASE4":4979,"NA":4981},{"trials":4964,"activeCount":102},[],{"trials":4966,"activeCount":102},[4967],{"nctId":2100,"briefTitle":2101,"status":125,"phases":4968,"primaryCompletion":761,"completion":578,"start":1257,"enrollment":986,"conditions":4969,"interventions":4970},[90],[29,2104,671,700,35,2105,1194,2106],[2108,1682],{"trials":4972,"activeCount":102},[4973],{"nctId":665,"briefTitle":666,"status":125,"phases":4974,"primaryCompletion":355,"completion":355,"start":668,"enrollment":669,"conditions":4975,"interventions":4976},[91],[671,672],[97,674],{"trials":4978,"activeCount":102},[],{"trials":4980,"activeCount":102},[],{"trials":4982,"activeCount":102},[],{"intervention":4458,"totalTrials":158,"cells":4984},{"EARLY_PHASE1":4985,"PHASE1":4987,"PHASE2":4989,"PHASE3":5006,"PHASE4":5008,"NA":5010},{"trials":4986,"activeCount":102},[],{"trials":4988,"activeCount":102},[],{"trials":4990,"activeCount":102},[4991,5002],{"nctId":4992,"briefTitle":4993,"status":125,"phases":4994,"primaryCompletion":4995,"completion":4995,"start":4996,"enrollment":9,"conditions":4997,"interventions":4999},"NCT03417154","Nivolumab and Oral Cyclophosphamide for R\u002FR AML and HIgh Risk MDS",[91],"2022-01-25","2018-08-13",[26,4998],"Higher Risk Myelodysplastic Syndrome",[4458,5000,5001],"Low dose Cyclophosphamide (CTX) Daily","Low dose Cyclophosphamide (CTX) Every 7 Days",{"nctId":4449,"briefTitle":4450,"status":125,"phases":5003,"primaryCompletion":4452,"completion":4453,"start":4454,"enrollment":907,"conditions":5004,"interventions":5005},[91],[4456],[4458,4459,4460],{"trials":5007,"activeCount":102},[],{"trials":5009,"activeCount":102},[],{"trials":5011,"activeCount":102},[],{"intervention":5013,"totalTrials":158,"cells":5014},"DT2219ARL",{"EARLY_PHASE1":5015,"PHASE1":5017,"PHASE2":5027,"PHASE3":5041,"PHASE4":5043,"NA":5045},{"trials":5016,"activeCount":102},[],{"trials":5018,"activeCount":102},[5019],{"nctId":5020,"briefTitle":5021,"status":125,"phases":5022,"primaryCompletion":5023,"completion":5023,"start":5024,"enrollment":1374,"conditions":5025,"interventions":5026},"NCT00889408","DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma",[90],"2014-07-21","2013-12-02",[15,18],[5013],{"trials":5028,"activeCount":102},[5029],{"nctId":5030,"briefTitle":5031,"status":125,"phases":5032,"primaryCompletion":5033,"completion":5033,"start":5034,"enrollment":579,"conditions":5035,"interventions":5040},"NCT02370160","HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma",[90,91],"2018-04-08","2015-12-21",[5036,5037,5038,5039],"Refractory B-Lineage Leukemia","Relapsed B-Lineage Leukemia","Refractory B-Lineage Lymphoma","Relapsed B-Lineage Lymphoma",[5013],{"trials":5042,"activeCount":102},[],{"trials":5044,"activeCount":102},[],{"trials":5046,"activeCount":102},[],{"intervention":4383,"totalTrials":158,"cells":5048},{"EARLY_PHASE1":5049,"PHASE1":5051,"PHASE2":5057,"PHASE3":5063,"PHASE4":5065,"NA":5067},{"trials":5050,"activeCount":102},[],{"trials":5052,"activeCount":102},[5053],{"nctId":153,"briefTitle":154,"status":125,"phases":5054,"primaryCompletion":156,"completion":156,"start":157,"enrollment":158,"conditions":5055,"interventions":5056},[90],[24,160,161],[42,97,163,164,165],{"trials":5058,"activeCount":102},[5059],{"nctId":4375,"briefTitle":4376,"status":125,"phases":5060,"primaryCompletion":4378,"completion":4379,"start":4380,"enrollment":1374,"conditions":5061,"interventions":5062},[91],[26,175],[3692,4383,303,4384,4385],{"trials":5064,"activeCount":102},[],{"trials":5066,"activeCount":102},[],{"trials":5068,"activeCount":102},[],{"intervention":3308,"totalTrials":158,"cells":5070},{"EARLY_PHASE1":5071,"PHASE1":5073,"PHASE2":5075,"PHASE3":5090,"PHASE4":5092,"NA":5094},{"trials":5072,"activeCount":102},[],{"trials":5074,"activeCount":102},[],{"trials":5076,"activeCount":102},[5077,5081],{"nctId":3299,"briefTitle":3300,"status":125,"phases":5078,"primaryCompletion":3302,"completion":3303,"start":3304,"enrollment":864,"conditions":5079,"interventions":5080},[91],[2117],[3307,497,3308,3309],{"nctId":5082,"briefTitle":5083,"status":307,"phases":5084,"primaryCompletion":5085,"completion":5085,"start":5086,"enrollment":102,"conditions":5087,"interventions":5088},"NCT05705700","Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP)",[91],"2030-01","2023-02",[2117],[5089,3308],"Dutasteride",{"trials":5091,"activeCount":102},[],{"trials":5093,"activeCount":102},[],{"trials":5095,"activeCount":102},[],{"intervention":3309,"totalTrials":158,"cells":5097},{"EARLY_PHASE1":5098,"PHASE1":5100,"PHASE2":5102,"PHASE3":5112,"PHASE4":5114,"NA":5116},{"trials":5099,"activeCount":102},[],{"trials":5101,"activeCount":102},[],{"trials":5103,"activeCount":102},[5104,5108],{"nctId":3299,"briefTitle":3300,"status":125,"phases":5105,"primaryCompletion":3302,"completion":3303,"start":3304,"enrollment":864,"conditions":5106,"interventions":5107},[91],[2117],[3307,497,3308,3309],{"nctId":2205,"briefTitle":2206,"status":108,"phases":5109,"primaryCompletion":894,"completion":894,"start":2208,"enrollment":426,"conditions":5110,"interventions":5111},[91],[15,18],[392,2211,2212,2213,804,2214,2215,2216,2154],{"trials":5113,"activeCount":102},[],{"trials":5115,"activeCount":102},[],{"trials":5117,"activeCount":102},[],{"intervention":5119,"totalTrials":158,"cells":5120},"Bevacizumab",{"EARLY_PHASE1":5121,"PHASE1":5123,"PHASE2":5125,"PHASE3":5140,"PHASE4":5142,"NA":5144},{"trials":5122,"activeCount":102},[],{"trials":5124,"activeCount":102},[],{"trials":5126,"activeCount":102},[5127,5136],{"nctId":5128,"briefTitle":5129,"status":108,"phases":5130,"primaryCompletion":532,"completion":532,"start":5131,"enrollment":1013,"conditions":5132,"interventions":5134},"NCT02988843","Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors",[91],"2017-03-29",[5133],"Germ Cell Tumor",[5135,5119],"Brentuximab Vedotin",{"nctId":4777,"briefTitle":4778,"status":125,"phases":5137,"primaryCompletion":4380,"completion":4380,"start":1280,"enrollment":645,"conditions":5138,"interventions":5139},[91],[35],[4782,4437],{"trials":5141,"activeCount":102},[],{"trials":5143,"activeCount":102},[],{"trials":5145,"activeCount":102},[],{"intervention":731,"totalTrials":158,"cells":5147},{"EARLY_PHASE1":5148,"PHASE1":5150,"PHASE2":5152,"PHASE3":5162,"PHASE4":5164,"NA":5166},{"trials":5149,"activeCount":102},[],{"trials":5151,"activeCount":102},[],{"trials":5153,"activeCount":102},[5154,5158],{"nctId":1073,"briefTitle":1074,"status":125,"phases":5155,"primaryCompletion":172,"completion":1076,"start":1077,"enrollment":33,"conditions":5156,"interventions":5157},[91],[964,1079,966,965,1080,1081],[42,242,741,824,731,899,1083],{"nctId":722,"briefTitle":723,"status":125,"phases":5159,"primaryCompletion":725,"completion":725,"start":726,"enrollment":727,"conditions":5160,"interventions":5161},[90,91],[190],[253,730,118,120,288,731,118,120],{"trials":5163,"activeCount":102},[],{"trials":5165,"activeCount":102},[],{"trials":5167,"activeCount":102},[],{"intervention":572,"totalTrials":158,"cells":5169},{"EARLY_PHASE1":5170,"PHASE1":5172,"PHASE2":5174,"PHASE3":5184,"PHASE4":5186,"NA":5188},{"trials":5171,"activeCount":102},[],{"trials":5173,"activeCount":102},[],{"trials":5175,"activeCount":102},[5176,5180],{"nctId":564,"briefTitle":565,"status":108,"phases":5177,"primaryCompletion":567,"completion":568,"start":569,"enrollment":460,"conditions":5178,"interventions":5179},[90,91],[15,18],[253,572,573,118,120],{"nctId":758,"briefTitle":759,"status":108,"phases":5181,"primaryCompletion":761,"completion":761,"start":110,"enrollment":36,"conditions":5182,"interventions":5183},[91],[297,24,763],[149,97,765,766,612],{"trials":5185,"activeCount":102},[],{"trials":5187,"activeCount":102},[],{"trials":5189,"activeCount":102},[],{"intervention":5191,"totalTrials":1013,"cells":5192},"Gemcitabine, Carboplatin, Bevacizumab",{"EARLY_PHASE1":5193,"PHASE1":5195,"PHASE2":5197,"PHASE3":5207,"PHASE4":5209,"NA":5211},{"trials":5194,"activeCount":102},[],{"trials":5196,"activeCount":102},[],{"trials":5198,"activeCount":102},[5199],{"nctId":5200,"briefTitle":5201,"status":125,"phases":5202,"primaryCompletion":5203,"completion":5203,"start":2115,"enrollment":1281,"conditions":5204,"interventions":5206},"NCT00400803","Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb\u002FIV Non-small Cell Lung Cancer",[91],"2010-05",[5205],"Carcinoma, Non-Small-Cell Lung",[5191],{"trials":5208,"activeCount":102},[],{"trials":5210,"activeCount":102},[],{"trials":5212,"activeCount":102},[],{"intervention":210,"totalTrials":1013,"cells":5214},{"EARLY_PHASE1":5215,"PHASE1":5217,"PHASE2":5219,"PHASE3":5225,"PHASE4":5227,"NA":5229},{"trials":5216,"activeCount":102},[],{"trials":5218,"activeCount":102},[],{"trials":5220,"activeCount":102},[5221],{"nctId":182,"briefTitle":183,"status":125,"phases":5222,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":5223,"interventions":5224},[91],[190,191,192,193,21,194,195,196,197,198,199,200,201,202,203,32,204,205],[149,42,97,207,208,209,210,211],{"trials":5226,"activeCount":102},[],{"trials":5228,"activeCount":102},[],{"trials":5230,"activeCount":102},[],{"intervention":211,"totalTrials":1013,"cells":5232},{"EARLY_PHASE1":5233,"PHASE1":5235,"PHASE2":5237,"PHASE3":5243,"PHASE4":5245,"NA":5247},{"trials":5234,"activeCount":102},[],{"trials":5236,"activeCount":102},[],{"trials":5238,"activeCount":102},[5239],{"nctId":182,"briefTitle":183,"status":125,"phases":5240,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":5241,"interventions":5242},[91],[190,191,192,193,21,194,195,196,197,198,199,200,201,202,203,32,204,205],[149,42,97,207,208,209,210,211],{"trials":5244,"activeCount":102},[],{"trials":5246,"activeCount":102},[],{"trials":5248,"activeCount":102},[],{"intervention":5250,"totalTrials":1013,"cells":5251},"Mesenchymal stromal cells",{"EARLY_PHASE1":5252,"PHASE1":5254,"PHASE2":5256,"PHASE3":5270,"PHASE4":5272,"NA":5274},{"trials":5253,"activeCount":102},[],{"trials":5255,"activeCount":102},[],{"trials":5257,"activeCount":102},[5258],{"nctId":5259,"briefTitle":5260,"status":125,"phases":5261,"primaryCompletion":5262,"completion":5263,"start":5264,"enrollment":1137,"conditions":5265,"interventions":5269},"NCT04466098","Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)",[91],"2022-02-25","2024-12-31","2020-07-30",[5266,5267,5268],"Acute Respiratory Distress Syndrome","ARDS (Moderate or Severe)","COVID-19 Pneumonia",[5250],{"trials":5271,"activeCount":102},[],{"trials":5273,"activeCount":102},[],{"trials":5275,"activeCount":102},[],{"intervention":5277,"totalTrials":1013,"cells":5278},"fondaparinux sodium",{"EARLY_PHASE1":5279,"PHASE1":5281,"PHASE2":5283,"PHASE3":5292,"PHASE4":5294,"NA":5296},{"trials":5280,"activeCount":102},[],{"trials":5282,"activeCount":102},[],{"trials":5284,"activeCount":102},[5285],{"nctId":5286,"briefTitle":5287,"status":125,"phases":5288,"primaryCompletion":250,"completion":250,"start":1221,"enrollment":1351,"conditions":5289,"interventions":5291},"NCT00381888","Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer",[91],[4416,3295,297,24,1194,5290,4600,4601],"Thromboembolism",[5277],{"trials":5293,"activeCount":102},[],{"trials":5295,"activeCount":102},[],{"trials":5297,"activeCount":102},[],{"intervention":2142,"totalTrials":1013,"cells":5299},{"EARLY_PHASE1":5300,"PHASE1":5302,"PHASE2":5304,"PHASE3":5310,"PHASE4":5312,"NA":5314},{"trials":5301,"activeCount":102},[],{"trials":5303,"activeCount":102},[],{"trials":5305,"activeCount":102},[5306],{"nctId":2135,"briefTitle":2136,"status":108,"phases":5307,"primaryCompletion":2138,"completion":2138,"start":2139,"enrollment":669,"conditions":5308,"interventions":5309},[91],[2105],[2129,2142],{"trials":5311,"activeCount":102},[],{"trials":5313,"activeCount":102},[],{"trials":5315,"activeCount":102},[],{"intervention":5317,"totalTrials":1013,"cells":5318},"Pamidronate",{"EARLY_PHASE1":5319,"PHASE1":5321,"PHASE2":5323,"PHASE3":5337,"PHASE4":5339,"NA":5341},{"trials":5320,"activeCount":102},[],{"trials":5322,"activeCount":102},[],{"trials":5324,"activeCount":102},[5325],{"nctId":5326,"briefTitle":5327,"status":125,"phases":5328,"primaryCompletion":5329,"completion":5329,"start":5330,"enrollment":5331,"conditions":5332,"interventions":5335},"NCT02074631","Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation",[91],"2022-10-06","2015-02",63,[5333,5334],"Osteopenia","Osteoporosis",[5317,5336],"Calcium and vitamin D",{"trials":5338,"activeCount":102},[],{"trials":5340,"activeCount":102},[],{"trials":5342,"activeCount":102},[],{"intervention":5336,"totalTrials":1013,"cells":5344},{"EARLY_PHASE1":5345,"PHASE1":5347,"PHASE2":5349,"PHASE3":5355,"PHASE4":5357,"NA":5359},{"trials":5346,"activeCount":102},[],{"trials":5348,"activeCount":102},[],{"trials":5350,"activeCount":102},[5351],{"nctId":5326,"briefTitle":5327,"status":125,"phases":5352,"primaryCompletion":5329,"completion":5329,"start":5330,"enrollment":5331,"conditions":5353,"interventions":5354},[91],[5333,5334],[5317,5336],{"trials":5356,"activeCount":102},[],{"trials":5358,"activeCount":102},[],{"trials":5360,"activeCount":102},[],{"intervention":4666,"totalTrials":1013,"cells":5362},{"EARLY_PHASE1":5363,"PHASE1":5365,"PHASE2":5367,"PHASE3":5373,"PHASE4":5375,"NA":5377},{"trials":5364,"activeCount":102},[],{"trials":5366,"activeCount":102},[],{"trials":5368,"activeCount":102},[5369],{"nctId":4658,"briefTitle":4659,"status":125,"phases":5370,"primaryCompletion":4661,"completion":4661,"start":4662,"enrollment":36,"conditions":5371,"interventions":5372},[91],[26,4664,21],[4397,4666,4667],{"trials":5374,"activeCount":102},[],{"trials":5376,"activeCount":102},[],{"trials":5378,"activeCount":102},[],{"intervention":4667,"totalTrials":1013,"cells":5380},{"EARLY_PHASE1":5381,"PHASE1":5383,"PHASE2":5385,"PHASE3":5391,"PHASE4":5393,"NA":5395},{"trials":5382,"activeCount":102},[],{"trials":5384,"activeCount":102},[],{"trials":5386,"activeCount":102},[5387],{"nctId":4658,"briefTitle":4659,"status":125,"phases":5388,"primaryCompletion":4661,"completion":4661,"start":4662,"enrollment":36,"conditions":5389,"interventions":5390},[91],[26,4664,21],[4397,4666,4667],{"trials":5392,"activeCount":102},[],{"trials":5394,"activeCount":102},[],{"trials":5396,"activeCount":102},[],{"intervention":5398,"totalTrials":1013,"cells":5399},"IL-15",{"EARLY_PHASE1":5400,"PHASE1":5402,"PHASE2":5404,"PHASE3":5414,"PHASE4":5416,"NA":5418},{"trials":5401,"activeCount":102},[],{"trials":5403,"activeCount":102},[],{"trials":5405,"activeCount":102},[5406],{"nctId":5407,"briefTitle":5408,"status":125,"phases":5409,"primaryCompletion":5410,"completion":5410,"start":5411,"enrollment":790,"conditions":5412,"interventions":5413},"NCT02395822","MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients",[91],"2016-12-01","2015-10-01",[190],[5398],{"trials":5415,"activeCount":102},[],{"trials":5417,"activeCount":102},[],{"trials":5419,"activeCount":102},[],{"intervention":5421,"totalTrials":1013,"cells":5422},"topical gemcitabine hydrochloride",{"EARLY_PHASE1":5423,"PHASE1":5425,"PHASE2":5427,"PHASE3":5436,"PHASE4":5438,"NA":5440},{"trials":5424,"activeCount":102},[],{"trials":5426,"activeCount":102},[],{"trials":5428,"activeCount":102},[5429],{"nctId":5430,"briefTitle":5431,"status":125,"phases":5432,"primaryCompletion":4465,"completion":4465,"start":5433,"enrollment":579,"conditions":5434,"interventions":5435},"NCT00610740","CerviPrep for Applying Topical Gemcitabine to the Cervix in Treating Patients With Primary Endometrial, Cervical, or Ovarian Epithelial Cancer",[91],"2006-07",[4416,3295,24],[5421],{"trials":5437,"activeCount":102},[],{"trials":5439,"activeCount":102},[],{"trials":5441,"activeCount":102},[],{"intervention":314,"totalTrials":1013,"cells":5443},{"EARLY_PHASE1":5444,"PHASE1":5446,"PHASE2":5448,"PHASE3":5454,"PHASE4":5456,"NA":5458},{"trials":5445,"activeCount":102},[],{"trials":5447,"activeCount":102},[],{"trials":5449,"activeCount":102},[5450],{"nctId":305,"briefTitle":306,"status":307,"phases":5451,"primaryCompletion":309,"completion":309,"start":310,"enrollment":102,"conditions":5452,"interventions":5453},[90,91],[312],[314,42,97],{"trials":5455,"activeCount":102},[],{"trials":5457,"activeCount":102},[],{"trials":5459,"activeCount":102},[],{"intervention":323,"totalTrials":1013,"cells":5461},{"EARLY_PHASE1":5462,"PHASE1":5464,"PHASE2":5466,"PHASE3":5472,"PHASE4":5474,"NA":5476},{"trials":5463,"activeCount":102},[],{"trials":5465,"activeCount":102},[],{"trials":5467,"activeCount":102},[5468],{"nctId":316,"briefTitle":317,"status":125,"phases":5469,"primaryCompletion":319,"completion":319,"start":320,"enrollment":30,"conditions":5470,"interventions":5471},[91],[15],[253,323,118,120],{"trials":5473,"activeCount":102},[],{"trials":5475,"activeCount":102},[],{"trials":5477,"activeCount":102},[],{"intervention":5479,"totalTrials":1013,"cells":5480},"Autologous Plasmablasts",{"EARLY_PHASE1":5481,"PHASE1":5483,"PHASE2":5485,"PHASE3":5498,"PHASE4":5500,"NA":5502},{"trials":5482,"activeCount":102},[],{"trials":5484,"activeCount":102},[],{"trials":5486,"activeCount":102},[5487],{"nctId":5488,"briefTitle":5489,"status":307,"phases":5490,"primaryCompletion":5491,"completion":5491,"start":5492,"enrollment":102,"conditions":5493,"interventions":5497},"NCT04284254","MT2018-18: Sleeping Beauty Transposon-Engineered Plasmablasts for Hurler Syndrome Post Allo HSCT",[90,91],"2023-06","2022-12",[5494,5495,5496],"Mucopolysaccharidosis Type IH (MPS IH, Hurler Syndrome)","Mucopolysaccharidosis Type IH","MPS IH, Hurler Syndrome",[5479],{"trials":5499,"activeCount":102},[],{"trials":5501,"activeCount":102},[],{"trials":5503,"activeCount":102},[],{"intervention":5505,"totalTrials":1013,"cells":5506},"Pregnyl®",{"EARLY_PHASE1":5507,"PHASE1":5509,"PHASE2":5511,"PHASE3":5523,"PHASE4":5525,"NA":5527},{"trials":5508,"activeCount":102},[],{"trials":5510,"activeCount":102},[],{"trials":5512,"activeCount":102},[5513],{"nctId":5514,"briefTitle":5515,"status":125,"phases":5516,"primaryCompletion":5517,"completion":5518,"start":789,"enrollment":5519,"conditions":5520,"interventions":5522},"NCT02525029","Study of Pregnyl as Adjunct Therapy for High-Risk or Refractory Acute GVHD",[90,91],"2021-05","2022-04",53,[5521],"Graft vs Host Disease",[5505],{"trials":5524,"activeCount":102},[],{"trials":5526,"activeCount":102},[],{"trials":5528,"activeCount":102},[],{"intervention":348,"totalTrials":1013,"cells":5530},{"EARLY_PHASE1":5531,"PHASE1":5533,"PHASE2":5535,"PHASE3":5541,"PHASE4":5543,"NA":5545},{"trials":5532,"activeCount":102},[],{"trials":5534,"activeCount":102},[],{"trials":5536,"activeCount":102},[5537],{"nctId":334,"briefTitle":335,"status":307,"phases":5538,"primaryCompletion":337,"completion":337,"start":338,"enrollment":102,"conditions":5539,"interventions":5540},[90,91],[263,26,191,340,341,342,194,195,343,197,198,199,344,345,201,202,346],[348,349,42,97,350],{"trials":5542,"activeCount":102},[],{"trials":5544,"activeCount":102},[],{"trials":5546,"activeCount":102},[],{"intervention":349,"totalTrials":1013,"cells":5548},{"EARLY_PHASE1":5549,"PHASE1":5551,"PHASE2":5553,"PHASE3":5559,"PHASE4":5561,"NA":5563},{"trials":5550,"activeCount":102},[],{"trials":5552,"activeCount":102},[],{"trials":5554,"activeCount":102},[5555],{"nctId":334,"briefTitle":335,"status":307,"phases":5556,"primaryCompletion":337,"completion":337,"start":338,"enrollment":102,"conditions":5557,"interventions":5558},[90,91],[263,26,191,340,341,342,194,195,343,197,198,199,344,345,201,202,346],[348,349,42,97,350],{"trials":5560,"activeCount":102},[],{"trials":5562,"activeCount":102},[],{"trials":5564,"activeCount":102},[],{"intervention":5566,"totalTrials":1013,"cells":5567},"deferasirox",{"EARLY_PHASE1":5568,"PHASE1":5570,"PHASE2":5572,"PHASE3":5581,"PHASE4":5583,"NA":5585},{"trials":5569,"activeCount":102},[],{"trials":5571,"activeCount":102},[],{"trials":5573,"activeCount":102},[5574],{"nctId":5575,"briefTitle":5576,"status":108,"phases":5577,"primaryCompletion":457,"completion":567,"start":819,"enrollment":1438,"conditions":5578,"interventions":5580},"NCT00602446","Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant",[91],[29,5579,15,18,115,21,494,24],"Iron Overload",[5566],{"trials":5582,"activeCount":102},[],{"trials":5584,"activeCount":102},[],{"trials":5586,"activeCount":102},[],{"intervention":5000,"totalTrials":1013,"cells":5588},{"EARLY_PHASE1":5589,"PHASE1":5591,"PHASE2":5593,"PHASE3":5599,"PHASE4":5601,"NA":5603},{"trials":5590,"activeCount":102},[],{"trials":5592,"activeCount":102},[],{"trials":5594,"activeCount":102},[5595],{"nctId":4992,"briefTitle":4993,"status":125,"phases":5596,"primaryCompletion":4995,"completion":4995,"start":4996,"enrollment":9,"conditions":5597,"interventions":5598},[91],[26,4998],[4458,5000,5001],{"trials":5600,"activeCount":102},[],{"trials":5602,"activeCount":102},[],{"trials":5604,"activeCount":102},[],{"intervention":5001,"totalTrials":1013,"cells":5606},{"EARLY_PHASE1":5607,"PHASE1":5609,"PHASE2":5611,"PHASE3":5617,"PHASE4":5619,"NA":5621},{"trials":5608,"activeCount":102},[],{"trials":5610,"activeCount":102},[],{"trials":5612,"activeCount":102},[5613],{"nctId":4992,"briefTitle":4993,"status":125,"phases":5614,"primaryCompletion":4995,"completion":4995,"start":4996,"enrollment":9,"conditions":5615,"interventions":5616},[91],[26,4998],[4458,5000,5001],{"trials":5618,"activeCount":102},[],{"trials":5620,"activeCount":102},[],{"trials":5622,"activeCount":102},[],{"intervention":5624,"totalTrials":1013,"cells":5625},"Aldesleukin: All Patients",{"EARLY_PHASE1":5626,"PHASE1":5628,"PHASE2":5630,"PHASE3":5645,"PHASE4":5647,"NA":5649},{"trials":5627,"activeCount":102},[],{"trials":5629,"activeCount":102},[],{"trials":5631,"activeCount":102},[5632],{"nctId":5633,"briefTitle":5634,"status":125,"phases":5635,"primaryCompletion":5636,"completion":5637,"start":5638,"enrollment":1438,"conditions":5639,"interventions":5641},"NCT03850691","Radiation and Combination Immunotherapy for Melanoma",[91],"2021-05-04","2022-12-12","2019-05-28",[5640],"Metastatic Melanoma",[5624,5642,5643,5644],"Nivolumab: Cohort 1","Nivolumab: Cohort 2","Ipilimumab: Cohort 2",{"trials":5646,"activeCount":102},[],{"trials":5648,"activeCount":102},[],{"trials":5650,"activeCount":102},[],{"intervention":5642,"totalTrials":1013,"cells":5652},{"EARLY_PHASE1":5653,"PHASE1":5655,"PHASE2":5657,"PHASE3":5663,"PHASE4":5665,"NA":5667},{"trials":5654,"activeCount":102},[],{"trials":5656,"activeCount":102},[],{"trials":5658,"activeCount":102},[5659],{"nctId":5633,"briefTitle":5634,"status":125,"phases":5660,"primaryCompletion":5636,"completion":5637,"start":5638,"enrollment":1438,"conditions":5661,"interventions":5662},[91],[5640],[5624,5642,5643,5644],{"trials":5664,"activeCount":102},[],{"trials":5666,"activeCount":102},[],{"trials":5668,"activeCount":102},[],{"intervention":5643,"totalTrials":1013,"cells":5670},{"EARLY_PHASE1":5671,"PHASE1":5673,"PHASE2":5675,"PHASE3":5681,"PHASE4":5683,"NA":5685},{"trials":5672,"activeCount":102},[],{"trials":5674,"activeCount":102},[],{"trials":5676,"activeCount":102},[5677],{"nctId":5633,"briefTitle":5634,"status":125,"phases":5678,"primaryCompletion":5636,"completion":5637,"start":5638,"enrollment":1438,"conditions":5679,"interventions":5680},[91],[5640],[5624,5642,5643,5644],{"trials":5682,"activeCount":102},[],{"trials":5684,"activeCount":102},[],{"trials":5686,"activeCount":102},[],{"intervention":5644,"totalTrials":1013,"cells":5688},{"EARLY_PHASE1":5689,"PHASE1":5691,"PHASE2":5693,"PHASE3":5699,"PHASE4":5701,"NA":5703},{"trials":5690,"activeCount":102},[],{"trials":5692,"activeCount":102},[],{"trials":5694,"activeCount":102},[5695],{"nctId":5633,"briefTitle":5634,"status":125,"phases":5696,"primaryCompletion":5636,"completion":5637,"start":5638,"enrollment":1438,"conditions":5697,"interventions":5698},[91],[5640],[5624,5642,5643,5644],{"trials":5700,"activeCount":102},[],{"trials":5702,"activeCount":102},[],{"trials":5704,"activeCount":102},[],{"intervention":5706,"totalTrials":1013,"cells":5707},"Fecal Microbiota Transplant",{"EARLY_PHASE1":5708,"PHASE1":5710,"PHASE2":5712,"PHASE3":5725,"PHASE4":5727,"NA":5729},{"trials":5709,"activeCount":102},[],{"trials":5711,"activeCount":102},[],{"trials":5713,"activeCount":102},[5714],{"nctId":5715,"briefTitle":5716,"status":125,"phases":5717,"primaryCompletion":5718,"completion":5719,"start":5720,"enrollment":5721,"conditions":5722,"interventions":5724},"NCT03678493","A Study of FMT in Patients With AML Allo HSCT in Recipients",[91],"2022-02-11","2023-12-04","2019-09-09",100,[26,5723],"Allogeneic Hematopoietic Cell Transplantation",[5706],{"trials":5726,"activeCount":102},[],{"trials":5728,"activeCount":102},[],{"trials":5730,"activeCount":102},[],{"intervention":5732,"totalTrials":1013,"cells":5733},"Campath, Busulfan, Clofarabine",{"EARLY_PHASE1":5734,"PHASE1":5736,"PHASE2":5738,"PHASE3":5748,"PHASE4":5750,"NA":5752},{"trials":5735,"activeCount":102},[],{"trials":5737,"activeCount":102},[],{"trials":5739,"activeCount":102},[5740],{"nctId":5741,"briefTitle":5742,"status":108,"phases":5743,"primaryCompletion":4424,"completion":4424,"start":5744,"enrollment":112,"conditions":5745,"interventions":5747},"NCT00638820","Reduced Intensity AlloTransplant For Osteopetrosis",[91],"2007-09",[5746],"Osteopetrosis",[5732],{"trials":5749,"activeCount":102},[],{"trials":5751,"activeCount":102},[],{"trials":5753,"activeCount":102},[],{"intervention":5755,"totalTrials":1013,"cells":5756},"naltrexone",{"EARLY_PHASE1":5757,"PHASE1":5759,"PHASE2":5761,"PHASE3":5769,"PHASE4":5771,"NA":5773},{"trials":5758,"activeCount":102},[],{"trials":5760,"activeCount":102},[],{"trials":5762,"activeCount":102},[5763],{"nctId":5764,"briefTitle":5765,"status":108,"phases":5766,"primaryCompletion":1220,"completion":1220,"start":5433,"enrollment":295,"conditions":5767,"interventions":5768},"NCT00379197","Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer",[91],[29],[5755],{"trials":5770,"activeCount":102},[],{"trials":5772,"activeCount":102},[],{"trials":5774,"activeCount":102},[],{"intervention":396,"totalTrials":1013,"cells":5776},{"EARLY_PHASE1":5777,"PHASE1":5779,"PHASE2":5781,"PHASE3":5787,"PHASE4":5789,"NA":5791},{"trials":5778,"activeCount":102},[],{"trials":5780,"activeCount":102},[],{"trials":5782,"activeCount":102},[5783],{"nctId":384,"briefTitle":385,"status":307,"phases":5784,"primaryCompletion":387,"completion":387,"start":388,"enrollment":102,"conditions":5785,"interventions":5786},[91],[18],[391,118,392,393,394,222,395,396],{"trials":5788,"activeCount":102},[],{"trials":5790,"activeCount":102},[],{"trials":5792,"activeCount":102},[],{"intervention":5794,"totalTrials":1013,"cells":5795},"ONC201",{"EARLY_PHASE1":5796,"PHASE1":5798,"PHASE2":5800,"PHASE3":5810,"PHASE4":5812,"NA":5814},{"trials":5797,"activeCount":102},[],{"trials":5799,"activeCount":102},[],{"trials":5801,"activeCount":102},[5802],{"nctId":5803,"briefTitle":5804,"status":307,"phases":5805,"primaryCompletion":5263,"completion":5806,"start":5807,"enrollment":102,"conditions":5808,"interventions":5809},"NCT04629209","A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma",[91],"2025-06-30","2024-06-28",[3421],[5794],{"trials":5811,"activeCount":102},[],{"trials":5813,"activeCount":102},[],{"trials":5815,"activeCount":102},[],{"intervention":4384,"totalTrials":1013,"cells":5817},{"EARLY_PHASE1":5818,"PHASE1":5820,"PHASE2":5822,"PHASE3":5828,"PHASE4":5830,"NA":5832},{"trials":5819,"activeCount":102},[],{"trials":5821,"activeCount":102},[],{"trials":5823,"activeCount":102},[5824],{"nctId":4375,"briefTitle":4376,"status":125,"phases":5825,"primaryCompletion":4378,"completion":4379,"start":4380,"enrollment":1374,"conditions":5826,"interventions":5827},[91],[26,175],[3692,4383,303,4384,4385],{"trials":5829,"activeCount":102},[],{"trials":5831,"activeCount":102},[],{"trials":5833,"activeCount":102},[],{"intervention":4385,"totalTrials":1013,"cells":5835},{"EARLY_PHASE1":5836,"PHASE1":5838,"PHASE2":5840,"PHASE3":5846,"PHASE4":5848,"NA":5850},{"trials":5837,"activeCount":102},[],{"trials":5839,"activeCount":102},[],{"trials":5841,"activeCount":102},[5842],{"nctId":4375,"briefTitle":4376,"status":125,"phases":5843,"primaryCompletion":4378,"completion":4379,"start":4380,"enrollment":1374,"conditions":5844,"interventions":5845},[91],[26,175],[3692,4383,303,4384,4385],{"trials":5847,"activeCount":102},[],{"trials":5849,"activeCount":102},[],{"trials":5851,"activeCount":102},[],{"intervention":431,"totalTrials":1013,"cells":5853},{"EARLY_PHASE1":5854,"PHASE1":5856,"PHASE2":5858,"PHASE3":5864,"PHASE4":5866,"NA":5868},{"trials":5855,"activeCount":102},[],{"trials":5857,"activeCount":102},[],{"trials":5859,"activeCount":102},[5860],{"nctId":422,"briefTitle":423,"status":108,"phases":5861,"primaryCompletion":249,"completion":425,"start":294,"enrollment":426,"conditions":5862,"interventions":5863},[91],[428],[430,42,97,431,164],{"trials":5865,"activeCount":102},[],{"trials":5867,"activeCount":102},[],{"trials":5869,"activeCount":102},[],{"intervention":3307,"totalTrials":1013,"cells":5871},{"EARLY_PHASE1":5872,"PHASE1":5874,"PHASE2":5876,"PHASE3":5882,"PHASE4":5884,"NA":5886},{"trials":5873,"activeCount":102},[],{"trials":5875,"activeCount":102},[],{"trials":5877,"activeCount":102},[5878],{"nctId":3299,"briefTitle":3300,"status":125,"phases":5879,"primaryCompletion":3302,"completion":3303,"start":3304,"enrollment":864,"conditions":5880,"interventions":5881},[91],[2117],[3307,497,3308,3309],{"trials":5883,"activeCount":102},[],{"trials":5885,"activeCount":102},[],{"trials":5887,"activeCount":102},[],{"intervention":452,"totalTrials":1013,"cells":5889},{"EARLY_PHASE1":5890,"PHASE1":5892,"PHASE2":5894,"PHASE3":5900,"PHASE4":5902,"NA":5904},{"trials":5891,"activeCount":102},[],{"trials":5893,"activeCount":102},[],{"trials":5895,"activeCount":102},[5896],{"nctId":433,"briefTitle":434,"status":125,"phases":5897,"primaryCompletion":436,"completion":437,"start":438,"enrollment":426,"conditions":5898,"interventions":5899},[91],[264,26,440,202,441,192,175,442,237,32,412,443,343,197,198,444,200,445,446,447,448,449,411,450,193],[42,97,209,151,452,207],{"trials":5901,"activeCount":102},[],{"trials":5903,"activeCount":102},[],{"trials":5905,"activeCount":102},[],{"intervention":5907,"totalTrials":1013,"cells":5908},"Fulvestrant",{"EARLY_PHASE1":5909,"PHASE1":5911,"PHASE2":5913,"PHASE3":5922,"PHASE4":5924,"NA":5926},{"trials":5910,"activeCount":102},[],{"trials":5912,"activeCount":102},[],{"trials":5914,"activeCount":102},[5915],{"nctId":5916,"briefTitle":5917,"status":125,"phases":5918,"primaryCompletion":4465,"completion":3325,"start":5919,"enrollment":4828,"conditions":5920,"interventions":5921},"NCT00617188","Fulvestrant in Treating Patients With Recurrent Ovarian Epithelial Cancer",[91],"2007-06",[24],[5907],{"trials":5923,"activeCount":102},[],{"trials":5925,"activeCount":102},[],{"trials":5927,"activeCount":102},[],{"intervention":5929,"totalTrials":1013,"cells":5930},"Haplo HCT \u003C55 years old",{"EARLY_PHASE1":5931,"PHASE1":5933,"PHASE2":5935,"PHASE3":5950,"PHASE4":5952,"NA":5954},{"trials":5932,"activeCount":102},[],{"trials":5934,"activeCount":102},[],{"trials":5936,"activeCount":102},[5937],{"nctId":5938,"briefTitle":5939,"status":125,"phases":5940,"primaryCompletion":5941,"completion":5942,"start":5943,"enrollment":2688,"conditions":5944,"interventions":5945},"NCT02988466","Reduced Intensity (RIC) Conditioning And Transplantation of HLA-Haplo-HCT",[91],"2023-05-02","2025-03-24","2017-01-24",[773],[5929,5946,5947,5948,5949],"Haplo HCT ≥55 years old","GVHD Prophylaxis","Haplo HCT ≥55 and \u003C 65 years old","Haplo HCT ≥65 and ≤75 years old",{"trials":5951,"activeCount":102},[],{"trials":5953,"activeCount":102},[],{"trials":5955,"activeCount":102},[],{"intervention":5946,"totalTrials":1013,"cells":5957},{"EARLY_PHASE1":5958,"PHASE1":5960,"PHASE2":5962,"PHASE3":5968,"PHASE4":5970,"NA":5972},{"trials":5959,"activeCount":102},[],{"trials":5961,"activeCount":102},[],{"trials":5963,"activeCount":102},[5964],{"nctId":5938,"briefTitle":5939,"status":125,"phases":5965,"primaryCompletion":5941,"completion":5942,"start":5943,"enrollment":2688,"conditions":5966,"interventions":5967},[91],[773],[5929,5946,5947,5948,5949],{"trials":5969,"activeCount":102},[],{"trials":5971,"activeCount":102},[],{"trials":5973,"activeCount":102},[],{"intervention":5947,"totalTrials":1013,"cells":5975},{"EARLY_PHASE1":5976,"PHASE1":5978,"PHASE2":5980,"PHASE3":5986,"PHASE4":5988,"NA":5990},{"trials":5977,"activeCount":102},[],{"trials":5979,"activeCount":102},[],{"trials":5981,"activeCount":102},[5982],{"nctId":5938,"briefTitle":5939,"status":125,"phases":5983,"primaryCompletion":5941,"completion":5942,"start":5943,"enrollment":2688,"conditions":5984,"interventions":5985},[91],[773],[5929,5946,5947,5948,5949],{"trials":5987,"activeCount":102},[],{"trials":5989,"activeCount":102},[],{"trials":5991,"activeCount":102},[],{"intervention":5948,"totalTrials":1013,"cells":5993},{"EARLY_PHASE1":5994,"PHASE1":5996,"PHASE2":5998,"PHASE3":6004,"PHASE4":6006,"NA":6008},{"trials":5995,"activeCount":102},[],{"trials":5997,"activeCount":102},[],{"trials":5999,"activeCount":102},[6000],{"nctId":5938,"briefTitle":5939,"status":125,"phases":6001,"primaryCompletion":5941,"completion":5942,"start":5943,"enrollment":2688,"conditions":6002,"interventions":6003},[91],[773],[5929,5946,5947,5948,5949],{"trials":6005,"activeCount":102},[],{"trials":6007,"activeCount":102},[],{"trials":6009,"activeCount":102},[],{"intervention":5949,"totalTrials":1013,"cells":6011},{"EARLY_PHASE1":6012,"PHASE1":6014,"PHASE2":6016,"PHASE3":6022,"PHASE4":6024,"NA":6026},{"trials":6013,"activeCount":102},[],{"trials":6015,"activeCount":102},[],{"trials":6017,"activeCount":102},[6018],{"nctId":5938,"briefTitle":5939,"status":125,"phases":6019,"primaryCompletion":5941,"completion":5942,"start":5943,"enrollment":2688,"conditions":6020,"interventions":6021},[91],[773],[5929,5946,5947,5948,5949],{"trials":6023,"activeCount":102},[],{"trials":6025,"activeCount":102},[],{"trials":6027,"activeCount":102},[],{"intervention":6029,"totalTrials":1013,"cells":6030},"Unmanipulated UCB",{"EARLY_PHASE1":6031,"PHASE1":6033,"PHASE2":6035,"PHASE3":6046,"PHASE4":6048,"NA":6050},{"trials":6032,"activeCount":102},[],{"trials":6034,"activeCount":102},[],{"trials":6036,"activeCount":102},[6037],{"nctId":6038,"briefTitle":6039,"status":307,"phases":6040,"primaryCompletion":6041,"completion":6042,"start":4379,"enrollment":102,"conditions":6043,"interventions":6044},"NCT02765997","StemRegenin-1 Expanded vs Unexpanded UCB for High Risk Heme Malignancies",[91],"2020-06","2022-06",[26,191,192,272],[6029,6045],"SR-1 UCB",{"trials":6047,"activeCount":102},[],{"trials":6049,"activeCount":102},[],{"trials":6051,"activeCount":102},[],{"intervention":6045,"totalTrials":1013,"cells":6053},{"EARLY_PHASE1":6054,"PHASE1":6056,"PHASE2":6058,"PHASE3":6064,"PHASE4":6066,"NA":6068},{"trials":6055,"activeCount":102},[],{"trials":6057,"activeCount":102},[],{"trials":6059,"activeCount":102},[6060],{"nctId":6038,"briefTitle":6039,"status":307,"phases":6061,"primaryCompletion":6041,"completion":6042,"start":4379,"enrollment":102,"conditions":6062,"interventions":6063},[91],[26,191,192,272],[6029,6045],{"trials":6065,"activeCount":102},[],{"trials":6067,"activeCount":102},[],{"trials":6069,"activeCount":102},[],{"intervention":4309,"totalTrials":1013,"cells":6071},{"EARLY_PHASE1":6072,"PHASE1":6074,"PHASE2":6076,"PHASE3":6082,"PHASE4":6084,"NA":6086},{"trials":6073,"activeCount":102},[],{"trials":6075,"activeCount":102},[],{"trials":6077,"activeCount":102},[6078],{"nctId":4302,"briefTitle":4303,"status":108,"phases":6079,"primaryCompletion":4305,"completion":4305,"start":4306,"enrollment":36,"conditions":6080,"interventions":6081},[91],[29],[4309,253],{"trials":6083,"activeCount":102},[],{"trials":6085,"activeCount":102},[],{"trials":6087,"activeCount":102},[],{"intervention":6089,"totalTrials":1013,"cells":6090},"Ruxolitinib 10 MG Oral",{"EARLY_PHASE1":6091,"PHASE1":6093,"PHASE2":6095,"PHASE3":6108,"PHASE4":6110,"NA":6112},{"trials":6092,"activeCount":102},[],{"trials":6094,"activeCount":102},[],{"trials":6096,"activeCount":102},[6097],{"nctId":6098,"briefTitle":6099,"status":108,"phases":6100,"primaryCompletion":6101,"completion":6101,"start":6102,"enrollment":1454,"conditions":6103,"interventions":6105},"NCT05123040","Ruxolitinib, Human Chorionic Gonadotropin (uhCG\u002FEGF), and Dose De-escalated Corticosteroids",[90,91],"2026-02-27","2023-06-05",[6104],"Acute-graft-versus-host Disease",[6089,6106,6107],"hCG","Corticosteroids",{"trials":6109,"activeCount":102},[],{"trials":6111,"activeCount":102},[],{"trials":6113,"activeCount":102},[],{"intervention":6106,"totalTrials":1013,"cells":6115},{"EARLY_PHASE1":6116,"PHASE1":6118,"PHASE2":6120,"PHASE3":6126,"PHASE4":6128,"NA":6130},{"trials":6117,"activeCount":102},[],{"trials":6119,"activeCount":102},[],{"trials":6121,"activeCount":102},[6122],{"nctId":6098,"briefTitle":6099,"status":108,"phases":6123,"primaryCompletion":6101,"completion":6101,"start":6102,"enrollment":1454,"conditions":6124,"interventions":6125},[90,91],[6104],[6089,6106,6107],{"trials":6127,"activeCount":102},[],{"trials":6129,"activeCount":102},[],{"trials":6131,"activeCount":102},[],{"intervention":6107,"totalTrials":1013,"cells":6133},{"EARLY_PHASE1":6134,"PHASE1":6136,"PHASE2":6138,"PHASE3":6144,"PHASE4":6146,"NA":6148},{"trials":6135,"activeCount":102},[],{"trials":6137,"activeCount":102},[],{"trials":6139,"activeCount":102},[6140],{"nctId":6098,"briefTitle":6099,"status":108,"phases":6141,"primaryCompletion":6101,"completion":6101,"start":6102,"enrollment":1454,"conditions":6142,"interventions":6143},[90,91],[6104],[6089,6106,6107],{"trials":6145,"activeCount":102},[],{"trials":6147,"activeCount":102},[],{"trials":6149,"activeCount":102},[],{"intervention":2356,"totalTrials":1013,"cells":6151},{"EARLY_PHASE1":6152,"PHASE1":6154,"PHASE2":6156,"PHASE3":6162,"PHASE4":6164,"NA":6166},{"trials":6153,"activeCount":102},[],{"trials":6155,"activeCount":102},[],{"trials":6157,"activeCount":102},[6158],{"nctId":2351,"briefTitle":2352,"status":108,"phases":6159,"primaryCompletion":930,"completion":930,"start":2208,"enrollment":426,"conditions":6160,"interventions":6161},[90,91],[297,24,763],[1702,2356],{"trials":6163,"activeCount":102},[],{"trials":6165,"activeCount":102},[],{"trials":6167,"activeCount":102},[],{"intervention":6169,"totalTrials":1013,"cells":6170},"VIC- 1911",{"EARLY_PHASE1":6171,"PHASE1":6173,"PHASE2":6175,"PHASE3":6185,"PHASE4":6187,"NA":6189},{"trials":6172,"activeCount":102},[],{"trials":6174,"activeCount":102},[],{"trials":6176,"activeCount":102},[6177],{"nctId":6178,"briefTitle":6179,"status":125,"phases":6180,"primaryCompletion":6181,"completion":5806,"start":6182,"enrollment":358,"conditions":6183,"interventions":6184},"NCT05120570","PTCy + Sirolimus\u002FVIC-1911 as GVHD Prophylaxis in Myeloablative PBSC Transplantation",[90,91],"2024-09-19","2022-03-17",[264,21,414,18],[6169],{"trials":6186,"activeCount":102},[],{"trials":6188,"activeCount":102},[],{"trials":6190,"activeCount":102},[],{"intervention":6192,"totalTrials":1013,"cells":6193},"Induction Chemotherapy",{"EARLY_PHASE1":6194,"PHASE1":6196,"PHASE2":6198,"PHASE3":6210,"PHASE4":6212,"NA":6214},{"trials":6195,"activeCount":102},[],{"trials":6197,"activeCount":102},[],{"trials":6199,"activeCount":102},[6200],{"nctId":6201,"briefTitle":6202,"status":108,"phases":6203,"primaryCompletion":6204,"completion":6205,"start":6206,"enrollment":952,"conditions":6207,"interventions":6209},"NCT00167180","Post Transplant Donor Lymphocyte Infusion",[91],"2017-11-21","2018-12-24","2004-01",[941,6208,32,175,834,942,266],"Lymphomas",[6192],{"trials":6211,"activeCount":102},[],{"trials":6213,"activeCount":102},[],{"trials":6215,"activeCount":102},[],{"intervention":4460,"totalTrials":1013,"cells":6217},{"EARLY_PHASE1":6218,"PHASE1":6220,"PHASE2":6222,"PHASE3":6228,"PHASE4":6230,"NA":6232},{"trials":6219,"activeCount":102},[],{"trials":6221,"activeCount":102},[],{"trials":6223,"activeCount":102},[6224],{"nctId":4449,"briefTitle":4450,"status":125,"phases":6225,"primaryCompletion":4452,"completion":4453,"start":4454,"enrollment":907,"conditions":6226,"interventions":6227},[91],[4456],[4458,4459,4460],{"trials":6229,"activeCount":102},[],{"trials":6231,"activeCount":102},[],{"trials":6233,"activeCount":102},[],{"intervention":5135,"totalTrials":1013,"cells":6235},{"EARLY_PHASE1":6236,"PHASE1":6238,"PHASE2":6240,"PHASE3":6246,"PHASE4":6248,"NA":6250},{"trials":6237,"activeCount":102},[],{"trials":6239,"activeCount":102},[],{"trials":6241,"activeCount":102},[6242],{"nctId":5128,"briefTitle":5129,"status":108,"phases":6243,"primaryCompletion":532,"completion":532,"start":5131,"enrollment":1013,"conditions":6244,"interventions":6245},[91],[5133],[5135,5119],{"trials":6247,"activeCount":102},[],{"trials":6249,"activeCount":102},[],{"trials":6251,"activeCount":102},[],{"intervention":6253,"totalTrials":1013,"cells":6254},"Cyclophosphamide, Fludarabine",{"EARLY_PHASE1":6255,"PHASE1":6257,"PHASE2":6259,"PHASE3":6267,"PHASE4":6269,"NA":6271},{"trials":6256,"activeCount":102},[],{"trials":6258,"activeCount":102},[],{"trials":6260,"activeCount":102},[6261],{"nctId":6262,"briefTitle":6263,"status":108,"phases":6264,"primaryCompletion":4597,"completion":4597,"start":4598,"enrollment":358,"conditions":6265,"interventions":6266},"NCT00167206","Stem Cell Transplantation for Fanconi Anemia",[90,91],[219],[6253],{"trials":6268,"activeCount":102},[],{"trials":6270,"activeCount":102},[],{"trials":6272,"activeCount":102},[],{"intervention":6274,"totalTrials":1013,"cells":6275},"Indoximod",{"EARLY_PHASE1":6276,"PHASE1":6278,"PHASE2":6280,"PHASE3":6292,"PHASE4":6294,"NA":6296},{"trials":6277,"activeCount":102},[],{"trials":6279,"activeCount":102},[],{"trials":6281,"activeCount":102},[6282],{"nctId":6283,"briefTitle":6284,"status":125,"phases":6285,"primaryCompletion":6286,"completion":6286,"start":6287,"enrollment":3563,"conditions":6288,"interventions":6290},"NCT01560923","Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer",[91],"2018-12-12","2012-10-01",[6289],"Metastatic Prostate Cancer",[6274,6291],"Sipuleucel-T",{"trials":6293,"activeCount":102},[],{"trials":6295,"activeCount":102},[],{"trials":6297,"activeCount":102},[],{"intervention":6291,"totalTrials":1013,"cells":6299},{"EARLY_PHASE1":6300,"PHASE1":6302,"PHASE2":6304,"PHASE3":6310,"PHASE4":6312,"NA":6314},{"trials":6301,"activeCount":102},[],{"trials":6303,"activeCount":102},[],{"trials":6305,"activeCount":102},[6306],{"nctId":6283,"briefTitle":6284,"status":125,"phases":6307,"primaryCompletion":6286,"completion":6286,"start":6287,"enrollment":3563,"conditions":6308,"interventions":6309},[91],[6289],[6274,6291],{"trials":6311,"activeCount":102},[],{"trials":6313,"activeCount":102},[],{"trials":6315,"activeCount":102},[],{"intervention":6317,"totalTrials":1013,"cells":6318},"Activated charcoal",{"EARLY_PHASE1":6319,"PHASE1":6321,"PHASE2":6323,"PHASE3":6333,"PHASE4":6335,"NA":6337},{"trials":6320,"activeCount":102},[],{"trials":6322,"activeCount":102},[],{"trials":6324,"activeCount":102},[6325],{"nctId":6326,"briefTitle":6327,"status":307,"phases":6328,"primaryCompletion":6329,"completion":6329,"start":6330,"enrollment":102,"conditions":6331,"interventions":6332},"NCT04928950","Charcoal in Lung Cancer Patients Undergoing TEMLA",[91],"2025-01","2022-01-26",[35],[6317],{"trials":6334,"activeCount":102},[],{"trials":6336,"activeCount":102},[],{"trials":6338,"activeCount":102},[],{"intervention":544,"totalTrials":1013,"cells":6340},{"EARLY_PHASE1":6341,"PHASE1":6343,"PHASE2":6345,"PHASE3":6351,"PHASE4":6353,"NA":6355},{"trials":6342,"activeCount":102},[],{"trials":6344,"activeCount":102},[],{"trials":6346,"activeCount":102},[6347],{"nctId":538,"briefTitle":539,"status":108,"phases":6348,"primaryCompletion":172,"completion":541,"start":248,"enrollment":522,"conditions":6349,"interventions":6350},[90,91],[15,18,32,21],[118,120,544,545],{"trials":6352,"activeCount":102},[],{"trials":6354,"activeCount":102},[],{"trials":6356,"activeCount":102},[],{"intervention":545,"totalTrials":1013,"cells":6358},{"EARLY_PHASE1":6359,"PHASE1":6361,"PHASE2":6363,"PHASE3":6369,"PHASE4":6371,"NA":6373},{"trials":6360,"activeCount":102},[],{"trials":6362,"activeCount":102},[],{"trials":6364,"activeCount":102},[6365],{"nctId":538,"briefTitle":539,"status":108,"phases":6366,"primaryCompletion":172,"completion":541,"start":248,"enrollment":522,"conditions":6367,"interventions":6368},[90,91],[15,18,32,21],[118,120,544,545],{"trials":6370,"activeCount":102},[],{"trials":6372,"activeCount":102},[],{"trials":6374,"activeCount":102},[],{"intervention":6376,"totalTrials":1013,"cells":6377},"mitomycin C",{"EARLY_PHASE1":6378,"PHASE1":6380,"PHASE2":6382,"PHASE3":6391,"PHASE4":6393,"NA":6395},{"trials":6379,"activeCount":102},[],{"trials":6381,"activeCount":102},[],{"trials":6383,"activeCount":102},[6384],{"nctId":6385,"briefTitle":6386,"status":108,"phases":6387,"primaryCompletion":1204,"completion":1204,"start":4767,"enrollment":1013,"conditions":6388,"interventions":6390},"NCT00265863","Mitomycin as a Hyperthermic Peritoneal Perfusion in Treating Patients With Malignant Ascites",[91],[6389],"Metastatic Cancer",[6376],{"trials":6392,"activeCount":102},[],{"trials":6394,"activeCount":102},[],{"trials":6396,"activeCount":102},[],{"intervention":1083,"totalTrials":1013,"cells":6398},{"EARLY_PHASE1":6399,"PHASE1":6401,"PHASE2":6403,"PHASE3":6409,"PHASE4":6411,"NA":6413},{"trials":6400,"activeCount":102},[],{"trials":6402,"activeCount":102},[],{"trials":6404,"activeCount":102},[6405],{"nctId":1073,"briefTitle":1074,"status":125,"phases":6406,"primaryCompletion":172,"completion":1076,"start":1077,"enrollment":33,"conditions":6407,"interventions":6408},[91],[964,1079,966,965,1080,1081],[42,242,741,824,731,899,1083],{"trials":6410,"activeCount":102},[],{"trials":6412,"activeCount":102},[],{"trials":6414,"activeCount":102},[],{"intervention":562,"totalTrials":1013,"cells":6416},{"EARLY_PHASE1":6417,"PHASE1":6419,"PHASE2":6421,"PHASE3":6427,"PHASE4":6429,"NA":6431},{"trials":6418,"activeCount":102},[],{"trials":6420,"activeCount":102},[],{"trials":6422,"activeCount":102},[6423],{"nctId":554,"briefTitle":555,"status":307,"phases":6424,"primaryCompletion":557,"completion":557,"start":558,"enrollment":102,"conditions":6425,"interventions":6426},[91],[26,174],[561,239,97,562],{"trials":6428,"activeCount":102},[],{"trials":6430,"activeCount":102},[],{"trials":6432,"activeCount":102},[],{"intervention":5089,"totalTrials":1013,"cells":6434},{"EARLY_PHASE1":6435,"PHASE1":6437,"PHASE2":6439,"PHASE3":6445,"PHASE4":6447,"NA":6449},{"trials":6436,"activeCount":102},[],{"trials":6438,"activeCount":102},[],{"trials":6440,"activeCount":102},[6441],{"nctId":5082,"briefTitle":5083,"status":307,"phases":6442,"primaryCompletion":5085,"completion":5085,"start":5086,"enrollment":102,"conditions":6443,"interventions":6444},[91],[2117],[5089,3308],{"trials":6446,"activeCount":102},[],{"trials":6448,"activeCount":102},[],{"trials":6450,"activeCount":102},[],{"intervention":602,"totalTrials":1013,"cells":6452},{"EARLY_PHASE1":6453,"PHASE1":6455,"PHASE2":6457,"PHASE3":6463,"PHASE4":6465,"NA":6467},{"trials":6454,"activeCount":102},[],{"trials":6456,"activeCount":102},[],{"trials":6458,"activeCount":102},[6459],{"nctId":595,"briefTitle":596,"status":108,"phases":6460,"primaryCompletion":598,"completion":598,"start":599,"enrollment":358,"conditions":6461,"interventions":6462},[91],[15,21],[253,222,602,118,119,120,224,121],{"trials":6464,"activeCount":102},[],{"trials":6466,"activeCount":102},[],{"trials":6468,"activeCount":102},[],{"intervention":6470,"totalTrials":1013,"cells":6471},"Infusion of Treg",{"EARLY_PHASE1":6472,"PHASE1":6474,"PHASE2":6476,"PHASE3":6487,"PHASE4":6489,"NA":6491},{"trials":6473,"activeCount":102},[],{"trials":6475,"activeCount":102},[],{"trials":6477,"activeCount":102},[6478],{"nctId":6479,"briefTitle":6480,"status":108,"phases":6481,"primaryCompletion":6482,"completion":6482,"start":6483,"enrollment":112,"conditions":6484,"interventions":6486},"NCT02991898","Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies",[91],"2019-06-20","2017-02-16",[174,410,441,192,21,442,194,195,922,197,198,199,200,237,32,190,6485,407],"Biphenotypic Leukemia",[6470],{"trials":6488,"activeCount":102},[],{"trials":6490,"activeCount":102},[],{"trials":6492,"activeCount":102},[],{"intervention":6494,"totalTrials":1013,"cells":6495},"N-803",{"EARLY_PHASE1":6496,"PHASE1":6498,"PHASE2":6500,"PHASE3":6513,"PHASE4":6515,"NA":6517},{"trials":6497,"activeCount":102},[],{"trials":6499,"activeCount":102},[],{"trials":6501,"activeCount":102},[6502],{"nctId":6503,"briefTitle":6504,"status":125,"phases":6505,"primaryCompletion":6506,"completion":6507,"start":6508,"enrollment":6509,"conditions":6510,"interventions":6512},"NCT02989844","Relapse Prophylaxis With N-803 for AML and MDS Pts Following Allo HSCT",[91],"2022-03-19","2022-08-31","2017-04-12",20,[4707,6511],"Myelodysplastic Syndrome (MDS)",[6494],{"trials":6514,"activeCount":102},[],{"trials":6516,"activeCount":102},[],{"trials":6518,"activeCount":102},[],{"intervention":610,"totalTrials":1013,"cells":6520},{"EARLY_PHASE1":6521,"PHASE1":6523,"PHASE2":6525,"PHASE3":6531,"PHASE4":6533,"NA":6535},{"trials":6522,"activeCount":102},[],{"trials":6524,"activeCount":102},[],{"trials":6526,"activeCount":102},[6527],{"nctId":604,"briefTitle":605,"status":307,"phases":6528,"primaryCompletion":607,"completion":607,"start":378,"enrollment":102,"conditions":6529,"interventions":6530},[91],[190],[610,611,97,42,612],{"trials":6532,"activeCount":102},[],{"trials":6534,"activeCount":102},[],{"trials":6536,"activeCount":102},[],{"intervention":611,"totalTrials":1013,"cells":6538},{"EARLY_PHASE1":6539,"PHASE1":6541,"PHASE2":6543,"PHASE3":6549,"PHASE4":6551,"NA":6553},{"trials":6540,"activeCount":102},[],{"trials":6542,"activeCount":102},[],{"trials":6544,"activeCount":102},[6545],{"nctId":604,"briefTitle":605,"status":307,"phases":6546,"primaryCompletion":607,"completion":607,"start":378,"enrollment":102,"conditions":6547,"interventions":6548},[91],[190],[610,611,97,42,612],{"trials":6550,"activeCount":102},[],{"trials":6552,"activeCount":102},[],{"trials":6554,"activeCount":102},[],{"intervention":1295,"totalTrials":1013,"cells":6556},{"EARLY_PHASE1":6557,"PHASE1":6559,"PHASE2":6561,"PHASE3":6567,"PHASE4":6569,"NA":6571},{"trials":6558,"activeCount":102},[],{"trials":6560,"activeCount":102},[],{"trials":6562,"activeCount":102},[6563],{"nctId":1276,"briefTitle":1277,"status":125,"phases":6564,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":6565,"interventions":6566},[91],[1283,1284,1285,1286,1287,1288,1289,1290,1291],[561,242,1293,626,1294,1295],{"trials":6568,"activeCount":102},[],{"trials":6570,"activeCount":102},[],{"trials":6572,"activeCount":102},[],{"intervention":2203,"totalTrials":1013,"cells":6574},{"EARLY_PHASE1":6575,"PHASE1":6577,"PHASE2":6579,"PHASE3":6585,"PHASE4":6587,"NA":6589},{"trials":6576,"activeCount":102},[],{"trials":6578,"activeCount":102},[],{"trials":6580,"activeCount":102},[6581],{"nctId":2196,"briefTitle":2197,"status":108,"phases":6582,"primaryCompletion":2199,"completion":2199,"start":2200,"enrollment":1013,"conditions":6583,"interventions":6584},[90,91],[15],[119,392,222,804,224,395,2203],{"trials":6586,"activeCount":102},[],{"trials":6588,"activeCount":102},[],{"trials":6590,"activeCount":102},[],{"intervention":6592,"totalTrials":1013,"cells":6593},"Tamoxifen",{"EARLY_PHASE1":6594,"PHASE1":6596,"PHASE2":6598,"PHASE3":6607,"PHASE4":6609,"NA":6611},{"trials":6595,"activeCount":102},[],{"trials":6597,"activeCount":102},[],{"trials":6599,"activeCount":102},[6600],{"nctId":6601,"briefTitle":6602,"status":108,"phases":6603,"primaryCompletion":1678,"completion":1678,"start":6604,"enrollment":3519,"conditions":6605,"interventions":6606},"NCT00290654","Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ",[91],"2002-12",[29],[6592],{"trials":6608,"activeCount":102},[],{"trials":6610,"activeCount":102},[],{"trials":6612,"activeCount":102},[],{"intervention":6614,"totalTrials":1013,"cells":6615},"Busulfan, Cyclophosphamide, ATG",{"EARLY_PHASE1":6616,"PHASE1":6618,"PHASE2":6620,"PHASE3":6632,"PHASE4":6634,"NA":6636},{"trials":6617,"activeCount":102},[],{"trials":6619,"activeCount":102},[],{"trials":6621,"activeCount":102},[6622],{"nctId":6623,"briefTitle":6624,"status":125,"phases":6625,"primaryCompletion":4424,"completion":5203,"start":4287,"enrollment":144,"conditions":6626,"interventions":6631},"NCT00176917","Stem Cell Transplantation for Hurler",[91],[6627,6628,6629,6630],"Mucopolysaccharidosis I","Mucopolysaccharidosis VI","Mannosidosis","Mucolipidosis Type II (I-cell Disease)",[6614],{"trials":6633,"activeCount":102},[],{"trials":6635,"activeCount":102},[],{"trials":6637,"activeCount":102},[],{"intervention":6639,"totalTrials":1013,"cells":6640},"Leuprolide",{"EARLY_PHASE1":6641,"PHASE1":6643,"PHASE2":6645,"PHASE3":6658,"PHASE4":6660,"NA":6662},{"trials":6642,"activeCount":102},[],{"trials":6644,"activeCount":102},[],{"trials":6646,"activeCount":102},[6647],{"nctId":6648,"briefTitle":6649,"status":108,"phases":6650,"primaryCompletion":6651,"completion":6651,"start":6652,"enrollment":33,"conditions":6653,"interventions":6655},"NCT01343368","Preservation of Ovarian Function After Hematopoietic Cell Transplant",[91],"2015-04","2011-07",[32,236,6654,26,710],"Hodgkin Disease",[6639,6656,6657],"hematopoietic cell transplant","reduced intensity allogeneic HCT",{"trials":6659,"activeCount":102},[],{"trials":6661,"activeCount":102},[],{"trials":6663,"activeCount":102},[],{"intervention":6656,"totalTrials":1013,"cells":6665},{"EARLY_PHASE1":6666,"PHASE1":6668,"PHASE2":6670,"PHASE3":6676,"PHASE4":6678,"NA":6680},{"trials":6667,"activeCount":102},[],{"trials":6669,"activeCount":102},[],{"trials":6671,"activeCount":102},[6672],{"nctId":6648,"briefTitle":6649,"status":108,"phases":6673,"primaryCompletion":6651,"completion":6651,"start":6652,"enrollment":33,"conditions":6674,"interventions":6675},[91],[32,236,6654,26,710],[6639,6656,6657],{"trials":6677,"activeCount":102},[],{"trials":6679,"activeCount":102},[],{"trials":6681,"activeCount":102},[],{"intervention":6657,"totalTrials":1013,"cells":6683},{"EARLY_PHASE1":6684,"PHASE1":6686,"PHASE2":6688,"PHASE3":6694,"PHASE4":6696,"NA":6698},{"trials":6685,"activeCount":102},[],{"trials":6687,"activeCount":102},[],{"trials":6689,"activeCount":102},[6690],{"nctId":6648,"briefTitle":6649,"status":108,"phases":6691,"primaryCompletion":6651,"completion":6651,"start":6652,"enrollment":33,"conditions":6692,"interventions":6693},[91],[32,236,6654,26,710],[6639,6656,6657],{"trials":6695,"activeCount":102},[],{"trials":6697,"activeCount":102},[],{"trials":6699,"activeCount":102},[],{"intervention":688,"totalTrials":1013,"cells":6701},{"EARLY_PHASE1":6702,"PHASE1":6704,"PHASE2":6706,"PHASE3":6712,"PHASE4":6714,"NA":6716},{"trials":6703,"activeCount":102},[],{"trials":6705,"activeCount":102},[],{"trials":6707,"activeCount":102},[6708],{"nctId":676,"briefTitle":677,"status":678,"phases":6709,"primaryCompletion":680,"completion":491,"start":681,"enrollment":16,"conditions":6710,"interventions":6711},[90,91],[683,684,685,686],[688,42,97,689,690,691],{"trials":6713,"activeCount":102},[],{"trials":6715,"activeCount":102},[],{"trials":6717,"activeCount":102},[],{"intervention":689,"totalTrials":1013,"cells":6719},{"EARLY_PHASE1":6720,"PHASE1":6722,"PHASE2":6724,"PHASE3":6730,"PHASE4":6732,"NA":6734},{"trials":6721,"activeCount":102},[],{"trials":6723,"activeCount":102},[],{"trials":6725,"activeCount":102},[6726],{"nctId":676,"briefTitle":677,"status":678,"phases":6727,"primaryCompletion":680,"completion":491,"start":681,"enrollment":16,"conditions":6728,"interventions":6729},[90,91],[683,684,685,686],[688,42,97,689,690,691],{"trials":6731,"activeCount":102},[],{"trials":6733,"activeCount":102},[],{"trials":6735,"activeCount":102},[],{"intervention":690,"totalTrials":1013,"cells":6737},{"EARLY_PHASE1":6738,"PHASE1":6740,"PHASE2":6742,"PHASE3":6748,"PHASE4":6750,"NA":6752},{"trials":6739,"activeCount":102},[],{"trials":6741,"activeCount":102},[],{"trials":6743,"activeCount":102},[6744],{"nctId":676,"briefTitle":677,"status":678,"phases":6745,"primaryCompletion":680,"completion":491,"start":681,"enrollment":16,"conditions":6746,"interventions":6747},[90,91],[683,684,685,686],[688,42,97,689,690,691],{"trials":6749,"activeCount":102},[],{"trials":6751,"activeCount":102},[],{"trials":6753,"activeCount":102},[],{"intervention":691,"totalTrials":1013,"cells":6755},{"EARLY_PHASE1":6756,"PHASE1":6758,"PHASE2":6760,"PHASE3":6766,"PHASE4":6768,"NA":6770},{"trials":6757,"activeCount":102},[],{"trials":6759,"activeCount":102},[],{"trials":6761,"activeCount":102},[6762],{"nctId":676,"briefTitle":677,"status":678,"phases":6763,"primaryCompletion":680,"completion":491,"start":681,"enrollment":16,"conditions":6764,"interventions":6765},[90,91],[683,684,685,686],[688,42,97,689,690,691],{"trials":6767,"activeCount":102},[],{"trials":6769,"activeCount":102},[],{"trials":6771,"activeCount":102},[],{"intervention":6773,"totalTrials":1013,"cells":6774},"Interleukin-2 & Ipilimumab",{"EARLY_PHASE1":6775,"PHASE1":6777,"PHASE2":6779,"PHASE3":6792,"PHASE4":6794,"NA":6796},{"trials":6776,"activeCount":102},[],{"trials":6778,"activeCount":102},[],{"trials":6780,"activeCount":102},[6781],{"nctId":6782,"briefTitle":6783,"status":307,"phases":6784,"primaryCompletion":6785,"completion":6785,"start":6786,"enrollment":102,"conditions":6787,"interventions":6791},"NCT03297463","Radiation Therapy With Combination Immunotherapy for Relapsed\u002FRefractory Metastatic Melanoma",[90,91],"2020-02-01","2018-01-31",[5640,6788,6789,6790],"Pulmonary Metastases","Hepatic Metastases","Brain Metastases",[6773,6773],{"trials":6793,"activeCount":102},[],{"trials":6795,"activeCount":102},[],{"trials":6797,"activeCount":102},[],{"intervention":6799,"totalTrials":1013,"cells":6800},"Exemestane",{"EARLY_PHASE1":6801,"PHASE1":6803,"PHASE2":6805,"PHASE3":6816,"PHASE4":6818,"NA":6820},{"trials":6802,"activeCount":102},[],{"trials":6804,"activeCount":102},[],{"trials":6806,"activeCount":102},[6807],{"nctId":6808,"briefTitle":6809,"status":125,"phases":6810,"primaryCompletion":6811,"completion":6811,"start":6812,"enrollment":460,"conditions":6813,"interventions":6815},"NCT02666105","Exemestane in Post-Menopausal Women With NSCLC",[91],"2022-02-28","2018-09-27",[6814],"Non-Small Cell Lung Cancer",[6799],{"trials":6817,"activeCount":102},[],{"trials":6819,"activeCount":102},[],{"trials":6821,"activeCount":102},[],{"intervention":1726,"totalTrials":1013,"cells":6823},{"EARLY_PHASE1":6824,"PHASE1":6826,"PHASE2":6828,"PHASE3":6834,"PHASE4":6836,"NA":6838},{"trials":6825,"activeCount":102},[],{"trials":6827,"activeCount":102},[],{"trials":6829,"activeCount":102},[6830],{"nctId":1717,"briefTitle":1718,"status":125,"phases":6831,"primaryCompletion":1720,"completion":1721,"start":1722,"enrollment":16,"conditions":6832,"interventions":6833},[90,91],[1724],[285,1726],{"trials":6835,"activeCount":102},[],{"trials":6837,"activeCount":102},[],{"trials":6839,"activeCount":102},[],{"intervention":3329,"totalTrials":1013,"cells":6841},{"EARLY_PHASE1":6842,"PHASE1":6844,"PHASE2":6846,"PHASE3":6852,"PHASE4":6854,"NA":6856},{"trials":6843,"activeCount":102},[],{"trials":6845,"activeCount":102},[],{"trials":6847,"activeCount":102},[6848],{"nctId":3322,"briefTitle":3323,"status":108,"phases":6849,"primaryCompletion":110,"completion":3325,"start":3326,"enrollment":27,"conditions":6850,"interventions":6851},[91],[35],[1790,2119,3329],{"trials":6853,"activeCount":102},[],{"trials":6855,"activeCount":102},[],{"trials":6857,"activeCount":102},[],{"intervention":742,"totalTrials":1013,"cells":6859},{"EARLY_PHASE1":6860,"PHASE1":6862,"PHASE2":6864,"PHASE3":6870,"PHASE4":6872,"NA":6874},{"trials":6861,"activeCount":102},[],{"trials":6863,"activeCount":102},[],{"trials":6865,"activeCount":102},[6866],{"nctId":733,"briefTitle":734,"status":125,"phases":6867,"primaryCompletion":736,"completion":736,"start":458,"enrollment":737,"conditions":6868,"interventions":6869},[90,91],[739],[97,42,741,742],{"trials":6871,"activeCount":102},[],{"trials":6873,"activeCount":102},[],{"trials":6875,"activeCount":102},[],{"intervention":6877,"totalTrials":1013,"cells":6878},"Laronidase ERT",{"EARLY_PHASE1":6879,"PHASE1":6881,"PHASE2":6883,"PHASE3":6892,"PHASE4":6894,"NA":6896},{"trials":6880,"activeCount":102},[],{"trials":6882,"activeCount":102},[],{"trials":6884,"activeCount":102},[6885],{"nctId":6886,"briefTitle":6887,"status":125,"phases":6888,"primaryCompletion":6889,"completion":6889,"start":4598,"enrollment":1374,"conditions":6890,"interventions":6891},"NCT00176891","Stem Cell Transplant w\u002FLaronidase for Hurler",[91],"2012-11",[6627,648],[6877],{"trials":6893,"activeCount":102},[],{"trials":6895,"activeCount":102},[],{"trials":6897,"activeCount":102},[],{"intervention":2214,"totalTrials":1013,"cells":6899},{"EARLY_PHASE1":6900,"PHASE1":6902,"PHASE2":6904,"PHASE3":6910,"PHASE4":6912,"NA":6914},{"trials":6901,"activeCount":102},[],{"trials":6903,"activeCount":102},[],{"trials":6905,"activeCount":102},[6906],{"nctId":2205,"briefTitle":2206,"status":108,"phases":6907,"primaryCompletion":894,"completion":894,"start":2208,"enrollment":426,"conditions":6908,"interventions":6909},[91],[15,18],[392,2211,2212,2213,804,2214,2215,2216,2154],{"trials":6911,"activeCount":102},[],{"trials":6913,"activeCount":102},[],{"trials":6915,"activeCount":102},[],{"intervention":2216,"totalTrials":1013,"cells":6917},{"EARLY_PHASE1":6918,"PHASE1":6920,"PHASE2":6922,"PHASE3":6928,"PHASE4":6930,"NA":6932},{"trials":6919,"activeCount":102},[],{"trials":6921,"activeCount":102},[],{"trials":6923,"activeCount":102},[6924],{"nctId":2205,"briefTitle":2206,"status":108,"phases":6925,"primaryCompletion":894,"completion":894,"start":2208,"enrollment":426,"conditions":6926,"interventions":6927},[91],[15,18],[392,2211,2212,2213,804,2214,2215,2216,2154],{"trials":6929,"activeCount":102},[],{"trials":6931,"activeCount":102},[],{"trials":6933,"activeCount":102},[],{"intervention":775,"totalTrials":1013,"cells":6935},{"EARLY_PHASE1":6936,"PHASE1":6938,"PHASE2":6940,"PHASE3":6946,"PHASE4":6948,"NA":6950},{"trials":6937,"activeCount":102},[],{"trials":6939,"activeCount":102},[],{"trials":6941,"activeCount":102},[6942],{"nctId":768,"briefTitle":769,"status":307,"phases":6943,"primaryCompletion":771,"completion":771,"start":492,"enrollment":102,"conditions":6944,"interventions":6945},[91],[773],[775,42,97],{"trials":6947,"activeCount":102},[],{"trials":6949,"activeCount":102},[],{"trials":6951,"activeCount":102},[],{"intervention":6953,"totalTrials":1013,"cells":6954},"everolimus",{"EARLY_PHASE1":6955,"PHASE1":6957,"PHASE2":6959,"PHASE3":6968,"PHASE4":6970,"NA":6972},{"trials":6956,"activeCount":102},[],{"trials":6958,"activeCount":102},[],{"trials":6960,"activeCount":102},[6961],{"nctId":6962,"briefTitle":6963,"status":307,"phases":6964,"primaryCompletion":6965,"completion":6965,"start":3325,"enrollment":102,"conditions":6966,"interventions":6967},"NCT00855114","Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery",[91],"2009-06",[29],[6953],{"trials":6969,"activeCount":102},[],{"trials":6971,"activeCount":102},[],{"trials":6973,"activeCount":102},[],{"intervention":6975,"totalTrials":1013,"cells":6976},"paclitaxel albumin-stabilized nanoparticle formulation",{"EARLY_PHASE1":6977,"PHASE1":6979,"PHASE2":6981,"PHASE3":6990,"PHASE4":6992,"NA":6994},{"trials":6978,"activeCount":102},[],{"trials":6980,"activeCount":102},[],{"trials":6982,"activeCount":102},[6983],{"nctId":6984,"briefTitle":6985,"status":307,"phases":6986,"primaryCompletion":598,"completion":598,"start":598,"enrollment":102,"conditions":6987,"interventions":6988},"NCT00748163","Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer",[91],[35],[6975,6989],"sunitinib malate",{"trials":6991,"activeCount":102},[],{"trials":6993,"activeCount":102},[],{"trials":6995,"activeCount":102},[],{"intervention":6989,"totalTrials":1013,"cells":6997},{"EARLY_PHASE1":6998,"PHASE1":7000,"PHASE2":7002,"PHASE3":7008,"PHASE4":7010,"NA":7012},{"trials":6999,"activeCount":102},[],{"trials":7001,"activeCount":102},[],{"trials":7003,"activeCount":102},[7004],{"nctId":6984,"briefTitle":6985,"status":307,"phases":7005,"primaryCompletion":598,"completion":598,"start":598,"enrollment":102,"conditions":7006,"interventions":7007},[91],[35],[6975,6989],{"trials":7009,"activeCount":102},[],{"trials":7011,"activeCount":102},[],{"trials":7013,"activeCount":102},[],{"intervention":793,"totalTrials":1013,"cells":7015},{"EARLY_PHASE1":7016,"PHASE1":7018,"PHASE2":7020,"PHASE3":7026,"PHASE4":7028,"NA":7030},{"trials":7017,"activeCount":102},[],{"trials":7019,"activeCount":102},[],{"trials":7021,"activeCount":102},[7022],{"nctId":784,"briefTitle":785,"status":125,"phases":7023,"primaryCompletion":787,"completion":788,"start":789,"enrollment":790,"conditions":7024,"interventions":7025},[91],[739],[288,97,42,208,420,793,87],{"trials":7027,"activeCount":102},[],{"trials":7029,"activeCount":102},[],{"trials":7031,"activeCount":102},[],{"intervention":7033,"totalTrials":1013,"cells":7034},"ALT-803 Subcutaneous",{"EARLY_PHASE1":7035,"PHASE1":7037,"PHASE2":7039,"PHASE3":7053,"PHASE4":7055,"NA":7057},{"trials":7036,"activeCount":102},[],{"trials":7038,"activeCount":102},[],{"trials":7040,"activeCount":102},[7041],{"nctId":7042,"briefTitle":7043,"status":125,"phases":7044,"primaryCompletion":7045,"completion":7045,"start":7046,"enrollment":669,"conditions":7047,"interventions":7051},"NCT03054909","IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer",[91],"2022-02-16","2017-09-19",[7048,7049,7050],"FIGO Stage III and IV Ovarian Cancer","FIGO Stage III and IV Fallopian Tube Cancer","FIGO Stage III Primary Peritoneal Cancer",[7033,7052],"ALT-803 Intraperitoneal",{"trials":7054,"activeCount":102},[],{"trials":7056,"activeCount":102},[],{"trials":7058,"activeCount":102},[],{"intervention":7052,"totalTrials":1013,"cells":7060},{"EARLY_PHASE1":7061,"PHASE1":7063,"PHASE2":7065,"PHASE3":7071,"PHASE4":7073,"NA":7075},{"trials":7062,"activeCount":102},[],{"trials":7064,"activeCount":102},[],{"trials":7066,"activeCount":102},[7067],{"nctId":7042,"briefTitle":7043,"status":125,"phases":7068,"primaryCompletion":7045,"completion":7045,"start":7046,"enrollment":669,"conditions":7069,"interventions":7070},[91],[7048,7049,7050],[7033,7052],{"trials":7072,"activeCount":102},[],{"trials":7074,"activeCount":102},[],{"trials":7076,"activeCount":102},[],{"intervention":4337,"totalTrials":1013,"cells":7078},{"EARLY_PHASE1":7079,"PHASE1":7081,"PHASE2":7083,"PHASE3":7089,"PHASE4":7091,"NA":7093},{"trials":7080,"activeCount":102},[],{"trials":7082,"activeCount":102},[],{"trials":7084,"activeCount":102},[7085],{"nctId":4331,"briefTitle":4332,"status":125,"phases":7086,"primaryCompletion":2126,"completion":2126,"start":319,"enrollment":30,"conditions":7087,"interventions":7088},[91],[4335],[253,4337],{"trials":7090,"activeCount":102},[],{"trials":7092,"activeCount":102},[],{"trials":7094,"activeCount":102},[],{"intervention":136,"totalTrials":112,"cells":7096},{"EARLY_PHASE1":7097,"PHASE1":7099,"PHASE2":7118,"PHASE3":7120,"PHASE4":7122,"NA":7124},{"trials":7098,"activeCount":102},[],{"trials":7100,"activeCount":102},[7101,7105,7109],{"nctId":4483,"briefTitle":4484,"status":307,"phases":7102,"primaryCompletion":4486,"completion":4487,"start":4488,"enrollment":102,"conditions":7103,"interventions":7104},[90],[4490,4491,4492,4493,4494],[136,2130],{"nctId":123,"briefTitle":124,"status":125,"phases":7106,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":7107,"interventions":7108},[90],[26,132,133],[135,136,42,97],{"nctId":7110,"briefTitle":7111,"status":108,"phases":7112,"primaryCompletion":7113,"completion":7113,"start":7114,"enrollment":1013,"conditions":7115,"interventions":7117},"NCT05708924","MT2021-27 FT538 Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",[90],"2024-08-06","2023-04-28",[1713,3451,24,7116,297],"Peritoneal Cancer",[136,2239],{"trials":7119,"activeCount":102},[],{"trials":7121,"activeCount":102},[],{"trials":7123,"activeCount":102},[],{"trials":7125,"activeCount":102},[],{"intervention":7127,"totalTrials":158,"cells":7128},"Imiquimod",{"EARLY_PHASE1":7129,"PHASE1":7131,"PHASE2":7154,"PHASE3":7156,"PHASE4":7158,"NA":7160},{"trials":7130,"activeCount":102},[],{"trials":7132,"activeCount":102},[7133,7144],{"nctId":7134,"briefTitle":7135,"status":108,"phases":7136,"primaryCompletion":7137,"completion":7138,"start":7139,"enrollment":1137,"conditions":7140,"interventions":7142},"NCT01400672","Imiquimod\u002FBrain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma",[90],"2016-03-07","2018-10-08","2012-07-17",[7141],"Diffuse Intrinsic Pontine Glioma",[7143,7127],"Tumor Lysate Vaccine",{"nctId":7145,"briefTitle":7146,"status":125,"phases":7147,"primaryCompletion":2151,"completion":668,"start":2139,"enrollment":1137,"conditions":7148,"interventions":7152},"NCT01171469","Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor",[90],[7149,3421,1359,7150,7151],"Brain Tumor","Ependymoma","Anaplastic Astrocytoma",[7153,7127],"Dendritic Cells",{"trials":7155,"activeCount":102},[],{"trials":7157,"activeCount":102},[],{"trials":7159,"activeCount":102},[],{"trials":7161,"activeCount":102},[],{"intervention":4592,"totalTrials":158,"cells":7163},{"EARLY_PHASE1":7164,"PHASE1":7166,"PHASE2":7176,"PHASE3":7178,"PHASE4":7180,"NA":7182},{"trials":7165,"activeCount":102},[],{"trials":7167,"activeCount":102},[7168,7172],{"nctId":4587,"briefTitle":4588,"status":108,"phases":7169,"primaryCompletion":111,"completion":111,"start":459,"enrollment":1438,"conditions":7170,"interventions":7171},[90],[35],[3297,4592],{"nctId":4894,"briefTitle":4895,"status":125,"phases":7173,"primaryCompletion":458,"completion":4380,"start":4897,"enrollment":790,"conditions":7174,"interventions":7175},[90],[763],[4447,4900,4592],{"trials":7177,"activeCount":102},[],{"trials":7179,"activeCount":102},[],{"trials":7181,"activeCount":102},[],{"trials":7183,"activeCount":102},[],{"intervention":7185,"totalTrials":158,"cells":7186},"Mesenchymal Stem Cells",{"EARLY_PHASE1":7187,"PHASE1":7189,"PHASE2":7209,"PHASE3":7211,"PHASE4":7213,"NA":7215},{"trials":7188,"activeCount":102},[],{"trials":7190,"activeCount":102},[7191,7200],{"nctId":7192,"briefTitle":7193,"status":307,"phases":7194,"primaryCompletion":7195,"completion":7196,"start":643,"enrollment":102,"conditions":7197,"interventions":7199},"NCT02410239","MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)",[90],"2017-07","2022-07",[7198],"Cerebral Adrenoleukodystrophy",[7185],{"nctId":7201,"briefTitle":7202,"status":678,"phases":7203,"primaryCompletion":3862,"completion":7204,"start":7205,"enrollment":1454,"conditions":7206,"interventions":7207},"NCT06030648","MT2022-01: MSCs for ALD",[90],"2028-05-01","2023-08-28",[7198],[7208],"Mesenchymal stem cells",{"trials":7210,"activeCount":102},[],{"trials":7212,"activeCount":102},[],{"trials":7214,"activeCount":102},[],{"trials":7216,"activeCount":102},[],{"intervention":4359,"totalTrials":158,"cells":7218},{"EARLY_PHASE1":7219,"PHASE1":7221,"PHASE2":7236,"PHASE3":7238,"PHASE4":7240,"NA":7242},{"trials":7220,"activeCount":102},[],{"trials":7222,"activeCount":102},[7223,7232],{"nctId":7224,"briefTitle":7225,"status":125,"phases":7226,"primaryCompletion":1306,"completion":7227,"start":7228,"enrollment":460,"conditions":7229,"interventions":7231},"NCT03081780","Open Label NK Cell Infusion (FATE-NK100) With Subq IL-2 in Adults With AML",[90],"2020-12-01","2017-04-27",[380,7230],"Relapsed Acute Myelogenous Leukemia",[4359],{"nctId":4351,"briefTitle":4352,"status":125,"phases":7233,"primaryCompletion":4354,"completion":4354,"start":4355,"enrollment":1454,"conditions":7234,"interventions":7235},[90],[4357,297,298],[4359,303],{"trials":7237,"activeCount":102},[],{"trials":7239,"activeCount":102},[],{"trials":7241,"activeCount":102},[],{"trials":7243,"activeCount":102},[],{"intervention":2239,"totalTrials":158,"cells":7245},{"EARLY_PHASE1":7246,"PHASE1":7248,"PHASE2":7258,"PHASE3":7260,"PHASE4":7262,"NA":7264},{"trials":7247,"activeCount":102},[],{"trials":7249,"activeCount":102},[7250,7254],{"nctId":2230,"briefTitle":2231,"status":125,"phases":7251,"primaryCompletion":2233,"completion":2233,"start":2234,"enrollment":112,"conditions":7252,"interventions":7253},[90],[24,2236,1002],[2238,2239,164],{"nctId":7110,"briefTitle":7111,"status":108,"phases":7255,"primaryCompletion":7113,"completion":7113,"start":7114,"enrollment":1013,"conditions":7256,"interventions":7257},[90],[1713,3451,24,7116,297],[136,2239],{"trials":7259,"activeCount":102},[],{"trials":7261,"activeCount":102},[],{"trials":7263,"activeCount":102},[],{"trials":7265,"activeCount":102},[],{"intervention":7267,"totalTrials":1013,"cells":7268},"Voriconazole",{"EARLY_PHASE1":7269,"PHASE1":7271,"PHASE2":7284,"PHASE3":7286,"PHASE4":7288,"NA":7290},{"trials":7270,"activeCount":102},[],{"trials":7272,"activeCount":102},[7273],{"nctId":7274,"briefTitle":7275,"status":125,"phases":7276,"primaryCompletion":7277,"completion":7278,"start":7279,"enrollment":7280,"conditions":7281,"interventions":7283},"NCT02227797","MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant Patients",[90],"2017-09-08","2019-03-01","2015-01-19",66,[7282],"Fungal Infection",[7267],{"trials":7285,"activeCount":102},[],{"trials":7287,"activeCount":102},[],{"trials":7289,"activeCount":102},[],{"trials":7291,"activeCount":102},[],{"intervention":4418,"totalTrials":1013,"cells":7293},{"EARLY_PHASE1":7294,"PHASE1":7296,"PHASE2":7302,"PHASE3":7304,"PHASE4":7306,"NA":7308},{"trials":7295,"activeCount":102},[],{"trials":7297,"activeCount":102},[7298],{"nctId":4412,"briefTitle":4413,"status":307,"phases":7299,"primaryCompletion":110,"completion":110,"start":1221,"enrollment":102,"conditions":7300,"interventions":7301},[90],[4416],[4405,4418],{"trials":7303,"activeCount":102},[],{"trials":7305,"activeCount":102},[],{"trials":7307,"activeCount":102},[],{"trials":7309,"activeCount":102},[],{"intervention":7143,"totalTrials":1013,"cells":7311},{"EARLY_PHASE1":7312,"PHASE1":7314,"PHASE2":7320,"PHASE3":7322,"PHASE4":7324,"NA":7326},{"trials":7313,"activeCount":102},[],{"trials":7315,"activeCount":102},[7316],{"nctId":7134,"briefTitle":7135,"status":108,"phases":7317,"primaryCompletion":7137,"completion":7138,"start":7139,"enrollment":1137,"conditions":7318,"interventions":7319},[90],[7141],[7143,7127],{"trials":7321,"activeCount":102},[],{"trials":7323,"activeCount":102},[],{"trials":7325,"activeCount":102},[],{"trials":7327,"activeCount":102},[],{"intervention":4428,"totalTrials":1013,"cells":7329},{"EARLY_PHASE1":7330,"PHASE1":7332,"PHASE2":7338,"PHASE3":7340,"PHASE4":7342,"NA":7344},{"trials":7331,"activeCount":102},[],{"trials":7333,"activeCount":102},[7334],{"nctId":4420,"briefTitle":4421,"status":125,"phases":7335,"primaryCompletion":2139,"completion":4423,"start":4424,"enrollment":358,"conditions":7336,"interventions":7337},[90],[29,2104,671,35,4426,2105,2117,1194],[4405,4428,4429],{"trials":7339,"activeCount":102},[],{"trials":7341,"activeCount":102},[],{"trials":7343,"activeCount":102},[],{"trials":7345,"activeCount":102},[],{"intervention":4429,"totalTrials":1013,"cells":7347},{"EARLY_PHASE1":7348,"PHASE1":7350,"PHASE2":7356,"PHASE3":7358,"PHASE4":7360,"NA":7362},{"trials":7349,"activeCount":102},[],{"trials":7351,"activeCount":102},[7352],{"nctId":4420,"briefTitle":4421,"status":125,"phases":7353,"primaryCompletion":2139,"completion":4423,"start":4424,"enrollment":358,"conditions":7354,"interventions":7355},[90],[29,2104,671,35,4426,2105,2117,1194],[4405,4428,4429],{"trials":7357,"activeCount":102},[],{"trials":7359,"activeCount":102},[],{"trials":7361,"activeCount":102},[],{"trials":7363,"activeCount":102},[],{"intervention":4831,"totalTrials":1013,"cells":7365},{"EARLY_PHASE1":7366,"PHASE1":7368,"PHASE2":7374,"PHASE3":7376,"PHASE4":7378,"NA":7380},{"trials":7367,"activeCount":102},[],{"trials":7369,"activeCount":102},[7370],{"nctId":4825,"briefTitle":4826,"status":125,"phases":7371,"primaryCompletion":818,"completion":818,"start":4380,"enrollment":4828,"conditions":7372,"interventions":7373},[90],[190,175],[3692,4831],{"trials":7375,"activeCount":102},[],{"trials":7377,"activeCount":102},[],{"trials":7379,"activeCount":102},[],{"trials":7381,"activeCount":102},[],{"intervention":7383,"totalTrials":1013,"cells":7384},"Pazopanib",{"EARLY_PHASE1":7385,"PHASE1":7387,"PHASE2":7399,"PHASE3":7401,"PHASE4":7403,"NA":7405},{"trials":7386,"activeCount":102},[],{"trials":7388,"activeCount":102},[7389],{"nctId":7390,"briefTitle":7391,"status":108,"phases":7392,"primaryCompletion":7393,"completion":7393,"start":567,"enrollment":522,"conditions":7394,"interventions":7397},"NCT01012362","Study of Pazopanib and Ixabepilone in Patients With Solid Tumors",[90],"2013-02",[29,35,7395,2105,671,700,1194,7396],"Colon Cancer","Hepatocellular Cancer",[7383,7398],"Ixabepilone",{"trials":7400,"activeCount":102},[],{"trials":7402,"activeCount":102},[],{"trials":7404,"activeCount":102},[],{"trials":7406,"activeCount":102},[],{"intervention":7398,"totalTrials":1013,"cells":7408},{"EARLY_PHASE1":7409,"PHASE1":7411,"PHASE2":7417,"PHASE3":7419,"PHASE4":7421,"NA":7423},{"trials":7410,"activeCount":102},[],{"trials":7412,"activeCount":102},[7413],{"nctId":7390,"briefTitle":7391,"status":108,"phases":7414,"primaryCompletion":7393,"completion":7393,"start":567,"enrollment":522,"conditions":7415,"interventions":7416},[90],[29,35,7395,2105,671,700,1194,7396],[7383,7398],{"trials":7418,"activeCount":102},[],{"trials":7420,"activeCount":102},[],{"trials":7422,"activeCount":102},[],{"trials":7424,"activeCount":102},[],{"intervention":7426,"totalTrials":1013,"cells":7427},"Coriolus versicolor extract",{"EARLY_PHASE1":7428,"PHASE1":7430,"PHASE2":7438,"PHASE3":7440,"PHASE4":7442,"NA":7444},{"trials":7429,"activeCount":102},[],{"trials":7431,"activeCount":102},[7432],{"nctId":7433,"briefTitle":7434,"status":125,"phases":7435,"primaryCompletion":4444,"completion":4444,"start":905,"enrollment":832,"conditions":7436,"interventions":7437},"NCT00680667","Clinical Trial of Trametes Versicolor in Women With Breast Cancer",[90],[29],[7426],{"trials":7439,"activeCount":102},[],{"trials":7441,"activeCount":102},[],{"trials":7443,"activeCount":102},[],{"trials":7445,"activeCount":102},[],{"intervention":7447,"totalTrials":1013,"cells":7448},"CMV-MVA Triplex Vaccine",{"EARLY_PHASE1":7449,"PHASE1":7451,"PHASE2":7461,"PHASE3":7463,"PHASE4":7465,"NA":7467},{"trials":7450,"activeCount":102},[],{"trials":7452,"activeCount":102},[7453],{"nctId":7454,"briefTitle":7455,"status":125,"phases":7456,"primaryCompletion":7457,"completion":7457,"start":7458,"enrollment":1245,"conditions":7459,"interventions":7460},"NCT03383055","CMV-MVA Triplex Vac.Enhance Adap. NK Cell Recon. After Auto HSCT in pt Lymphoid Malig",[90],"2021-07-10","2018-11-16",[18,32],[7447],{"trials":7462,"activeCount":102},[],{"trials":7464,"activeCount":102},[],{"trials":7466,"activeCount":102},[],{"trials":7468,"activeCount":102},[],{"intervention":7470,"totalTrials":1013,"cells":7471},"iTreg",{"EARLY_PHASE1":7472,"PHASE1":7474,"PHASE2":7485,"PHASE3":7487,"PHASE4":7489,"NA":7491},{"trials":7473,"activeCount":102},[],{"trials":7475,"activeCount":102},[7476],{"nctId":7477,"briefTitle":7478,"status":125,"phases":7479,"primaryCompletion":7480,"completion":7481,"start":7482,"enrollment":358,"conditions":7483,"interventions":7484},"NCT01634217","Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation",[90],"2017-12-01","2018-12-01","2013-11-08",[190,191,192,236,237,194,32,175],[7470],{"trials":7486,"activeCount":102},[],{"trials":7488,"activeCount":102},[],{"trials":7490,"activeCount":102},[],{"trials":7492,"activeCount":102},[],{"intervention":7494,"totalTrials":1013,"cells":7495},"IRT Laronidase",{"EARLY_PHASE1":7496,"PHASE1":7498,"PHASE2":7509,"PHASE3":7511,"PHASE4":7513,"NA":7515},{"trials":7497,"activeCount":102},[],{"trials":7499,"activeCount":102},[7500],{"nctId":7501,"briefTitle":7502,"status":125,"phases":7503,"primaryCompletion":7504,"completion":7505,"start":7506,"enrollment":4828,"conditions":7507,"interventions":7508},"NCT00638547","Intrathecal Enzyme Replacement for Hurler Syndrome",[90],"2017-02-18","2018-11-18","2008-01-02",[648],[7494],{"trials":7510,"activeCount":102},[],{"trials":7512,"activeCount":102},[],{"trials":7514,"activeCount":102},[],{"trials":7516,"activeCount":102},[],{"intervention":7518,"totalTrials":1013,"cells":7519},"anti-CD45 monoclonal antibody AHN-12",{"EARLY_PHASE1":7520,"PHASE1":7522,"PHASE2":7530,"PHASE3":7532,"PHASE4":7534,"NA":7536},{"trials":7521,"activeCount":102},[],{"trials":7523,"activeCount":102},[7524],{"nctId":7525,"briefTitle":7526,"status":108,"phases":7527,"primaryCompletion":4878,"completion":4878,"start":1909,"enrollment":1438,"conditions":7528,"interventions":7529},"NCT00618696","Yttrium Y 90 Anti-CD45 Monoclonal Antibody AHN-12 in Treating Patients With Advanced Leukemia",[90],[15,21],[7518],{"trials":7531,"activeCount":102},[],{"trials":7533,"activeCount":102},[],{"trials":7535,"activeCount":102},[],{"trials":7537,"activeCount":102},[],{"intervention":7539,"totalTrials":1013,"cells":7540},"Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells",{"EARLY_PHASE1":7541,"PHASE1":7543,"PHASE2":7556,"PHASE3":7558,"PHASE4":7560,"NA":7562},{"trials":7542,"activeCount":102},[],{"trials":7544,"activeCount":102},[7545],{"nctId":7546,"briefTitle":7547,"status":125,"phases":7548,"primaryCompletion":7549,"completion":7549,"start":7550,"enrollment":7551,"conditions":7552,"interventions":7555},"NCT03019666","Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL",[90],"2022-08-15","2017-10-18",39,[32,236,684,199,197,7553,7554,198],"Indolent B Cell Lymphoma","Primary Mediastinal Lymphoma",[7539],{"trials":7557,"activeCount":102},[],{"trials":7559,"activeCount":102},[],{"trials":7561,"activeCount":102},[],{"trials":7563,"activeCount":102},[],{"intervention":7565,"totalTrials":1013,"cells":7566},"FT516",{"EARLY_PHASE1":7567,"PHASE1":7569,"PHASE2":7580,"PHASE3":7582,"PHASE4":7584,"NA":7586},{"trials":7568,"activeCount":102},[],{"trials":7570,"activeCount":102},[7571],{"nctId":7572,"briefTitle":7573,"status":125,"phases":7574,"primaryCompletion":7575,"completion":7575,"start":7576,"enrollment":895,"conditions":7577,"interventions":7579},"NCT04363346","Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia",[90],"2021-02-18","2020-05-14",[7578],"COVID-19",[7565],{"trials":7581,"activeCount":102},[],{"trials":7583,"activeCount":102},[],{"trials":7585,"activeCount":102},[],{"trials":7587,"activeCount":102},[],{"intervention":2238,"totalTrials":1013,"cells":7589},{"EARLY_PHASE1":7590,"PHASE1":7592,"PHASE2":7598,"PHASE3":7600,"PHASE4":7602,"NA":7604},{"trials":7591,"activeCount":102},[],{"trials":7593,"activeCount":102},[7594],{"nctId":2230,"briefTitle":2231,"status":125,"phases":7595,"primaryCompletion":2233,"completion":2233,"start":2234,"enrollment":112,"conditions":7596,"interventions":7597},[90],[24,2236,1002],[2238,2239,164],{"trials":7599,"activeCount":102},[],{"trials":7601,"activeCount":102},[],{"trials":7603,"activeCount":102},[],{"trials":7605,"activeCount":102},[],{"intervention":7153,"totalTrials":1013,"cells":7607},{"EARLY_PHASE1":7608,"PHASE1":7610,"PHASE2":7616,"PHASE3":7618,"PHASE4":7620,"NA":7622},{"trials":7609,"activeCount":102},[],{"trials":7611,"activeCount":102},[7612],{"nctId":7145,"briefTitle":7146,"status":125,"phases":7613,"primaryCompletion":2151,"completion":668,"start":2139,"enrollment":1137,"conditions":7614,"interventions":7615},[90],[7149,3421,1359,7150,7151],[7153,7127],{"trials":7617,"activeCount":102},[],{"trials":7619,"activeCount":102},[],{"trials":7621,"activeCount":102},[],{"trials":7623,"activeCount":102},[],{"intervention":135,"totalTrials":1013,"cells":7625},{"EARLY_PHASE1":7626,"PHASE1":7628,"PHASE2":7634,"PHASE3":7636,"PHASE4":7638,"NA":7640},{"trials":7627,"activeCount":102},[],{"trials":7629,"activeCount":102},[7630],{"nctId":123,"briefTitle":124,"status":125,"phases":7631,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":7632,"interventions":7633},[90],[26,132,133],[135,136,42,97],{"trials":7635,"activeCount":102},[],{"trials":7637,"activeCount":102},[],{"trials":7639,"activeCount":102},[],{"trials":7641,"activeCount":102},[],{"intervention":7643,"totalTrials":1013,"cells":7644},"keyhole limpet hemocyanin",{"EARLY_PHASE1":7645,"PHASE1":7647,"PHASE2":7657,"PHASE3":7659,"PHASE4":7661,"NA":7663},{"trials":7646,"activeCount":102},[],{"trials":7648,"activeCount":102},[7649],{"nctId":7650,"briefTitle":7651,"status":108,"phases":7652,"primaryCompletion":5203,"completion":5203,"start":7653,"enrollment":33,"conditions":7654,"interventions":7655},"NCT00369291","CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant",[90],"2003-09",[5133,15,18,115],[7643,7656],"tetanus toxoid",{"trials":7658,"activeCount":102},[],{"trials":7660,"activeCount":102},[],{"trials":7662,"activeCount":102},[],{"trials":7664,"activeCount":102},[],{"intervention":7666,"totalTrials":1013,"cells":7667},"ritonavir",{"EARLY_PHASE1":7668,"PHASE1":7670,"PHASE2":7679,"PHASE3":7681,"PHASE4":7683,"NA":7685},{"trials":7669,"activeCount":102},[],{"trials":7671,"activeCount":102},[7672],{"nctId":7673,"briefTitle":7674,"status":125,"phases":7675,"primaryCompletion":4305,"completion":4305,"start":7676,"enrollment":1245,"conditions":7677,"interventions":7678},"NCT01009437","Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer",[90],"2010-05-26",[29],[7666],{"trials":7680,"activeCount":102},[],{"trials":7682,"activeCount":102},[],{"trials":7684,"activeCount":102},[],{"trials":7686,"activeCount":102},[],{"intervention":1196,"totalTrials":1013,"cells":7688},{"EARLY_PHASE1":7689,"PHASE1":7691,"PHASE2":7697,"PHASE3":7699,"PHASE4":7701,"NA":7703},{"trials":7690,"activeCount":102},[],{"trials":7692,"activeCount":102},[7693],{"nctId":1183,"briefTitle":1184,"status":108,"phases":7694,"primaryCompletion":1077,"completion":1186,"start":1187,"enrollment":295,"conditions":7695,"interventions":7696},[90],[1189,1190,1191,700,1192,494,24,1193,1194],[1196,223,222,912,1197],{"trials":7698,"activeCount":102},[],{"trials":7700,"activeCount":102},[],{"trials":7702,"activeCount":102},[],{"trials":7704,"activeCount":102},[],{"intervention":7706,"totalTrials":1013,"cells":7707},"90Y-AHN-12",{"EARLY_PHASE1":7708,"PHASE1":7710,"PHASE2":7718,"PHASE3":7720,"PHASE4":7722,"NA":7724},{"trials":7709,"activeCount":102},[],{"trials":7711,"activeCount":102},[7712],{"nctId":7713,"briefTitle":7714,"status":108,"phases":7715,"primaryCompletion":4305,"completion":4305,"start":558,"enrollment":1137,"conditions":7716,"interventions":7717},"NCT01207076","AHN-12 Biodistribution in Advanced Leukemia",[90],[190,175,174,192],[7706],{"trials":7719,"activeCount":102},[],{"trials":7721,"activeCount":102},[],{"trials":7723,"activeCount":102},[],{"trials":7725,"activeCount":102},[],{"intervention":7727,"totalTrials":1013,"cells":7728},"CD4+CD25+ regulatory T cells",{"EARLY_PHASE1":7729,"PHASE1":7731,"PHASE2":7739,"PHASE3":7741,"PHASE4":7743,"NA":7745},{"trials":7730,"activeCount":102},[],{"trials":7732,"activeCount":102},[7733],{"nctId":7734,"briefTitle":7735,"status":108,"phases":7736,"primaryCompletion":568,"completion":568,"start":319,"enrollment":112,"conditions":7737,"interventions":7738},"NCT00725062","Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant",[90],[114,15,18,115,21],[7727],{"trials":7740,"activeCount":102},[],{"trials":7742,"activeCount":102},[],{"trials":7744,"activeCount":102},[],{"trials":7746,"activeCount":102},[],{"intervention":7748,"totalTrials":1013,"cells":7749},"Romiplostim",{"EARLY_PHASE1":7750,"PHASE1":7752,"PHASE2":7763,"PHASE3":7765,"PHASE4":7767,"NA":7769},{"trials":7751,"activeCount":102},[],{"trials":7753,"activeCount":102},[7754],{"nctId":7755,"briefTitle":7756,"status":125,"phases":7757,"primaryCompletion":7758,"completion":7759,"start":7760,"enrollment":30,"conditions":7761,"interventions":7762},"NCT02046291","Safety of Romiplostim (Nplate®) Following UCBT",[90],"2020-12-12","2021-06-01","2015-04-10",[773],[7748],{"trials":7764,"activeCount":102},[],{"trials":7766,"activeCount":102},[],{"trials":7768,"activeCount":102},[],{"trials":7770,"activeCount":102},[],{"intervention":7772,"totalTrials":1013,"cells":7773},"Indole-3-Carbinol",{"EARLY_PHASE1":7774,"PHASE1":7776,"PHASE2":7789,"PHASE3":7791,"PHASE4":7793,"NA":7795},{"trials":7775,"activeCount":102},[],{"trials":7777,"activeCount":102},[7778],{"nctId":7779,"briefTitle":7780,"status":125,"phases":7781,"primaryCompletion":7782,"completion":7782,"start":7783,"enrollment":30,"conditions":7784,"interventions":7786},"NCT03687073","Trial of Indole-3-Carbinol and Silibinin",[90],"2021-05-07","2018-11-29",[7785],"Smoking",[7772,7787,7788],"Silibinin","Silibin",{"trials":7790,"activeCount":102},[],{"trials":7792,"activeCount":102},[],{"trials":7794,"activeCount":102},[],{"trials":7796,"activeCount":102},[],{"intervention":7787,"totalTrials":1013,"cells":7798},{"EARLY_PHASE1":7799,"PHASE1":7801,"PHASE2":7807,"PHASE3":7809,"PHASE4":7811,"NA":7813},{"trials":7800,"activeCount":102},[],{"trials":7802,"activeCount":102},[7803],{"nctId":7779,"briefTitle":7780,"status":125,"phases":7804,"primaryCompletion":7782,"completion":7782,"start":7783,"enrollment":30,"conditions":7805,"interventions":7806},[90],[7785],[7772,7787,7788],{"trials":7808,"activeCount":102},[],{"trials":7810,"activeCount":102},[],{"trials":7812,"activeCount":102},[],{"trials":7814,"activeCount":102},[],{"intervention":7788,"totalTrials":1013,"cells":7816},{"EARLY_PHASE1":7817,"PHASE1":7819,"PHASE2":7825,"PHASE3":7827,"PHASE4":7829,"NA":7831},{"trials":7818,"activeCount":102},[],{"trials":7820,"activeCount":102},[7821],{"nctId":7779,"briefTitle":7780,"status":125,"phases":7822,"primaryCompletion":7782,"completion":7782,"start":7783,"enrollment":30,"conditions":7823,"interventions":7824},[90],[7785],[7772,7787,7788],{"trials":7826,"activeCount":102},[],{"trials":7828,"activeCount":102},[],{"trials":7830,"activeCount":102},[],{"trials":7832,"activeCount":102},[],{"intervention":150,"totalTrials":1013,"cells":7834},{"EARLY_PHASE1":7835,"PHASE1":7837,"PHASE2":7843,"PHASE3":7845,"PHASE4":7847,"NA":7849},{"trials":7836,"activeCount":102},[],{"trials":7838,"activeCount":102},[7839],{"nctId":138,"briefTitle":139,"status":125,"phases":7840,"primaryCompletion":141,"completion":142,"start":143,"enrollment":144,"conditions":7841,"interventions":7842},[90],[15,18,32,146,21],[148,149,120,97,150,151],{"trials":7844,"activeCount":102},[],{"trials":7846,"activeCount":102},[],{"trials":7848,"activeCount":102},[],{"trials":7850,"activeCount":102},[],{"intervention":7852,"totalTrials":1013,"cells":7853},"Deuterated Phenanthrene",{"EARLY_PHASE1":7854,"PHASE1":7856,"PHASE2":7865,"PHASE3":7867,"PHASE4":7869,"NA":7871},{"trials":7855,"activeCount":102},[],{"trials":7857,"activeCount":102},[7858],{"nctId":7859,"briefTitle":7860,"status":125,"phases":7861,"primaryCompletion":7862,"completion":7862,"start":5410,"enrollment":7551,"conditions":7863,"interventions":7864},"NCT02999399","Glucobrassicin-Brussel Sprout Effect on D10 Phe Metabolism",[90],"2021-03-22",[7785],[7852],{"trials":7866,"activeCount":102},[],{"trials":7868,"activeCount":102},[],{"trials":7870,"activeCount":102},[],{"trials":7872,"activeCount":102},[],{"intervention":1667,"totalTrials":1013,"cells":7874},{"EARLY_PHASE1":7875,"PHASE1":7877,"PHASE2":7883,"PHASE3":7885,"PHASE4":7887,"NA":7889},{"trials":7876,"activeCount":102},[],{"trials":7878,"activeCount":102},[7879],{"nctId":1657,"briefTitle":1658,"status":125,"phases":7880,"primaryCompletion":1660,"completion":1661,"start":1662,"enrollment":669,"conditions":7881,"interventions":7882},[90],[1664,1665,684,685],[1667,285],{"trials":7884,"activeCount":102},[],{"trials":7886,"activeCount":102},[],{"trials":7888,"activeCount":102},[],{"trials":7890,"activeCount":102},[],{"intervention":165,"totalTrials":1013,"cells":7892},{"EARLY_PHASE1":7893,"PHASE1":7895,"PHASE2":7901,"PHASE3":7903,"PHASE4":7905,"NA":7907},{"trials":7894,"activeCount":102},[],{"trials":7896,"activeCount":102},[7897],{"nctId":153,"briefTitle":154,"status":125,"phases":7898,"primaryCompletion":156,"completion":156,"start":157,"enrollment":158,"conditions":7899,"interventions":7900},[90],[24,160,161],[42,97,163,164,165],{"trials":7902,"activeCount":102},[],{"trials":7904,"activeCount":102},[],{"trials":7906,"activeCount":102},[],{"trials":7908,"activeCount":102},[],{"intervention":4900,"totalTrials":1013,"cells":7910},{"EARLY_PHASE1":7911,"PHASE1":7913,"PHASE2":7919,"PHASE3":7921,"PHASE4":7923,"NA":7925},{"trials":7912,"activeCount":102},[],{"trials":7914,"activeCount":102},[7915],{"nctId":4894,"briefTitle":4895,"status":125,"phases":7916,"primaryCompletion":458,"completion":4380,"start":4897,"enrollment":790,"conditions":7917,"interventions":7918},[90],[763],[4447,4900,4592],{"trials":7920,"activeCount":102},[],{"trials":7922,"activeCount":102},[],{"trials":7924,"activeCount":102},[],{"trials":7926,"activeCount":102},[],{"intervention":7928,"totalTrials":1013,"cells":7929},"HCW9218",{"EARLY_PHASE1":7930,"PHASE1":7932,"PHASE2":7943,"PHASE3":7945,"PHASE4":7947,"NA":7949},{"trials":7931,"activeCount":102},[],{"trials":7933,"activeCount":102},[7934],{"nctId":7935,"briefTitle":7936,"status":125,"phases":7937,"primaryCompletion":7938,"completion":7939,"start":7940,"enrollment":579,"conditions":7941,"interventions":7942},"NCT05322408","HCW9218 in Select Advanced Solid Tumors",[90],"2025-01-02","2025-02-28","2022-04-01",[3451],[7928],{"trials":7944,"activeCount":102},[],{"trials":7946,"activeCount":102},[],{"trials":7948,"activeCount":102},[],{"trials":7950,"activeCount":102},[],{"intervention":178,"totalTrials":1013,"cells":7952},{"EARLY_PHASE1":7953,"PHASE1":7955,"PHASE2":7961,"PHASE3":7963,"PHASE4":7965,"NA":7967},{"trials":7954,"activeCount":102},[],{"trials":7956,"activeCount":102},[7957],{"nctId":167,"briefTitle":168,"status":125,"phases":7958,"primaryCompletion":170,"completion":171,"start":172,"enrollment":9,"conditions":7959,"interventions":7960},[90],[174,175,32],[118,119,42,121,177,178],{"trials":7962,"activeCount":102},[],{"trials":7964,"activeCount":102},[],{"trials":7966,"activeCount":102},[],{"trials":7968,"activeCount":102},[],{"intervention":7970,"totalTrials":1013,"cells":7971},"CD133KDEL",{"EARLY_PHASE1":7972,"PHASE1":7974,"PHASE2":7985,"PHASE3":7987,"PHASE4":7989,"NA":7991},{"trials":7973,"activeCount":102},[],{"trials":7975,"activeCount":102},[7976],{"nctId":7977,"briefTitle":7978,"status":307,"phases":7979,"primaryCompletion":7980,"completion":7980,"start":7981,"enrollment":102,"conditions":7982,"interventions":7984},"NCT02845414","Study of CD133KDEL Toxin in the Treatment for Solid Tumors",[90],"2022-01","2018-12",[7983],"Solid Tumors",[7970],{"trials":7986,"activeCount":102},[],{"trials":7988,"activeCount":102},[],{"trials":7990,"activeCount":102},[],{"trials":7992,"activeCount":102},[],{"intervention":4290,"totalTrials":1013,"cells":7994},{"EARLY_PHASE1":7995,"PHASE1":7997,"PHASE2":8003,"PHASE3":8005,"PHASE4":8007,"NA":8009},{"trials":7996,"activeCount":102},[],{"trials":7998,"activeCount":102},[7999],{"nctId":4284,"briefTitle":4285,"status":108,"phases":8000,"primaryCompletion":1909,"completion":1909,"start":4287,"conditions":8001,"interventions":8002},[90],[29,18],[253,222,4290],{"trials":8004,"activeCount":102},[],{"trials":8006,"activeCount":102},[],{"trials":8008,"activeCount":102},[],{"trials":8010,"activeCount":102},[],{"intervention":8012,"totalTrials":1013,"cells":8013},"Salmonella typhimurium",{"EARLY_PHASE1":8014,"PHASE1":8016,"PHASE2":8029,"PHASE3":8031,"PHASE4":8033,"NA":8035},{"trials":8015,"activeCount":102},[],{"trials":8017,"activeCount":102},[8018],{"nctId":8019,"briefTitle":8020,"status":125,"phases":8021,"primaryCompletion":338,"completion":8022,"start":568,"enrollment":27,"conditions":8023,"interventions":8028},"NCT01099631","IL-2 Expressing, Attenuated Salmonella Typhimurium in Unresectable Hepatic Spread",[90],"2014-06",[8024,1192,8025,8026,8027],"Cancer of the Liver","Hepatoma","Liver Neoplasms","Biliary Cancer",[8012],{"trials":8030,"activeCount":102},[],{"trials":8032,"activeCount":102},[],{"trials":8034,"activeCount":102},[],{"trials":8036,"activeCount":102},[],{"intervention":8038,"totalTrials":1013,"cells":8039},"Kava",{"EARLY_PHASE1":8040,"PHASE1":8054,"PHASE2":8056,"PHASE3":8058,"PHASE4":8060,"NA":8062},{"trials":8041,"activeCount":102},[8042],{"nctId":8043,"briefTitle":8044,"status":678,"phases":8045,"primaryCompletion":258,"completion":8046,"start":8047,"enrollment":907,"conditions":8048,"interventions":8053},"NCT06213298","Effect of Kava on Anxiety and Stress in Cancer Survivors",[89],"2028-11-01","2024-06-20",[8038,8049,8050,1713,8051,8052],"Anxiety","Stress","Depression","Sleep",[8038],{"trials":8055,"activeCount":102},[],{"trials":8057,"activeCount":102},[],{"trials":8059,"activeCount":102},[],{"trials":8061,"activeCount":102},[],{"trials":8063,"activeCount":102},[],{"intervention":8065,"totalTrials":1013,"cells":8066},"Activated charcoal and Tap Water",{"EARLY_PHASE1":8067,"PHASE1":8079,"PHASE2":8081,"PHASE3":8083,"PHASE4":8085,"NA":8087},{"trials":8068,"activeCount":102},[8069],{"nctId":8070,"briefTitle":8071,"status":125,"phases":8072,"primaryCompletion":8073,"completion":8073,"start":8074,"enrollment":9,"conditions":8075,"interventions":8077},"NCT04204772","A Pilot Feasibility Study of Activated Charcoal in Healthy Volunteers",[89],"2021-03-31","2020-01-22",[8076],"Healthy Adult Volunteers",[8065,8078],"Activated Charcoal and Apple Juice",{"trials":8080,"activeCount":102},[],{"trials":8082,"activeCount":102},[],{"trials":8084,"activeCount":102},[],{"trials":8086,"activeCount":102},[],{"trials":8088,"activeCount":102},[],{"intervention":8078,"totalTrials":1013,"cells":8090},{"EARLY_PHASE1":8091,"PHASE1":8097,"PHASE2":8099,"PHASE3":8101,"PHASE4":8103,"NA":8105},{"trials":8092,"activeCount":102},[8093],{"nctId":8070,"briefTitle":8071,"status":125,"phases":8094,"primaryCompletion":8073,"completion":8073,"start":8074,"enrollment":9,"conditions":8095,"interventions":8096},[89],[8076],[8065,8078],{"trials":8098,"activeCount":102},[],{"trials":8100,"activeCount":102},[],{"trials":8102,"activeCount":102},[],{"trials":8104,"activeCount":102},[],{"trials":8106,"activeCount":102},[],{"intervention":8108,"totalTrials":1013,"cells":8109},"intravenous narcotics",{"EARLY_PHASE1":8110,"PHASE1":8125,"PHASE2":8127,"PHASE3":8129,"PHASE4":8131,"NA":8133},{"trials":8111,"activeCount":102},[8112],{"nctId":8113,"briefTitle":8114,"status":125,"phases":8115,"primaryCompletion":8116,"completion":8116,"start":8117,"enrollment":8118,"conditions":8119,"interventions":8121},"NCT01705288","Implementation of a Rapid Recovery Program in Gynecologic Oncology Surgery: A Pilot Study",[89],"2016-08-24","2013-01-01",103,[4416,8120,24],"Uterine Endometrial Cancer",[8108,8122,8123,8124],"standard anesthesia","regional anesthesia","Non-steroidal anti-inflammatory drugs",{"trials":8126,"activeCount":102},[],{"trials":8128,"activeCount":102},[],{"trials":8130,"activeCount":102},[],{"trials":8132,"activeCount":102},[],{"trials":8134,"activeCount":102},[],{"intervention":8122,"totalTrials":1013,"cells":8136},{"EARLY_PHASE1":8137,"PHASE1":8143,"PHASE2":8145,"PHASE3":8147,"PHASE4":8149,"NA":8151},{"trials":8138,"activeCount":102},[8139],{"nctId":8113,"briefTitle":8114,"status":125,"phases":8140,"primaryCompletion":8116,"completion":8116,"start":8117,"enrollment":8118,"conditions":8141,"interventions":8142},[89],[4416,8120,24],[8108,8122,8123,8124],{"trials":8144,"activeCount":102},[],{"trials":8146,"activeCount":102},[],{"trials":8148,"activeCount":102},[],{"trials":8150,"activeCount":102},[],{"trials":8152,"activeCount":102},[],{"intervention":8123,"totalTrials":1013,"cells":8154},{"EARLY_PHASE1":8155,"PHASE1":8161,"PHASE2":8163,"PHASE3":8165,"PHASE4":8167,"NA":8169},{"trials":8156,"activeCount":102},[8157],{"nctId":8113,"briefTitle":8114,"status":125,"phases":8158,"primaryCompletion":8116,"completion":8116,"start":8117,"enrollment":8118,"conditions":8159,"interventions":8160},[89],[4416,8120,24],[8108,8122,8123,8124],{"trials":8162,"activeCount":102},[],{"trials":8164,"activeCount":102},[],{"trials":8166,"activeCount":102},[],{"trials":8168,"activeCount":102},[],{"trials":8170,"activeCount":102},[],{"intervention":8124,"totalTrials":1013,"cells":8172},{"EARLY_PHASE1":8173,"PHASE1":8179,"PHASE2":8181,"PHASE3":8183,"PHASE4":8185,"NA":8187},{"trials":8174,"activeCount":102},[8175],{"nctId":8113,"briefTitle":8114,"status":125,"phases":8176,"primaryCompletion":8116,"completion":8116,"start":8117,"enrollment":8118,"conditions":8177,"interventions":8178},[89],[4416,8120,24],[8108,8122,8123,8124],{"trials":8180,"activeCount":102},[],{"trials":8182,"activeCount":102},[],{"trials":8184,"activeCount":102},[],{"trials":8186,"activeCount":102},[],{"trials":8188,"activeCount":102},[],{"intervention":8190,"totalTrials":1013,"cells":8191},"Low Nicotine Content Cigarettes",{"EARLY_PHASE1":8192,"PHASE1":8204,"PHASE2":8206,"PHASE3":8208,"PHASE4":8210,"NA":8212},{"trials":8193,"activeCount":102},[8194],{"nctId":8195,"briefTitle":8196,"status":125,"phases":8197,"primaryCompletion":8198,"completion":8198,"start":8199,"enrollment":8200,"conditions":8201,"interventions":8203},"NCT04740008","Impact of Low Nicotine Cigarette Messaging on Perceptions and Cigarette Choices",[89],"2022-08-24","2021-04-20",64,[7785,8202],"Cigarette",[8190],{"trials":8205,"activeCount":102},[],{"trials":8207,"activeCount":102},[],{"trials":8209,"activeCount":102},[],{"trials":8211,"activeCount":102},[],{"trials":8213,"activeCount":102},[],{"intervention":222,"totalTrials":6509,"cells":8215},{"EARLY_PHASE1":8216,"PHASE1":8218,"PHASE2":8232,"PHASE3":8290,"PHASE4":8292,"NA":8294},{"trials":8217,"activeCount":102},[],{"trials":8219,"activeCount":102},[8220,8224,8228],{"nctId":1183,"briefTitle":1184,"status":108,"phases":8221,"primaryCompletion":1077,"completion":1186,"start":1187,"enrollment":295,"conditions":8222,"interventions":8223},[90],[1189,1190,1191,700,1192,494,24,1193,1194],[1196,223,222,912,1197],{"nctId":1199,"briefTitle":1200,"status":108,"phases":8225,"primaryCompletion":1202,"completion":1203,"start":1204,"enrollment":1205,"conditions":8226,"interventions":8227},[90],[1189,700,1192,1193,1194],[222,223,394,1208,912,1197,1209],{"nctId":4284,"briefTitle":4285,"status":108,"phases":8229,"primaryCompletion":1909,"completion":1909,"start":4287,"conditions":8230,"interventions":8231},[90],[29,18],[253,222,4290],{"trials":8233,"activeCount":102},[8234,8238,8242,8246,8250,8254,8258,8262,8266,8270,8274,8278,8282,8286],{"nctId":213,"briefTitle":214,"status":125,"phases":8235,"primaryCompletion":216,"completion":216,"start":217,"enrollment":36,"conditions":8236,"interventions":8237},[91],[219],[221,222,223,118,120,224,225],{"nctId":325,"briefTitle":326,"status":108,"phases":8239,"primaryCompletion":328,"start":329,"conditions":8240,"interventions":8241},[91],[15],[223,118,222,332],{"nctId":362,"briefTitle":363,"status":125,"phases":8243,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":8244,"interventions":8245},[91],[26,191,192,370,371,372,194,200,203,15,18,32,21],[222,118,119,120,121],{"nctId":384,"briefTitle":385,"status":307,"phases":8247,"primaryCompletion":387,"completion":387,"start":388,"enrollment":102,"conditions":8248,"interventions":8249},[91],[18],[391,118,392,393,394,222,395,396],{"nctId":518,"briefTitle":519,"status":125,"phases":8251,"primaryCompletion":216,"completion":216,"start":521,"enrollment":522,"conditions":8252,"interventions":8253},[90,91],[219],[525,97,42,302,526,300,420],{"nctId":1253,"briefTitle":1254,"status":125,"phases":8255,"primaryCompletion":1256,"completion":862,"start":1257,"enrollment":1258,"conditions":8256,"interventions":8257},[91],[15,21,1260,1261,1262,1263,1264,1265,1266,1267,372,1268,1269],[222,223,119,120,912,121],{"nctId":547,"briefTitle":548,"status":125,"phases":8259,"primaryCompletion":550,"completion":550,"start":329,"enrollment":368,"conditions":8260,"interventions":8261},[91],[18],[222,391,118,392,393,394,395],{"nctId":595,"briefTitle":596,"status":108,"phases":8263,"primaryCompletion":598,"completion":598,"start":599,"enrollment":358,"conditions":8264,"interventions":8265},[91],[15,21],[253,222,602,118,119,120,224,121],{"nctId":656,"briefTitle":657,"status":108,"phases":8267,"primaryCompletion":659,"completion":659,"start":329,"enrollment":660,"conditions":8268,"interventions":8269},[91],[115],[391,118,393,394,222,395,332,663],{"nctId":2196,"briefTitle":2197,"status":108,"phases":8271,"primaryCompletion":2199,"completion":2199,"start":2200,"enrollment":1013,"conditions":8272,"interventions":8273},[90,91],[15],[119,392,222,804,224,395,2203],{"nctId":713,"briefTitle":714,"status":108,"phases":8275,"primaryCompletion":716,"completion":716,"start":217,"enrollment":717,"conditions":8276,"interventions":8277},[91],[700,15,18,32,146,21],[221,118,119,720,121,222],{"nctId":4462,"briefTitle":4463,"status":108,"phases":8279,"primaryCompletion":4465,"completion":4465,"start":4466,"enrollment":1438,"conditions":8280,"interventions":8281},[91],[671],[222,4469,4405,3297,4447],{"nctId":1782,"briefTitle":1783,"status":125,"phases":8283,"primaryCompletion":1785,"completion":1785,"start":1786,"enrollment":1205,"conditions":8284,"interventions":8285},[91],[1190,24,1788],[1790,394,1208,1791,1197,1209,222],{"nctId":777,"briefTitle":778,"status":108,"phases":8287,"primaryCompletion":780,"completion":780,"start":329,"enrollment":27,"conditions":8288,"interventions":8289},[91],[15],[118,222,332],{"trials":8291,"activeCount":102},[],{"trials":8293,"activeCount":102},[],{"trials":8295,"activeCount":102},[8296,8300,8304],{"nctId":880,"briefTitle":881,"status":125,"phases":8297,"primaryCompletion":883,"completion":883,"start":884,"enrollment":98,"conditions":8298,"interventions":8299},[94],[886,15,18,21],[222,888,118,119,120,121],{"nctId":890,"briefTitle":891,"status":108,"phases":8301,"primaryCompletion":893,"completion":893,"start":894,"enrollment":895,"conditions":8302,"interventions":8303},[94],[174,26,175],[149,898,87,97,208,899,900,526,825],{"nctId":902,"briefTitle":903,"status":108,"phases":8305,"primaryCompletion":905,"completion":905,"start":906,"enrollment":907,"conditions":8306,"interventions":8307},[94],[886,909,219,114,15,18,115,21,910],[221,223,118,119,222,912,224,121],{"intervention":120,"totalTrials":790,"cells":8309},{"EARLY_PHASE1":8310,"PHASE1":8312,"PHASE2":8322,"PHASE3":8376,"PHASE4":8378,"NA":8380},{"trials":8311,"activeCount":102},[],{"trials":8313,"activeCount":102},[8314,8318],{"nctId":106,"briefTitle":107,"status":108,"phases":8315,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":8316,"interventions":8317},[90],[114,15,18,115,21,116],[118,119,120,121],{"nctId":138,"briefTitle":139,"status":125,"phases":8319,"primaryCompletion":141,"completion":142,"start":143,"enrollment":144,"conditions":8320,"interventions":8321},[90],[15,18,32,146,21],[148,149,120,97,150,151],{"trials":8323,"activeCount":102},[8324,8328,8332,8336,8340,8344,8348,8352,8356,8360,8364,8368,8372],{"nctId":213,"briefTitle":214,"status":125,"phases":8325,"primaryCompletion":216,"completion":216,"start":217,"enrollment":36,"conditions":8326,"interventions":8327},[91],[219],[221,222,223,118,120,224,225],{"nctId":1217,"briefTitle":1218,"status":108,"phases":8329,"primaryCompletion":1220,"completion":1220,"start":1221,"enrollment":1013,"conditions":8330,"interventions":8331},[91],[1223],[1225,120,912],{"nctId":245,"briefTitle":246,"status":108,"phases":8333,"primaryCompletion":248,"completion":249,"start":250,"enrollment":158,"conditions":8334,"interventions":8335},[91],[15],[253,118,120],{"nctId":316,"briefTitle":317,"status":125,"phases":8337,"primaryCompletion":319,"completion":319,"start":320,"enrollment":30,"conditions":8338,"interventions":8339},[91],[15],[253,323,118,120],{"nctId":362,"briefTitle":363,"status":125,"phases":8341,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":8342,"interventions":8343},[91],[26,191,192,370,371,372,194,200,203,15,18,32,21],[222,118,119,120,121],{"nctId":1905,"briefTitle":1906,"status":108,"phases":8345,"primaryCompletion":1908,"completion":1908,"start":1909,"enrollment":22,"conditions":8346,"interventions":8347},[91],[15,21],[221,120,1197],{"nctId":538,"briefTitle":539,"status":108,"phases":8349,"primaryCompletion":172,"completion":541,"start":248,"enrollment":522,"conditions":8350,"interventions":8351},[90,91],[15,18,32,21],[118,120,544,545],{"nctId":1253,"briefTitle":1254,"status":125,"phases":8353,"primaryCompletion":1256,"completion":862,"start":1257,"enrollment":1258,"conditions":8354,"interventions":8355},[91],[15,21,1260,1261,1262,1263,1264,1265,1266,1267,372,1268,1269],[222,223,119,120,912,121],{"nctId":564,"briefTitle":565,"status":108,"phases":8357,"primaryCompletion":567,"completion":568,"start":569,"enrollment":460,"conditions":8358,"interventions":8359},[90,91],[15,18],[253,572,573,118,120],{"nctId":595,"briefTitle":596,"status":108,"phases":8361,"primaryCompletion":598,"completion":598,"start":599,"enrollment":358,"conditions":8362,"interventions":8363},[91],[15,21],[253,222,602,118,119,120,224,121],{"nctId":693,"briefTitle":694,"status":125,"phases":8365,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":8366,"interventions":8367},[90,91],[29,700,15,18,115,21],[221,118,119,120,121],{"nctId":722,"briefTitle":723,"status":125,"phases":8369,"primaryCompletion":725,"completion":725,"start":726,"enrollment":727,"conditions":8370,"interventions":8371},[90,91],[190],[253,730,118,120,288,731,118,120],{"nctId":758,"briefTitle":759,"status":108,"phases":8373,"primaryCompletion":761,"completion":761,"start":110,"enrollment":36,"conditions":8374,"interventions":8375},[91],[297,24,763],[149,97,765,766,612],{"trials":8377,"activeCount":102},[],{"trials":8379,"activeCount":102},[],{"trials":8381,"activeCount":102},[8382,8386],{"nctId":880,"briefTitle":881,"status":125,"phases":8383,"primaryCompletion":883,"completion":883,"start":884,"enrollment":98,"conditions":8384,"interventions":8385},[94],[886,15,18,21],[222,888,118,119,120,121],{"nctId":927,"briefTitle":928,"status":108,"phases":8387,"primaryCompletion":930,"completion":930,"start":905,"enrollment":669,"conditions":8388,"interventions":8389},[94],[739],[223,118,120],{"intervention":221,"totalTrials":295,"cells":8391},{"EARLY_PHASE1":8392,"PHASE1":8394,"PHASE2":8396,"PHASE3":8434,"PHASE4":8444,"NA":8446},{"trials":8393,"activeCount":102},[],{"trials":8395,"activeCount":102},[],{"trials":8397,"activeCount":102},[8398,8402,8406,8410,8414,8418,8422,8426,8430],{"nctId":213,"briefTitle":214,"status":125,"phases":8399,"primaryCompletion":216,"completion":216,"start":217,"enrollment":36,"conditions":8400,"interventions":8401},[91],[219],[221,222,223,118,120,224,225],{"nctId":518,"briefTitle":519,"status":125,"phases":8403,"primaryCompletion":216,"completion":216,"start":521,"enrollment":522,"conditions":8404,"interventions":8405},[90,91],[219],[525,97,42,302,526,300,420],{"nctId":1905,"briefTitle":1906,"status":108,"phases":8407,"primaryCompletion":1908,"completion":1908,"start":1909,"enrollment":22,"conditions":8408,"interventions":8409},[91],[15,21],[221,120,1197],{"nctId":1073,"briefTitle":1074,"status":125,"phases":8411,"primaryCompletion":172,"completion":1076,"start":1077,"enrollment":33,"conditions":8412,"interventions":8413},[91],[964,1079,966,965,1080,1081],[42,242,741,824,731,899,1083],{"nctId":1708,"briefTitle":1709,"status":108,"phases":8415,"primaryCompletion":874,"completion":1711,"start":569,"enrollment":9,"conditions":8416,"interventions":8417},[91],[1713],[221,573,1715],{"nctId":693,"briefTitle":694,"status":125,"phases":8419,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":8420,"interventions":8421},[90,91],[29,700,15,18,115,21],[221,118,119,120,121],{"nctId":703,"briefTitle":704,"status":125,"phases":8423,"primaryCompletion":706,"completion":706,"start":707,"enrollment":708,"conditions":8424,"interventions":8425},[91],[710,15,18,21],[221,118,42,121,151],{"nctId":713,"briefTitle":714,"status":108,"phases":8427,"primaryCompletion":716,"completion":716,"start":217,"enrollment":717,"conditions":8428,"interventions":8429},[91],[700,15,18,32,146,21],[221,118,119,720,121,222],{"nctId":733,"briefTitle":734,"status":125,"phases":8431,"primaryCompletion":736,"completion":736,"start":458,"enrollment":737,"conditions":8432,"interventions":8433},[90,91],[739],[97,42,741,742],{"trials":8435,"activeCount":102},[8436,8440],{"nctId":797,"briefTitle":798,"status":307,"phases":8437,"primaryCompletion":800,"completion":800,"start":801,"enrollment":102,"conditions":8438,"interventions":8439},[92],[114,15,18],[221,118,119,804,224],{"nctId":1450,"briefTitle":1451,"status":125,"phases":8441,"primaryCompletion":1453,"completion":1453,"start":697,"enrollment":1454,"conditions":8442,"interventions":8443},[91,92],[1456,1457,1458],[844,87,221],{"trials":8445,"activeCount":102},[],{"trials":8447,"activeCount":102},[8448,8452],{"nctId":858,"briefTitle":859,"status":125,"phases":8449,"primaryCompletion":861,"completion":862,"start":863,"enrollment":864,"conditions":8450,"interventions":8451},[94],[754,822],[626,42,97,867,741],{"nctId":902,"briefTitle":903,"status":108,"phases":8453,"primaryCompletion":905,"completion":905,"start":906,"enrollment":907,"conditions":8454,"interventions":8455},[94],[886,909,219,114,15,18,115,21,910],[221,223,118,119,222,912,224,121],{"intervention":119,"totalTrials":295,"cells":8457},{"EARLY_PHASE1":8458,"PHASE1":8460,"PHASE2":8470,"PHASE3":8504,"PHASE4":8510,"NA":8512},{"trials":8459,"activeCount":102},[],{"trials":8461,"activeCount":102},[8462,8466],{"nctId":106,"briefTitle":107,"status":108,"phases":8463,"primaryCompletion":110,"completion":110,"start":111,"enrollment":112,"conditions":8464,"interventions":8465},[90],[114,15,18,115,21,116],[118,119,120,121],{"nctId":167,"briefTitle":168,"status":125,"phases":8467,"primaryCompletion":170,"completion":171,"start":172,"enrollment":9,"conditions":8468,"interventions":8469},[90],[174,175,32],[118,119,42,121,177,178],{"trials":8471,"activeCount":102},[8472,8476,8480,8484,8488,8492,8496,8500],{"nctId":290,"briefTitle":291,"status":125,"phases":8473,"primaryCompletion":293,"completion":293,"start":294,"enrollment":295,"conditions":8474,"interventions":8475},[91],[24,297,298,29],[42,97,300,301,164,302,302,303],{"nctId":362,"briefTitle":363,"status":125,"phases":8477,"primaryCompletion":365,"completion":366,"start":367,"enrollment":368,"conditions":8478,"interventions":8479},[91],[26,191,192,370,371,372,194,200,203,15,18,32,21],[222,118,119,120,121],{"nctId":518,"briefTitle":519,"status":125,"phases":8481,"primaryCompletion":216,"completion":216,"start":521,"enrollment":522,"conditions":8482,"interventions":8483},[90,91],[219],[525,97,42,302,526,300,420],{"nctId":1253,"briefTitle":1254,"status":125,"phases":8485,"primaryCompletion":1256,"completion":862,"start":1257,"enrollment":1258,"conditions":8486,"interventions":8487},[91],[15,21,1260,1261,1262,1263,1264,1265,1266,1267,372,1268,1269],[222,223,119,120,912,121],{"nctId":595,"briefTitle":596,"status":108,"phases":8489,"primaryCompletion":598,"completion":598,"start":599,"enrollment":358,"conditions":8490,"interventions":8491},[91],[15,21],[253,222,602,118,119,120,224,121],{"nctId":2196,"briefTitle":2197,"status":108,"phases":8493,"primaryCompletion":2199,"completion":2199,"start":2200,"enrollment":1013,"conditions":8494,"interventions":8495},[90,91],[15],[119,392,222,804,224,395,2203],{"nctId":693,"briefTitle":694,"status":125,"phases":8497,"primaryCompletion":696,"completion":696,"start":697,"enrollment":698,"conditions":8498,"interventions":8499},[90,91],[29,700,15,18,115,21],[221,118,119,120,121],{"nctId":713,"briefTitle":714,"status":108,"phases":8501,"primaryCompletion":716,"completion":716,"start":217,"enrollment":717,"conditions":8502,"interventions":8503},[91],[700,15,18,32,146,21],[221,118,119,720,121,222],{"trials":8505,"activeCount":102},[8506],{"nctId":797,"briefTitle":798,"status":307,"phases":8507,"primaryCompletion":800,"completion":800,"start":801,"enrollment":102,"conditions":8508,"interventions":8509},[92],[114,15,18],[221,118,119,804,224],{"trials":8511,"activeCount":102},[],{"trials":8513,"activeCount":102},[8514,8518],{"nctId":880,"briefTitle":881,"status":125,"phases":8515,"primaryCompletion":883,"completion":883,"start":884,"enrollment":98,"conditions":8516,"interventions":8517},[94],[886,15,18,21],[222,888,118,119,120,121],{"nctId":902,"briefTitle":903,"status":108,"phases":8519,"primaryCompletion":905,"completion":905,"start":906,"enrollment":907,"conditions":8520,"interventions":8521},[94],[886,909,219,114,15,18,115,21,910],[221,223,118,119,222,912,224,121],{"intervention":149,"totalTrials":895,"cells":8523},{"EARLY_PHASE1":8524,"PHASE1":8526,"PHASE2":8532,"PHASE3":8546,"PHASE4":8548,"NA":8550},{"trials":8525,"activeCount":102},[],{"trials":8527,"activeCount":102},[8528],{"nctId":138,"briefTitle":139,"status":125,"phases":8529,"primaryCompletion":141,"completion":142,"start":143,"enrollment":144,"conditions":8530,"interventions":8531},[90],[15,18,32,146,21],[148,149,120,97,150,151],{"trials":8533,"activeCount":102},[8534,8538,8542],{"nctId":182,"briefTitle":183,"status":125,"phases":8535,"primaryCompletion":185,"completion":186,"start":187,"enrollment":188,"conditions":8536,"interventions":8537},[91],[190,191,192,193,21,194,195,196,197,198,199,200,201,202,203,32,204,205],[149,42,97,207,208,209,210,211],{"nctId":375,"briefTitle":376,"status":108,"phases":8539,"primaryCompletion":378,"completion":378,"start":249,"enrollment":112,"conditions":8540,"interventions":8541},[91],[190,380],[149,42,97,286,87,382,303],{"nctId":758,"briefTitle":759,"status":108,"phases":8543,"primaryCompletion":761,"completion":761,"start":110,"enrollment":36,"conditions":8544,"interventions":8545},[91],[297,24,763],[149,97,765,766,612],{"trials":8547,"activeCount":102},[],{"trials":8549,"activeCount":102},[],{"trials":8551,"activeCount":102},[8552],{"nctId":890,"briefTitle":891,"status":108,"phases":8553,"primaryCompletion":893,"completion":893,"start":894,"enrollment":895,"conditions":8554,"interventions":8555},[94],[174,26,175],[149,898,87,97,208,899,900,526,825],{"intervention":1208,"totalTrials":1438,"cells":8557},{"EARLY_PHASE1":8558,"PHASE1":8560,"PHASE2":8566,"PHASE3":8572,"PHASE4":8574,"NA":8576},{"trials":8559,"activeCount":102},[],{"trials":8561,"activeCount":102},[8562],{"nctId":1199,"briefTitle":1200,"status":108,"phases":8563,"primaryCompletion":1202,"completion":1203,"start":1204,"enrollment":1205,"conditions":8564,"interventions":8565},[90],[1189,700,1192,1193,1194],[222,223,394,1208,912,1197,1209],{"trials":8567,"activeCount":102},[8568],{"nctId":1782,"briefTitle":1783,"status":125,"phases":8569,"primaryCompletion":1785,"completion":1785,"start":1786,"enrollment":1205,"conditions":8570,"interventions":8571},[91],[1190,24,1788],[1790,394,1208,1791,1197,1209,222],{"trials":8573,"activeCount":102},[],{"trials":8575,"activeCount":102},[],{"trials":8577,"activeCount":102},[8578,8587],{"nctId":8579,"briefTitle":8580,"status":125,"phases":8581,"primaryCompletion":8582,"completion":7196,"start":8583,"enrollment":261,"conditions":8584,"interventions":8585},"NCT00346125","PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma",[94],"2013-07-01","2006-04-10",[1194],[4469,2212,1208,8586],"pegylated liposomal doxorubicin hydrochloride",{"nctId":1346,"briefTitle":1347,"status":125,"phases":8588,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":8589,"interventions":8590},[94],[1353,1354,1355,1356,1357,1358,1193,1359,1360,1361,1362,1363],[1365,239,1209,243,87,242,496,1343,497,1366,1367,1368],{"intervention":1366,"totalTrials":1438,"cells":8592},{"EARLY_PHASE1":8593,"PHASE1":8595,"PHASE2":8597,"PHASE3":8607,"PHASE4":8609,"NA":8611},{"trials":8594,"activeCount":102},[],{"trials":8596,"activeCount":102},[],{"trials":8598,"activeCount":102},[8599,8603],{"nctId":3315,"briefTitle":3316,"status":108,"phases":8600,"primaryCompletion":110,"completion":1453,"start":3318,"enrollment":669,"conditions":8601,"interventions":8602},[91],[297,24,763],[1790,1791],{"nctId":1782,"briefTitle":1783,"status":125,"phases":8604,"primaryCompletion":1785,"completion":1785,"start":1786,"enrollment":1205,"conditions":8605,"interventions":8606},[91],[1190,24,1788],[1790,394,1208,1791,1197,1209,222],{"trials":8608,"activeCount":102},[],{"trials":8610,"activeCount":102},[],{"trials":8612,"activeCount":102},[8613,8617],{"nctId":3341,"briefTitle":3342,"status":108,"phases":8614,"primaryCompletion":3344,"completion":3345,"start":3346,"enrollment":1454,"conditions":8615,"interventions":8616},[94],[24,297,3348],[3350,497,1366],{"nctId":1346,"briefTitle":1347,"status":125,"phases":8618,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":8619,"interventions":8620},[94],[1353,1354,1355,1356,1357,1358,1193,1359,1360,1361,1362,1363],[1365,239,1209,243,87,242,496,1343,497,1366,1367,1368],{"intervention":561,"totalTrials":1438,"cells":8622},{"EARLY_PHASE1":8623,"PHASE1":8625,"PHASE2":8627,"PHASE3":8641,"PHASE4":8643,"NA":8645},{"trials":8624,"activeCount":102},[],{"trials":8626,"activeCount":102},[],{"trials":8628,"activeCount":102},[8629,8633,8637],{"nctId":554,"briefTitle":555,"status":307,"phases":8630,"primaryCompletion":557,"completion":557,"start":558,"enrollment":102,"conditions":8631,"interventions":8632},[91],[26,174],[561,239,97,562],{"nctId":1276,"briefTitle":1277,"status":125,"phases":8634,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":8635,"interventions":8636},[91],[1283,1284,1285,1286,1287,1288,1289,1290,1291],[561,242,1293,626,1294,1295],{"nctId":1708,"briefTitle":1709,"status":108,"phases":8638,"primaryCompletion":874,"completion":1711,"start":569,"enrollment":9,"conditions":8639,"interventions":8640},[91],[1713],[221,573,1715],{"trials":8642,"activeCount":102},[],{"trials":8644,"activeCount":102},[],{"trials":8646,"activeCount":102},[8647],{"nctId":1326,"briefTitle":1327,"status":125,"phases":8648,"primaryCompletion":1329,"completion":1329,"start":1330,"enrollment":112,"conditions":8649,"interventions":8650},[94],[1332,1333],[593,561,242,225,654,899],{"intervention":593,"totalTrials":1438,"cells":8652},{"EARLY_PHASE1":8653,"PHASE1":8655,"PHASE2":8657,"PHASE3":8667,"PHASE4":8673,"NA":8675},{"trials":8654,"activeCount":102},[],{"trials":8656,"activeCount":102},[],{"trials":8658,"activeCount":102},[8659,8663],{"nctId":575,"briefTitle":576,"status":108,"phases":8660,"primaryCompletion":578,"completion":578,"start":110,"enrollment":579,"conditions":8661,"interventions":8662},[91],[581,582,583,584,585,586,587,588,589,590,591],[97,593,87],{"nctId":640,"briefTitle":641,"status":125,"phases":8664,"primaryCompletion":643,"completion":644,"start":567,"enrollment":645,"conditions":8665,"interventions":8666},[91],[647,648,649,582,583,584,585,586,650,588,651,587,652],[593,97,87,654,420],{"trials":8668,"activeCount":102},[8669],{"nctId":837,"briefTitle":838,"status":125,"phases":8670,"primaryCompletion":840,"completion":840,"start":598,"enrollment":669,"conditions":8671,"interventions":8672},[91,92],[842],[593,97,87,844],{"trials":8674,"activeCount":102},[],{"trials":8676,"activeCount":102},[8677],{"nctId":1326,"briefTitle":1327,"status":125,"phases":8678,"primaryCompletion":1329,"completion":1329,"start":1330,"enrollment":112,"conditions":8679,"interventions":8680},[94],[1332,1333],[593,561,242,225,654,899],{"intervention":225,"totalTrials":112,"cells":8682},{"EARLY_PHASE1":8683,"PHASE1":8685,"PHASE2":8687,"PHASE3":8697,"PHASE4":8699,"NA":8701},{"trials":8684,"activeCount":102},[],{"trials":8686,"activeCount":102},[],{"trials":8688,"activeCount":102},[8689,8693],{"nctId":213,"briefTitle":214,"status":125,"phases":8690,"primaryCompletion":216,"completion":216,"start":217,"enrollment":36,"conditions":8691,"interventions":8692},[91],[219],[221,222,223,118,120,224,225],{"nctId":1276,"briefTitle":1277,"status":125,"phases":8694,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":8695,"interventions":8696},[91],[1283,1284,1285,1286,1287,1288,1289,1290,1291],[561,242,1293,626,1294,1295],{"trials":8698,"activeCount":102},[],{"trials":8700,"activeCount":102},[],{"trials":8702,"activeCount":102},[8703],{"nctId":1326,"briefTitle":1327,"status":125,"phases":8704,"primaryCompletion":1329,"completion":1329,"start":1330,"enrollment":112,"conditions":8705,"interventions":8706},[94],[1332,1333],[593,561,242,225,654,899],{"intervention":2212,"totalTrials":112,"cells":8708},{"EARLY_PHASE1":8709,"PHASE1":8711,"PHASE2":8713,"PHASE3":8719,"PHASE4":8721,"NA":8723},{"trials":8710,"activeCount":102},[],{"trials":8712,"activeCount":102},[],{"trials":8714,"activeCount":102},[8715],{"nctId":2205,"briefTitle":2206,"status":108,"phases":8716,"primaryCompletion":894,"completion":894,"start":2208,"enrollment":426,"conditions":8717,"interventions":8718},[91],[15,18],[392,2211,2212,2213,804,2214,2215,2216,2154],{"trials":8720,"activeCount":102},[],{"trials":8722,"activeCount":102},[],{"trials":8724,"activeCount":102},[8725,8729],{"nctId":8579,"briefTitle":8580,"status":125,"phases":8726,"primaryCompletion":8582,"completion":7196,"start":8583,"enrollment":261,"conditions":8727,"interventions":8728},[94],[1194],[4469,2212,1208,8586],{"nctId":8730,"briefTitle":8731,"status":125,"phases":8732,"primaryCompletion":293,"completion":1711,"start":2208,"enrollment":33,"conditions":8733,"interventions":8734},"NCT00895414","Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer",[94],[29],[2212,8735],"enalapril maleate",{"intervention":654,"totalTrials":112,"cells":8737},{"EARLY_PHASE1":8738,"PHASE1":8740,"PHASE2":8742,"PHASE3":8748,"PHASE4":8750,"NA":8752},{"trials":8739,"activeCount":102},[],{"trials":8741,"activeCount":102},[],{"trials":8743,"activeCount":102},[8744],{"nctId":640,"briefTitle":641,"status":125,"phases":8745,"primaryCompletion":643,"completion":644,"start":567,"enrollment":645,"conditions":8746,"interventions":8747},[91],[647,648,649,582,583,584,585,586,650,588,651,587,652],[593,97,87,654,420],{"trials":8749,"activeCount":102},[],{"trials":8751,"activeCount":102},[],{"trials":8753,"activeCount":102},[8754,8758],{"nctId":1326,"briefTitle":1327,"status":125,"phases":8755,"primaryCompletion":1329,"completion":1329,"start":1330,"enrollment":112,"conditions":8756,"interventions":8757},[94],[1332,1333],[593,561,242,225,654,899],{"nctId":914,"briefTitle":915,"status":108,"phases":8759,"primaryCompletion":917,"completion":917,"start":171,"enrollment":918,"conditions":8760,"interventions":8761},[94],[920,921,192,193,370,272,194,195,922,197,198,199,200,684,201,202,236,32],[42,97,654,924,925],{"intervention":8763,"totalTrials":158,"cells":8764},"Tetanus toxoid",{"EARLY_PHASE1":8765,"PHASE1":8767,"PHASE2":8773,"PHASE3":8775,"PHASE4":8777,"NA":8779},{"trials":8766,"activeCount":102},[],{"trials":8768,"activeCount":102},[8769],{"nctId":7650,"briefTitle":7651,"status":108,"phases":8770,"primaryCompletion":5203,"completion":5203,"start":7653,"enrollment":33,"conditions":8771,"interventions":8772},[90],[5133,15,18,115],[7643,7656],{"trials":8774,"activeCount":102},[],{"trials":8776,"activeCount":102},[],{"trials":8778,"activeCount":102},[],{"trials":8780,"activeCount":102},[8781],{"nctId":8782,"briefTitle":8783,"status":108,"phases":8784,"primaryCompletion":8785,"completion":8785,"start":8786,"enrollment":8787,"conditions":8788,"interventions":8789},"NCT00000105","Vaccination With Tetanus and KLH to Assess Immune Responses.",[],"2012-03","2002-07",112,[1713],[8790,8791,8792,8763],"Intracel KLH Vaccine","Biosyn KLH","Montanide ISA51",{"intervention":4469,"totalTrials":158,"cells":8794},{"EARLY_PHASE1":8795,"PHASE1":8797,"PHASE2":8799,"PHASE3":8805,"PHASE4":8807,"NA":8809},{"trials":8796,"activeCount":102},[],{"trials":8798,"activeCount":102},[],{"trials":8800,"activeCount":102},[8801],{"nctId":4462,"briefTitle":4463,"status":108,"phases":8802,"primaryCompletion":4465,"completion":4465,"start":4466,"enrollment":1438,"conditions":8803,"interventions":8804},[91],[671],[222,4469,4405,3297,4447],{"trials":8806,"activeCount":102},[],{"trials":8808,"activeCount":102},[],{"trials":8810,"activeCount":102},[8811],{"nctId":8579,"briefTitle":8580,"status":125,"phases":8812,"primaryCompletion":8582,"completion":7196,"start":8583,"enrollment":261,"conditions":8813,"interventions":8814},[94],[1194],[4469,2212,1208,8586],{"intervention":8816,"totalTrials":158,"cells":8817},"Laronidase",{"EARLY_PHASE1":8818,"PHASE1":8820,"PHASE2":8830,"PHASE3":8832,"PHASE4":8834,"NA":8836},{"trials":8819,"activeCount":102},[],{"trials":8821,"activeCount":102},[8822],{"nctId":8823,"briefTitle":8824,"status":125,"phases":8825,"primaryCompletion":8826,"completion":8826,"start":8827,"enrollment":832,"conditions":8828,"interventions":8829},"NCT01173016","Administration of IV Laronidase Post Bone Marrow Transplant in Hurler",[90],"2016-03-04","2012-05-29",[648],[8816],{"trials":8831,"activeCount":102},[],{"trials":8833,"activeCount":102},[],{"trials":8835,"activeCount":102},[],{"trials":8837,"activeCount":102},[8838],{"nctId":8839,"briefTitle":8840,"status":108,"phases":8841,"primaryCompletion":8842,"completion":8842,"start":1340,"enrollment":6509,"conditions":8843,"interventions":8845},"NCT01572636","Laronidase (Aldurazyme TM) Enzyme Replacement Therapy With Hematopoietic Stem Cell Transplant for Hurler Syndrome",[],"2018-05-01",[5495,8844,648],"MPS I",[8816],{"intervention":825,"totalTrials":158,"cells":8847},{"EARLY_PHASE1":8848,"PHASE1":8850,"PHASE2":8852,"PHASE3":8854,"PHASE4":8860,"NA":8862},{"trials":8849,"activeCount":102},[],{"trials":8851,"activeCount":102},[],{"trials":8853,"activeCount":102},[],{"trials":8855,"activeCount":102},[8856],{"nctId":815,"briefTitle":816,"status":125,"phases":8857,"primaryCompletion":818,"completion":492,"start":819,"enrollment":820,"conditions":8858,"interventions":8859},[91,92],[754,822],[824,97,42,825,302],{"trials":8861,"activeCount":102},[],{"trials":8863,"activeCount":102},[8864],{"nctId":890,"briefTitle":891,"status":108,"phases":8865,"primaryCompletion":893,"completion":893,"start":894,"enrollment":895,"conditions":8866,"interventions":8867},[94],[174,26,175],[149,898,87,97,208,899,900,526,825],{"intervention":924,"totalTrials":158,"cells":8869},{"EARLY_PHASE1":8870,"PHASE1":8872,"PHASE2":8874,"PHASE3":8880,"PHASE4":8882,"NA":8884},{"trials":8871,"activeCount":102},[],{"trials":8873,"activeCount":102},[],{"trials":8875,"activeCount":102},[8876],{"nctId":1276,"briefTitle":1277,"status":125,"phases":8877,"primaryCompletion":1279,"completion":1279,"start":1280,"enrollment":1281,"conditions":8878,"interventions":8879},[91],[1283,1284,1285,1286,1287,1288,1289,1290,1291],[561,242,1293,626,1294,1295],{"trials":8881,"activeCount":102},[],{"trials":8883,"activeCount":102},[],{"trials":8885,"activeCount":102},[8886],{"nctId":914,"briefTitle":915,"status":108,"phases":8887,"primaryCompletion":917,"completion":917,"start":171,"enrollment":918,"conditions":8888,"interventions":8889},[94],[920,921,192,193,370,272,194,195,922,197,198,199,200,684,201,202,236,32],[42,97,654,924,925],{"intervention":8790,"totalTrials":1013,"cells":8891},{"EARLY_PHASE1":8892,"PHASE1":8894,"PHASE2":8896,"PHASE3":8898,"PHASE4":8900,"NA":8902},{"trials":8893,"activeCount":102},[],{"trials":8895,"activeCount":102},[],{"trials":8897,"activeCount":102},[],{"trials":8899,"activeCount":102},[],{"trials":8901,"activeCount":102},[],{"trials":8903,"activeCount":102},[8904],{"nctId":8782,"briefTitle":8783,"status":108,"phases":8905,"primaryCompletion":8785,"completion":8785,"start":8786,"enrollment":8787,"conditions":8906,"interventions":8907},[],[1713],[8790,8791,8792,8763],{"intervention":8791,"totalTrials":1013,"cells":8909},{"EARLY_PHASE1":8910,"PHASE1":8912,"PHASE2":8914,"PHASE3":8916,"PHASE4":8918,"NA":8920},{"trials":8911,"activeCount":102},[],{"trials":8913,"activeCount":102},[],{"trials":8915,"activeCount":102},[],{"trials":8917,"activeCount":102},[],{"trials":8919,"activeCount":102},[],{"trials":8921,"activeCount":102},[8922],{"nctId":8782,"briefTitle":8783,"status":108,"phases":8923,"primaryCompletion":8785,"completion":8785,"start":8786,"enrollment":8787,"conditions":8924,"interventions":8925},[],[1713],[8790,8791,8792,8763],{"intervention":8792,"totalTrials":1013,"cells":8927},{"EARLY_PHASE1":8928,"PHASE1":8930,"PHASE2":8932,"PHASE3":8934,"PHASE4":8936,"NA":8938},{"trials":8929,"activeCount":102},[],{"trials":8931,"activeCount":102},[],{"trials":8933,"activeCount":102},[],{"trials":8935,"activeCount":102},[],{"trials":8937,"activeCount":102},[],{"trials":8939,"activeCount":102},[8940],{"nctId":8782,"briefTitle":8783,"status":108,"phases":8941,"primaryCompletion":8785,"completion":8785,"start":8786,"enrollment":8787,"conditions":8942,"interventions":8943},[],[1713],[8790,8791,8792,8763],{"intervention":8586,"totalTrials":1013,"cells":8945},{"EARLY_PHASE1":8946,"PHASE1":8948,"PHASE2":8950,"PHASE3":8952,"PHASE4":8954,"NA":8956},{"trials":8947,"activeCount":102},[],{"trials":8949,"activeCount":102},[],{"trials":8951,"activeCount":102},[],{"trials":8953,"activeCount":102},[],{"trials":8955,"activeCount":102},[],{"trials":8957,"activeCount":102},[8958],{"nctId":8579,"briefTitle":8580,"status":125,"phases":8959,"primaryCompletion":8582,"completion":7196,"start":8583,"enrollment":261,"conditions":8960,"interventions":8961},[94],[1194],[4469,2212,1208,8586],{"intervention":8735,"totalTrials":1013,"cells":8963},{"EARLY_PHASE1":8964,"PHASE1":8966,"PHASE2":8968,"PHASE3":8970,"PHASE4":8972,"NA":8974},{"trials":8965,"activeCount":102},[],{"trials":8967,"activeCount":102},[],{"trials":8969,"activeCount":102},[],{"trials":8971,"activeCount":102},[],{"trials":8973,"activeCount":102},[],{"trials":8975,"activeCount":102},[8976],{"nctId":8730,"briefTitle":8731,"status":125,"phases":8977,"primaryCompletion":293,"completion":1711,"start":2208,"enrollment":33,"conditions":8978,"interventions":8979},[94],[29],[2212,8735],{"intervention":3350,"totalTrials":1013,"cells":8981},{"EARLY_PHASE1":8982,"PHASE1":8984,"PHASE2":8986,"PHASE3":8988,"PHASE4":8990,"NA":8992},{"trials":8983,"activeCount":102},[],{"trials":8985,"activeCount":102},[],{"trials":8987,"activeCount":102},[],{"trials":8989,"activeCount":102},[],{"trials":8991,"activeCount":102},[],{"trials":8993,"activeCount":102},[8994],{"nctId":3341,"briefTitle":3342,"status":108,"phases":8995,"primaryCompletion":3344,"completion":3345,"start":3346,"enrollment":1454,"conditions":8996,"interventions":8997},[94],[24,297,3348],[3350,497,1366],{"intervention":8999,"totalTrials":1013,"cells":9000},"Reduced Toxicity Ablative Regimen",{"EARLY_PHASE1":9001,"PHASE1":9003,"PHASE2":9005,"PHASE3":9007,"PHASE4":9009,"NA":9011},{"trials":9002,"activeCount":102},[],{"trials":9004,"activeCount":102},[],{"trials":9006,"activeCount":102},[],{"trials":9008,"activeCount":102},[],{"trials":9010,"activeCount":102},[],{"trials":9012,"activeCount":102},[9013],{"nctId":9014,"briefTitle":9015,"status":108,"phases":9016,"primaryCompletion":9017,"completion":9017,"start":9018,"enrollment":1281,"conditions":9019,"interventions":9024},"NCT02179359","Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies",[94],"2024-11-21","2014-09-02",[623,9020,9021,512,9022,4181,1458,9023],"Transfusion Dependent Alpha- or Beta- Thalassemia","Diamond Blackfan Anemia","Glanzmann Thrombasthenia","Non-Malignant Hematologic Disorders",[8999,9025,9026],"Reduced Intensity Preparative Regimen","Myeloablative Preparative Regimen",{"intervention":9025,"totalTrials":1013,"cells":9028},{"EARLY_PHASE1":9029,"PHASE1":9031,"PHASE2":9033,"PHASE3":9035,"PHASE4":9037,"NA":9039},{"trials":9030,"activeCount":102},[],{"trials":9032,"activeCount":102},[],{"trials":9034,"activeCount":102},[],{"trials":9036,"activeCount":102},[],{"trials":9038,"activeCount":102},[],{"trials":9040,"activeCount":102},[9041],{"nctId":9014,"briefTitle":9015,"status":108,"phases":9042,"primaryCompletion":9017,"completion":9017,"start":9018,"enrollment":1281,"conditions":9043,"interventions":9044},[94],[623,9020,9021,512,9022,4181,1458,9023],[8999,9025,9026],{"intervention":9026,"totalTrials":1013,"cells":9046},{"EARLY_PHASE1":9047,"PHASE1":9049,"PHASE2":9051,"PHASE3":9053,"PHASE4":9055,"NA":9057},{"trials":9048,"activeCount":102},[],{"trials":9050,"activeCount":102},[],{"trials":9052,"activeCount":102},[],{"trials":9054,"activeCount":102},[],{"trials":9056,"activeCount":102},[],{"trials":9058,"activeCount":102},[9059],{"nctId":9014,"briefTitle":9015,"status":108,"phases":9060,"primaryCompletion":9017,"completion":9017,"start":9018,"enrollment":1281,"conditions":9061,"interventions":9062},[94],[623,9020,9021,512,9022,4181,1458,9023],[8999,9025,9026],{"intervention":878,"totalTrials":1013,"cells":9064},{"EARLY_PHASE1":9065,"PHASE1":9067,"PHASE2":9069,"PHASE3":9071,"PHASE4":9073,"NA":9075},{"trials":9066,"activeCount":102},[],{"trials":9068,"activeCount":102},[],{"trials":9070,"activeCount":102},[],{"trials":9072,"activeCount":102},[],{"trials":9074,"activeCount":102},[],{"trials":9076,"activeCount":102},[9077],{"nctId":869,"briefTitle":870,"status":108,"phases":9078,"primaryCompletion":872,"completion":873,"start":874,"enrollment":158,"conditions":9079,"interventions":9080},[94],[876,202,192],[42,97,878],{"intervention":1969,"totalTrials":1013,"cells":9082},{"EARLY_PHASE1":9083,"PHASE1":9085,"PHASE2":9087,"PHASE3":9089,"PHASE4":9091,"NA":9093},{"trials":9084,"activeCount":102},[],{"trials":9086,"activeCount":102},[],{"trials":9088,"activeCount":102},[],{"trials":9090,"activeCount":102},[],{"trials":9092,"activeCount":102},[],{"trials":9094,"activeCount":102},[9095],{"nctId":1961,"briefTitle":1962,"status":125,"phases":9096,"primaryCompletion":1964,"completion":1964,"start":558,"enrollment":426,"conditions":9097,"interventions":9098},[94],[1966,1967],[1969,1970,243],{"intervention":1970,"totalTrials":1013,"cells":9100},{"EARLY_PHASE1":9101,"PHASE1":9103,"PHASE2":9105,"PHASE3":9107,"PHASE4":9109,"NA":9111},{"trials":9102,"activeCount":102},[],{"trials":9104,"activeCount":102},[],{"trials":9106,"activeCount":102},[],{"trials":9108,"activeCount":102},[],{"trials":9110,"activeCount":102},[],{"trials":9112,"activeCount":102},[9113],{"nctId":1961,"briefTitle":1962,"status":125,"phases":9114,"primaryCompletion":1964,"completion":1964,"start":558,"enrollment":426,"conditions":9115,"interventions":9116},[94],[1966,1967],[1969,1970,243],{"intervention":9118,"totalTrials":1013,"cells":9119},"Influenza vaccine",{"EARLY_PHASE1":9120,"PHASE1":9122,"PHASE2":9124,"PHASE3":9126,"PHASE4":9128,"NA":9130},{"trials":9121,"activeCount":102},[],{"trials":9123,"activeCount":102},[],{"trials":9125,"activeCount":102},[],{"trials":9127,"activeCount":102},[],{"trials":9129,"activeCount":102},[],{"trials":9131,"activeCount":102},[9132],{"nctId":9133,"briefTitle":9134,"status":108,"phases":9135,"primaryCompletion":2126,"completion":2126,"start":2139,"enrollment":98,"conditions":9136,"interventions":9138},"NCT01215981","Influenza Vaccine Post Allogeneic Transplant",[94],[9137,263],"Hematopoietic Stem Cell Transplant",[9118,9118],{"intervention":9140,"totalTrials":1013,"cells":9141},"Selinexor",{"EARLY_PHASE1":9142,"PHASE1":9144,"PHASE2":9146,"PHASE3":9148,"PHASE4":9150,"NA":9152},{"trials":9143,"activeCount":102},[],{"trials":9145,"activeCount":102},[],{"trials":9147,"activeCount":102},[],{"trials":9149,"activeCount":102},[],{"trials":9151,"activeCount":102},[],{"trials":9153,"activeCount":102},[9154],{"nctId":9155,"briefTitle":9156,"status":9157,"phases":9158,"conditions":9159,"interventions":9160},"NCT03850704","Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma","NO_LONGER_AVAILABLE",[],[32],[9140],{"intervention":888,"totalTrials":1013,"cells":9162},{"EARLY_PHASE1":9163,"PHASE1":9165,"PHASE2":9167,"PHASE3":9169,"PHASE4":9171,"NA":9173},{"trials":9164,"activeCount":102},[],{"trials":9166,"activeCount":102},[],{"trials":9168,"activeCount":102},[],{"trials":9170,"activeCount":102},[],{"trials":9172,"activeCount":102},[],{"trials":9174,"activeCount":102},[9175],{"nctId":880,"briefTitle":881,"status":125,"phases":9176,"primaryCompletion":883,"completion":883,"start":884,"enrollment":98,"conditions":9177,"interventions":9178},[94],[886,15,18,21],[222,888,118,119,120,121],{"intervention":900,"totalTrials":1013,"cells":9180},{"EARLY_PHASE1":9181,"PHASE1":9183,"PHASE2":9185,"PHASE3":9187,"PHASE4":9189,"NA":9191},{"trials":9182,"activeCount":102},[],{"trials":9184,"activeCount":102},[],{"trials":9186,"activeCount":102},[],{"trials":9188,"activeCount":102},[],{"trials":9190,"activeCount":102},[],{"trials":9192,"activeCount":102},[9193],{"nctId":890,"briefTitle":891,"status":108,"phases":9194,"primaryCompletion":893,"completion":893,"start":894,"enrollment":895,"conditions":9195,"interventions":9196},[94],[174,26,175],[149,898,87,97,208,899,900,526,825],{"intervention":9198,"totalTrials":1013,"cells":9199},"Standard chemotherapy",{"EARLY_PHASE1":9200,"PHASE1":9202,"PHASE2":9204,"PHASE3":9206,"PHASE4":9208,"NA":9210},{"trials":9201,"activeCount":102},[],{"trials":9203,"activeCount":102},[],{"trials":9205,"activeCount":102},[],{"trials":9207,"activeCount":102},[],{"trials":9209,"activeCount":102},[],{"trials":9211,"activeCount":102},[9212],{"nctId":9213,"briefTitle":9214,"status":125,"phases":9215,"primaryCompletion":2208,"completion":458,"start":9216,"enrollment":907,"conditions":9217,"interventions":9219},"NCT00293293","Outcomes in Ovarian Cancer and Fallopian Tube Cancer Patients Using Complementary Alternative Medicine",[94],"2005-05",[24,9218,297],"Peritoneal Primary Cancer",[9198],{"intervention":9221,"totalTrials":1013,"cells":9222},"Modified Natural American Spirit-Tan or Green cigarettes injected with labeled NNK",{"EARLY_PHASE1":9223,"PHASE1":9225,"PHASE2":9227,"PHASE3":9229,"PHASE4":9231,"NA":9233},{"trials":9224,"activeCount":102},[],{"trials":9226,"activeCount":102},[],{"trials":9228,"activeCount":102},[],{"trials":9230,"activeCount":102},[],{"trials":9232,"activeCount":102},[],{"trials":9234,"activeCount":102},[9235],{"nctId":9236,"briefTitle":9237,"status":125,"phases":9238,"primaryCompletion":9239,"completion":9240,"start":9241,"enrollment":358,"conditions":9242,"interventions":9243},"NCT04228952","Metabolism of NNK in Japanese Americans",[],"2021-10-15","2025-04-14","2020-09-01",[7785],[9221],{"intervention":1344,"totalTrials":1013,"cells":9245},{"EARLY_PHASE1":9246,"PHASE1":9248,"PHASE2":9250,"PHASE3":9252,"PHASE4":9254,"NA":9256},{"trials":9247,"activeCount":102},[],{"trials":9249,"activeCount":102},[],{"trials":9251,"activeCount":102},[],{"trials":9253,"activeCount":102},[],{"trials":9255,"activeCount":102},[],{"trials":9257,"activeCount":102},[9258],{"nctId":1336,"briefTitle":1337,"status":125,"phases":9259,"primaryCompletion":1339,"completion":1339,"start":1340,"enrollment":295,"conditions":9260,"interventions":9261},[94],[494],[497,1343,499,1344,242,239],{"intervention":947,"totalTrials":1013,"cells":9263},{"EARLY_PHASE1":9264,"PHASE1":9266,"PHASE2":9268,"PHASE3":9270,"PHASE4":9272,"NA":9274},{"trials":9265,"activeCount":102},[],{"trials":9267,"activeCount":102},[],{"trials":9269,"activeCount":102},[],{"trials":9271,"activeCount":102},[],{"trials":9273,"activeCount":102},[],{"trials":9275,"activeCount":102},[9276],{"nctId":934,"briefTitle":935,"status":108,"phases":9277,"primaryCompletion":937,"completion":937,"start":938,"enrollment":939,"conditions":9278,"interventions":9279},[94],[941,266,834,371,942,943,944,945,32],[867,97,87,947,948],{"intervention":948,"totalTrials":1013,"cells":9281},{"EARLY_PHASE1":9282,"PHASE1":9284,"PHASE2":9286,"PHASE3":9288,"PHASE4":9290,"NA":9292},{"trials":9283,"activeCount":102},[],{"trials":9285,"activeCount":102},[],{"trials":9287,"activeCount":102},[],{"trials":9289,"activeCount":102},[],{"trials":9291,"activeCount":102},[],{"trials":9293,"activeCount":102},[9294],{"nctId":934,"briefTitle":935,"status":108,"phases":9295,"primaryCompletion":937,"completion":937,"start":938,"enrollment":939,"conditions":9296,"interventions":9297},[94],[941,266,834,371,942,943,944,945,32],[867,97,87,947,948],{"intervention":1367,"totalTrials":1013,"cells":9299},{"EARLY_PHASE1":9300,"PHASE1":9302,"PHASE2":9304,"PHASE3":9306,"PHASE4":9308,"NA":9310},{"trials":9301,"activeCount":102},[],{"trials":9303,"activeCount":102},[],{"trials":9305,"activeCount":102},[],{"trials":9307,"activeCount":102},[],{"trials":9309,"activeCount":102},[],{"trials":9311,"activeCount":102},[9312],{"nctId":1346,"briefTitle":1347,"status":125,"phases":9313,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":9314,"interventions":9315},[94],[1353,1354,1355,1356,1357,1358,1193,1359,1360,1361,1362,1363],[1365,239,1209,243,87,242,496,1343,497,1366,1367,1368],{"intervention":1368,"totalTrials":1013,"cells":9317},{"EARLY_PHASE1":9318,"PHASE1":9320,"PHASE2":9322,"PHASE3":9324,"PHASE4":9326,"NA":9328},{"trials":9319,"activeCount":102},[],{"trials":9321,"activeCount":102},[],{"trials":9323,"activeCount":102},[],{"trials":9325,"activeCount":102},[],{"trials":9327,"activeCount":102},[],{"trials":9329,"activeCount":102},[9330],{"nctId":1346,"briefTitle":1347,"status":125,"phases":9331,"primaryCompletion":1349,"completion":1349,"start":1350,"enrollment":1351,"conditions":9332,"interventions":9333},[94],[1353,1354,1355,1356,1357,1358,1193,1359,1360,1361,1362,1363],[1365,239,1209,243,87,242,496,1343,497,1366,1367,1368],{"intervention":9335,"totalTrials":1013,"cells":9336},"Naglazyme®",{"EARLY_PHASE1":9337,"PHASE1":9339,"PHASE2":9341,"PHASE3":9343,"PHASE4":9345,"NA":9347},{"trials":9338,"activeCount":102},[],{"trials":9340,"activeCount":102},[],{"trials":9342,"activeCount":102},[],{"trials":9344,"activeCount":102},[],{"trials":9346,"activeCount":102},[],{"trials":9348,"activeCount":102},[9349],{"nctId":9350,"briefTitle":9351,"status":108,"phases":9352,"primaryCompletion":9353,"completion":9353,"start":9354,"enrollment":1013,"conditions":9355,"interventions":9356},"NCT02156674","Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome",[94],"2019-12-01","2016-01-26",[582],[9335]]